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Abstract
Parkinson’s disease (PD) is an insidious neurodegenerative disorder characterized by a range of motor
symptoms which develop predominantly as a consequence of striatal dopamine depletion. The majority of PD
cases are idiopathic; however, discoveries of genetic mutations linked to familial forms of PD, including
mutations in the genes encoding DJ-1, parkin, and α-synuclein (α-syn), have provided insights into sporadic
PD pathogenesis.
Mutations in the gene encoding DJ-1 cause autosomal recessive early-onset PD (AREP). Though the
physiological role for DJ-1 is not fully elucidated, it is thought that DJ-1 mutations contribute to disease as a
consequence of a loss-of-function. Herein, we show that wild-type (WT) DJ-1 is a relatively stable and soluble
homodimer that has diffuse cellular distribution and that can protect mammalian cells against a variety of
noxious insults. Pathogenic mutant DJ-1 proteins, L10P, P158DEL, E163K, and L166P display diverse altered
biochemical properties. Thus, it is concluded that alterations to distinct DJ-1 residues may specifically affect
individual protein functions and may also implicate DJ-1 in a variety of biochemical pathways.
When expressed in mice, human pathogenic mutant A53T α-syn can aggregate and result in fatal motor
impairments. It was hypothesized that DJ-1 may act to modulate this effect. Herein, DJ-1 null transgenic
animals are generated and assessed for viability against toxic A53T α-syn. However, in double transgenic DJ-1
null mice expressing human pathogenic A53T α-syn, the consequences of DJ-1 deficiency are not apparent
and thus it is concluded that DJ-1 may not directly modulate α-syn nor mitigate the deleterious effects of α-syn
aggregation in vivo.
Parkin mutations cause AREP which is thought to develop secondary to a loss in parkin function. We discover
a novel endogenous parkin mutation in C3H mice, E398Q, which impairs the function of parkin in a similar
manner to that of pathogenic missense parkin mutations. It is therefore concluded that C3H mice may serve
as suitable models for future studies to assess the effects of parkin loss-of-function in vivo.
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ABSTRACT 
STUDIES OF DJ-1, PARKIN, AND ALPHA-SYNUCLEIN GIVE INSIGHTS INTO 
PLAUSIBLE MECHANISMS FOR PARKINSON’S DISEASE PATHOGENESIS 
Chenere P. Ramsey 
Advisor: Benoit I. Giasson, Ph.D. 
Parkinson’s disease (PD) is an insidious neurodegenerative disorder characterized 
by a range of motor symptoms which develop predominantly as a consequence of striatal 
dopamine depletion. The majority of PD cases are idiopathic; however, discoveries of 
genetic mutations linked to familial forms of PD, including mutations in the genes 
encoding DJ-1, parkin, and α-synuclein (α-syn), have provided insights into sporadic PD 
pathogenesis.   
 Mutations in the gene encoding DJ-1 cause autosomal recessive early-onset PD 
(AREP). Though the physiological role for DJ-1 is not fully elucidated, it is thought that 
DJ-1 mutations contribute to disease as a consequence of a loss-of-function. Herein, we 
show that wild-type (WT) DJ-1 is a relatively stable and soluble homodimer that has 
diffuse cellular distribution and that can protect mammalian cells against a variety of 
noxious insults. Pathogenic mutant DJ-1 proteins, L10P, P158DEL, E163K, and L166P 
display diverse altered biochemical properties. Thus, it is concluded that alterations to 
distinct DJ-1 residues may specifically affect individual protein functions and may also 
implicate DJ-1 in a variety of biochemical pathways. 
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When expressed in mice, human pathogenic mutant A53T α-syn can aggregate 
and result in fatal motor impairments. It was hypothesized that DJ-1 may act to modulate 
this effect. Herein, DJ-1 null transgenic animals are generated and assessed for viability 
against toxic A53T α-syn. However, in double transgenic DJ-1 null mice expressing 
human pathogenic A53T α-syn, the consequences of DJ-1 deficiency are not apparent and 
thus it is concluded that DJ-1 may not directly modulate α-syn nor mitigate the 
deleterious effects of α-syn aggregation in vivo. 
Parkin mutations cause AREP which is thought to develop secondary to a loss in 
parkin function. We discover a novel endogenous parkin mutation in C3H mice, E398Q 
which impairs the function of parkin in a similar manner to that of pathogenic missense 
parkin mutations. It is therefore concluded that C3H mice may serve as suitable models 
for future studies to assess the effects of parkin loss-of-function in vivo.  
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 1.1 “La maladie Parkinson” 
Dr. James Parkinson (1755-1824) was a surgeon who lived and worked in the 
southern part of London, England. Throughout his career, he wrote copiously on many 
topics related to medicine and politics. He is most well-known for his work, An Essay on 
the Shaking Palsy, which was written in 1817. In his essay, James Parkinson described a 
motor condition which was coined some years later as “La maladie Parkinson” (39).  
Parkinson’s account was based on conclusions drawn from only six patients (344).  He 
summarized the condition as, “Involuntary tremulous motion, with lessened muscular 
power…with a propensity to bend the trunk forward, and to pass from a walking to a 
running pace: the senses and intellect being uninjured”(344). According to Parkinson, 
these symptoms, which progressively worsened over time, eventually debilitated the 
affected individuals to the point of complete dependence on external care givers (344). 
The classical symptoms described by Parkinson are common to the insidious disorder that 
is known today as Parkinson’s disease (PD).   
1.2 PD: a neurodegenerative movement disorder 
 PD is the leading cause of parkinsonism. Parkinsonism is the term used to 
describe a group of symptoms that include tremor, slowness of movement (bradykinesia), 
rigidity, and postural instability. PD is one of several neurological disorders that produce 
similar symptoms (399;465). PD results from progressive degeneration of selective and 
heterogeneous neuronal populations (Figure 1-1) (234). Among the neuronal populations 
affected are the dopaminergic neurons (also known as the A9 group) of the substantia 
nigra pars compacta (SNpc). Although PD is not limited to the SNpc, degeneration of 
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Figure 1-1 
 
A schematic showing the sites of neurodegeneration and neurochemical pathways that are involved in PD.       
The sites of 
neurodegeneration 
are marked in dark 
blue. The colored 
arrows show the 
neurochemical 
pathways that are 
affected by the 
disease. Red arrows 
depict DA pathways, 
green arrows depict 
norepinephrine 
pathways, yellow 
arrows depict 
serotonin pathways, 
and turquoise  or 
purple arrows depict 
acetylcholine 
pathways. The same 
color scheme is also 
used in the inset 
which shows the 
destinations of the 
various 
neurochemical 
pathways from a 
saggital section view. 
Figure  is  from Lang 
and Lozano, New Eng J 
Med, 1998 (234). 
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the nigra plays a major role in the pathobiology of the disease (112).   
1.3 The direct/indirect pathways of motor control 
 Dopaminergic neurons of the SNpc release dopamine (DA) into the striatum via 
the nigrostriatal pathway (Figure 1-2A and B).  The striatum is largely composed of 
medium spiny neurons (MSNs). Striatal MSNs generally express either D1 DA receptors 
(striasome neurons) or D2 DA receptors (matriasome neurons) and can thereby be 
regulated in parallel with respect to the type of receptor that they express. Striasome 
MSNs are activated by DA while matriasome MSNs are inhibited by DA. Activation of 
striasome neurons facilitates movement in a pathway known as the direct pathway 
(Figure 1-2C)(92). Conversely, in the absence of DA, matriasome neurons are activated 
and this acts to inhibit movement in a pathway known as the indirect pathway. These 
processes require tight regulation and together, they play a role in fine-tuning motor 
control (92;195). 
1.4 Parkinsonism: the effects of depleted striatal DA content 
In PD, as nigral neurons degenerate, striatal DA levels significantly depreciate 
and this results in deactivation of the direct pathway while it simultaneously enhances the 
indirect pathway. The deregulation of these two pathways leads to the onset of motor 
impairments. PD is diagnosed if bradykinesia and at least one of the other cardinal 
parkinsonism symptoms presents (377). It is thought that motor impairments first develop 
when eighty percent of nigral neurons have already degenerated (234).  
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Figure 1-2 
 
 
 
            Nigrostriatal signaling pathways involved in movement. 
                     
  Part A shows a saggital illustration of the human brain. The grey area highlights the substantia nigra and the arrows depict 
nigral dopaminergic projections into the striatum. Part B shows the nigrostriatal pathway illustrated in coronal sections. 
Dopaminergic neurons in the substantia nigra pars compacta (“1”) release DA into the striatum which is composed of the 
caudate nucleus (“13”) and putamen (“7”). Part C is a magnification of the box drawn in B. Part C shows the direct and 
indirect pathways of DA neurotransmission. Inhibitory projections are depicted in red and excitatory projections are depicted 
in blue. DA excites striatal MSNs which express D1 DA receptors and simultaneously inhibits striatal MSNs which express 
D2 DA receptors. This affects subsequent basal ganglia signaling which is also illustrated in C.   
 
            Legend: 1-substantia nigra, 2-periaqueductal grey matter, 3-inferior colliculus, 4-cerebral aqueduct, 5-amygdala, 6-globus 
pallidus (Gpe-globus pallidus externus, Gpi-globus pallidus internus), 7-putamen, 8-ventral posterior thalamic nucleus, 9-
ventral lateral thalamic nucleus, 10-corpus callosum, 11-fornix, 12-cerebral cortex, 13-caudate nucleus, 14-internal capsule, 
15-cortical white matter, 16-mammillary body, 17-subthalamic nucleus  
 
        Figure 1-2 was generated using illustrations from Bear et al., An Illustrated Guide to Human Neuroanatomy, 2007 (30). 
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1.5 PD prevalence, risks, and causes 
 The worldwide prevalence of PD is difficult to ascertain (58). In the United 
States, PD is estimated to affect 1-2 percent of the population of age 65 years or older 
(465).  It is thought that 40,000 new cases of PD are diagnosed annually (465). Though 
the disease has existed for hundreds of years, the cause for PD is still largely a mystery. 
In fact, the only proven risk factor for idiopathic PD is old age (58;465). PD is rare in 
individuals before the age of 50 but the risk increases greatly among the elderly(58).   
A number of other risk factors for sporadic PD have also been proposed including 
gender, ethnicity, family history, exposure to various chemicals or infectious agents, head 
trauma, and even diet. However, many of these factors are controversial and have shown 
to be inconsistent between studies. It is thought that PD is a multifactorial disease and 
thus identifying a single cause has proven to be difficult (58;128). 
1.6 PD treatments: L-DOPA is effective but also has limitations 
 There are no available methods to stop the progression of neurodegeneration in 
PD; however, there are several pharmacologic treatments which act to temporarily abate 
disease symptoms (Table 1-1).  Each PD patient can respond differently to treatments 
and thus, medication selection and dosage is made on an individual basis and may change 
over the course of a patient’s disease progression (105).  L-dihydroxyphenylalanine (L-
DOPA) is one of the most effective symptomatic medications for PD (25). In 1961, small 
doses of L-DOPA (also known as levodopa) were first administered to PD patients as a 
means to transiently reverse motor impairments (105). Levodopa acts to supplement DA 
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that has been lost due to nigral degeneration. Unlike DA, levodopa can cross the blood 
brain barrier. Subsequently, it can be converted into DA by aromatic L-amino acid 
decarboxylase, an enzyme that is abundantly expressed in dopaminergic neurons (Figure 
1-3). PD patients typically respond well to levodopa treatments initially. Responsiveness 
to levodopa is often used as an indicator to distinguish PD from other types of 
parkinsonism. However, while PD patients respond well to levodopa during early 
treatments, for reasons that are poorly understood, the drug eventually loses its 
effectiveness after roughly 5 years of use. It also has a number of negative side effects 
(24;92;105). 
Table 1-1 (25;105;235) 
Treatment Mode of Action Examples Side Effects 
monamine oxidase 
(MAO)-B  
inhibitors  
Decreases endogenous 
dopamine (DA) catabolism 
selegiline; rasagiline effects resulting 
from interactions 
with other 
medications 
DA  receptor 
agonists  
Acts directly on DA receptors 
to mimic DA activity  
apomorphine, 
bromocriptine, 
pergolide, ropinirole, 
pramipexole 
 
nausea, 
vomiting, 
psychosis , 
dyskinesias  
DA precursors Converted to DA in the CNS 
as a form of DA replacement 
(often administered in 
combination with inhibitors 
of peripheral degradation 
enzymes) 
 levodopa/carbidopa, 
levodopa/benserazide, 
levodopa/entacapone, 
levodopa/tolcapone 
dyskinesias, 
nausea, wearing-
off effect 
Anticholinergics Restrict the action of 
acetylcholine, blocking nerve 
impulses at the level of the 
muscle 
benztropine, biperiden, 
diphenhydramine, 
ethopropazine, 
orphenadrine, 
procyclidine, 
trihexyphenidyl 
dry mouth, 
confusion, 
memory loss, 
nausea, blurred 
vision, 
constipation, 
urinary retention 
Antiglutamatergics blocks NMDA receptor ( not 
completely clear why this 
reduces parkinsonism)  
Amantadine Confusion, 
insomnia,  
hallucinations, 
leg swelling 
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Figure 1-3   Pathways of DA synthesis and catabolism. 
 
 
 
 
 
1.7 Hypotheses for PD pathogenesis 
With the increasing age of the population in advanced countries, the risk for PD 
will continue to rise. It is therefore of great interest to improve treatments and to 
determine better modes of disease prevention. Gaining insights into disease pathogenesis 
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will be crucial in this effort. PD may develop as a consequence of dysfunctions in various 
biochemical pathways (82;88;109;234;365). Hypotheses related to the effects of 
proteasome, oxidative, and mitochondrial impairments on PD pathogenesis will be briefly 
discussed below. 
1.8  The ubiquitin-proteasome system 
It is thought that PD may be caused by impairments in the ubiquitin-proteasome 
system (UPS) (31;79;323). In order for protein substrates to be degraded in the UPS 
pathway, a series of tightly controlled events must occur (73;159;160). First, ubiquitin-
activating enzymes (E1 enzymes) modify ubiquitin protein molecules in a two-step 
reaction which requires ATP.  Once ubiquitin molecules have been activated by E1 
enzymes, they are transferred to E2 ubiquitin-conjugating enzymes (E2 enzymes), 
forming E2 enzyme-ubiquitin complexes. Next, E3 ubiquitin-protein ligases (E3 ligases) 
act to facilitate covalent ligation of ubiquitin to protein substrates. 
 Different types of E3 ligases may facilitate protein-ubiquitin ligation by distinct 
mechanisms (160). Many E3 ligases can bind to protein substrates and corresponding E2 
enzymes simultaneously to form protein substrate-E3 ligase-E2 enzyme-ubiquitin 
complexes.  These complexes allow for the direct transfer of ubiquitin from E2 enzymes 
onto specific lysine residues of respective protein substrates. Once a substrate protein is 
ubiquitinated, E1, E2, and E3 enzymes can promote subsequent polyubiquitination of the 
substrate by covalent linkage of ubiquitin molecules onto residue Lys 48 of the 
previously conjugated ubiquitin molecule. The addition of a chain of at least four Lys-48-
10 
 
linked ubiquitin molecules onto a substrate protein marks the substrate for degradation by 
the 26S proteasome (73;159;160).  
The 26S proteasome is a complex consisting of a large protease (the 20S 
proteasome) and several regulatory subunits (19S/PA 700, PA 200, PA28) (3;323;369). It 
is arranged into a hollow symmetrical dumbbell-like structure with the catalytic 20S 
subunit at the central core and regulatory subunits on either end (3;73;369).  The 20S 
catalytic core possesses chymotrypsin-like, trypsin-like, and peptidylglutamyl-peptide 
hydrolase (PGPH)-like protease activities which act to break down substrate proteins into 
small 2-25 amino acid peptide fragments. Such peptides can be further hydrolyzed into 
individual amino acids which can be used to make new proteins (3;246;323).   
It is important to note that when clearing proteins via the UPS pathway, each E2 
enzyme only binds to a subset of E3 ligases and each E3 ligase only binds to a specific 
number of protein substrates. While there is likely some redundancy in this system, the 
failure of an E3 ligase to bind its substrates or to interact with corresponding E2 enzymes 
could result in substrate accumulation and subsequent protein aggregation. It is 
hypothesized that aggregated proteins can resist proteasomal degradation and that they 
may even clog and inactivate 20S catalytic subunits (323 and references therein). When 
misfolded proteins are not cleared, they can accumulate or aggregate, resulting in the 
formation of proteinaceous inclusions.  
1.9 Lewy bodies in PD and proteasome dysfunction 
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In 1910, Fritz Heinrich Lewy, a German born neurologist and histopathology 
specialist, presented a paper, To the Pathological Anatomy of the Paralysis Agitans, at the 
Seventh Annual Meeting of the Society of German Neurologists. During his presentation, 
Lewy described his discovery of intracellular “balls” that were detected in PD basal 
ganglia tissues during post mortem analyses. These “balls” were noted to be 
proteinaceous, eosinophilic and variable in size (382). In 1918, the term, “corpe de 
Lewy” or “Lewy bodies”, was first used to describe these pathologies (166;382). Today it 
is known that Lewy bodies (LBs) are the common neuropathological hallmark of PD 
(396).    
LBs are intraneuronal, cytoplamsic inclusions that typically only affect specific 
neuronal populations in PD brains. The classical LB is spherical in shape with a dense 
granular core and fibrillar halo (219;396)(Figure 1-4).  The preponderance of LBs in PD 
brains significantly links these pathologies to nerve cell degeneration. However, it is not 
fully understood what molecular events lead to LB formation (112). It is known that LBs 
are composed of deposits of aggregated proteins that are often ubiquitinated (356), and it 
is possible that these proteins may accumulate and associate into LBs as a consequence of 
proteasome impairments in PD. To support this idea, enzymatic analyses reveal that PD 
substantia nigra tissues demonstrate reduced proteasome activities (287;290).  
Additionally, decreased levels of regulatory subunits of the 26S proteasome have been 
observed in PD (287;288). These findings may link proteasome impairments to PD 
pathogenesis; however it is still unknown whether such changes may be causal of disease. 
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Figure 1-4 
 
 
 
 Lewy Body. The image shows multiple LBs in the same neuron 
of the SNpc stained with hematoxylin-eosin. Scale bar is 25μm.  
 
  Figure modified from Kovari et al., Brain Res Bull 2009 (219). 
 
 
 
 
1.10 Proteasome Inhibitors  
Studies to understand the effects of proteasome dysfunction in rodent and cell 
culture models of PD often utilize proteasome inhibitors such as carbobenzoyl-leu-leu-
leucinal (MG-132), lactacystin, and epoxomicin. MG-132 is a synthetic cell-permeable 
peptide-aldehyde that can reversibly bind and inhibit chymotrypsin-like activities of the 
20S proteasome (436;437). MG-132 is also known to inhibit calcium-modulated cysteine 
proteases (calpains) to a lesser degree (437). Lactacystin is a naturally occurring 
compound that was isolated from Actinomycetes in 1991 (326). It covalently binds to 
20S proteasome subunits and acts to inhibit chymotrypsin-like and trypsin-like activities 
in an irreversible manner while inhibiting PDPH-like activities in a reversible manner 
(108).  In aqueous solution, lactacystin is converted by hydrolysis into its active form, 
clasto-lactacystin-β-lactone (Omuralide) (97). Omuralide specifically inhibits the 
proteasome although it has also been shown to inhibit capthepsin A to a lesser degree 
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(246). Since both MG-132 and omuralide can inhibit proteases in addition to the 20S 
proteasome, when using these agents to study proteasome function, it is best to show 
similar effects with other proteasome inhibitors (246). One such inhibitor, epoxomicin, 
was originally isolated from an Actinomycetes strain in 1992 (149). Epoxomicin was 
later discovered to be a provocative, irreversible and selective inhibitor of all 3 protease 
activities of the 20S proteasome (293). Importantly, epoxomicin does not act to inhibit 
other known cellular proteases, making it a suitable agent in proteasome studies (293). 
1.11 Proteasome inhibitors are used to induce parkinsonism in rodent models. 
 There is evidence to suggest a strong link between the UPS and nigral neuronal 
health. For instance, it has been shown that intranigral injections of lactacystin into rats 
causes protein inclusion formation, nigral and extranigral lesions as well as parkinsonian-
like behavioral impairments (289;451;300;318). Epoxomicin has similar effects on rats, 
even when introduced systemically (292). Similarly, mice display nigral specific 
degeneration following MG-132 exposure (415).  MG-132 is also selectively toxic to 
primary dopaminergic neurons in culture (415).  It is not clear why proteasome inhibitors 
are particularly toxic to nigral neurons. Determining the answer to this question will give 
insights into the role of proteasome impairments in the etiology of PD.   
1.12 Reactive oxygen species and oxidative stress 
 Oxidative stress is a term used herein to describe cellular damage which results 
from reactive oxygen species (ROS).  The term ROS can be used to describe any strong 
electrophile which is composed in part by oxygen (15). In animal cells, while there are 
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various sources of ROS, ROS can be generated by mitochondria during the process of 
aerobic respiration (101;221;408). During respiration, in order to efficiently generate 
energy in the form of ATP, electrochemical proton gradients must be established across 
inner mitochondrial membranes (6). To generate these gradients, electrons are transferred 
from an initial electron donor to electron acceptors in various mitochondrial enzyme 
complexes which are together referred to as the electron transport chain (ETC). The 
transfer of electrons along the ETC begins at mitochondrial complex I (or alternatively at 
complex II) and proceeds in series until it terminates at mitochondrial complex IV. 
Complex IV then catalyzes a series of reactions which transfers reactive ETC electrons to 
O2 and this eventually results in the formation of water.   Prior to reaching complex IV, 
however, electrons can leak prematurely during each successive transfer along the ETC.  
The monoelectronic transfer of one of these leaked electrons to an O2 molecule forms 
superoxide (-.O2).  
Superoxide can be generated by mitochondria as well as other enzymes and can 
serve as a progenitor for other ROS (408;435). For example, mitochondrial superoxide 
dismutase dismutates -.O2 to hydrogen peroxide (H2O2), which is another ROS. H2O2 can 
readily diffuse across mitochondrial membranes and out into the cell where it can affect 
various cellular processes (64;221). Alternatively, in the presence of iron (Fe 2+), H2O2 
can be converted into highly reactive hydroxyl (.OH) radicals which are thought to be 
very damaging (221;78). In addition to H2O2 and 
.OH radicals,  -.O2 is also a progenitor 
for another extremely reactive species, peroxynitrite (ONOO-), which is formed by the 
reaction of -.O2 with nitric oxide (NO-) (183;221). ONOO- can lead to the generation of 
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additional reactive radicals including .OH radicals, nitrogen dioxide (.NO2), and 
carbonate (CO3.-) (417). 
1.13 Oxidative stress and peroxiredoxins 
If left unchecked, ROS can indiscriminately attack cellular proteins, lipids, and 
nucleic acids resulting in variable degrees of oxidative damage (9;64;215;435). To 
protect against this, healthy cells utilize a variety of regulatory enzymes that act to inhibit 
undesirable redox reactions (9;408). However, such compensatory enzymes can become 
overwhelmed when oxidants are overabundant, and the consequences of this can be fatal 
(215;221).  For example, the family of antioxidant peroxidase enzymes, peroxiredoxins 
(Prxs), acts to decompose H2O2 and other intracellular peroxides by reducing them to less 
reactive forms (147). In mammals, the Prx enzyme family is composed of six different 
isoforms which confers tissue and subcellular expression specificities to each of its 
members (193;222).  It is known that Prxs utilize conserved cysteine residues that donate 
electrons to peroxide substrates, resulting in the formation of Prx cysteine sulfenic acid 
(147;472). Ideally, following oxidation to sulfenic acid forms, Prxs can be subsequently 
reduced either by neighboring Prx molecules or by other electron donors (147;472).This 
serves to recharge Prx enzymes for future reactions. However, when peroxide levels are 
overwhelming, oxidation of Prxs to cyteine sulfinic or sulfonic acid forms can occur and 
these modifications have been shown to disrupt future Prx enzyme activities (147;472).   
1.14 Oxidative stress in PD 
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In a study to assess for expression of Prx isoforms in neurodegenerative diseases, 
a specific increase of PrxVI was detected in frontal cortex regions in PD brains as 
compared to normal, Down’s syndrome, or Alzheimer’s disease brains (222). 
Interestingly, this increase was not detected for other Prx isoforms, suggesting a specific 
role for PrxVI in PD (222). Confirming this idea, Power et al. reported increased levels of 
PrxVI in PD brain homogenates in comparison to homogenates from normal brains (360). 
Histological analyses also revealed that PD brains exhibited increased PrxVI staining as 
compared to controls (360). These findings could be correlated to an overabundance of 
oxidation in PD.  
Several common pathological markers for oxidative stress are known to be 
associated with PD including DNA and protein oxidation, lipid peroxidation and 
alterations in antioxidant levels (9;215;278). For instance, depleted levels of the 
antioxidant glutathione (GSH) can often correlate with severe nigral degeneration in PD 
(9;278). GSH is a tripeptide that is used as a souce of reducing equivalents in cells (278). 
Interestingly, GSH serves to reactivate PrxVI following its conversion to cysteine 
sulfenic acid forms (272). However, when GSH levels are depleted, it is possible that 
PrxVI could become inactivated by excessive oxidation and it is not known whether this 
could result in subsequent aggregation of the inactivated PrxVI enzyme. It is interesting 
to note that PrxVI co-localized to nigral Lewy inclusions in PD brains (360). This is one 
of many findings that may implicate a role for oxidative stress in LB formation. 
1.15 Oxidation in dopaminergic neurons  
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It is thought that dopaminergic neurons may be particularly vulnerable to 
oxidative stress since oxidation is inherent in these cells even in healthy individuals. It is 
known that DA can spontaneously oxidize to form electrophilic quinones, which can lead 
to oxidative damage of proteins (140;267). DA itself can be metabolized by MAO to 
form H2O2 (64). Additionally, the DA metabolite, 3,4-dihydroxyphenylacetic acid 
(DOPAC) can also be converted to quinones which generate ROS (64).Thus, without 
proper regulation, DA itself could promote oxidative stress which could result in 
dopaminergic neuron toxicity. However, the heterogeneous pattern of dopaminergic 
neurodegeneration in PD is confounding since dopaminergic neurons in extranigral brain 
regions are less affected in disease (94;162).  
1.16 Oxidative stress in PD models 
Experimental paradigms designed to better understand the role for oxidative stress 
on nigral neurodegeneration often utilize oxidizing agents such as paraquat, 6-
hydroxydopamine or H2O2. Reduction-oxidation cycling of paraquat leads to the 
formation of -.O2 radicals (362;48;36). Paraquat can also oxidize Fe3+ to Fe2+ which can 
then subsequently react with H2O2 to form 
.OH radicals (362). Paraquat also acts to 
increase nitric oxide levels, eventually leading to the formation of reactive ONOO- 
(89;330). Traditionally, paraquat has been used as an herbicide since it efficiently 
disrupts photosynthesis by scavenging electrons (414). Of interest to PD studies, paraquat 
exposure in rodents  results in nigrostriatal dopamine neuron degeneration and this can 
result in parkinsonian motor impairments (49;231;286;331;430). However, it is not fully 
understood why nigrostriatal neurons are particularly vulnerable to paraquat insult (36).  
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The oxidizing agent, 6-hydroxydopamine (6-OHDA), can act to generate -.O2, 
H2O2, or 
.OH radicals (78). Due to its close structural similarity to the catecholamines 
DA and norepinephrine, 6-OHDA is selectively taken up into catecholaminergic neurons 
where it can exert its deleterious effects (397). For instance, when 6-OHDA is infused 
into striatal or nigral tissues in various animal models, it results in dopaminergic 
neurodegeneration and behavioral impairments that resemble those observed in PD.  Thus 
6-OHDA is a tool that is widely used to model PD; however, it is somewhat limited since 
proteinaceous Lewy-like inclusions are not formed as a consequence of its use (397).   
Yet an additional oxidizing agent, H2O2, can be used to induce oxidative stress in 
vitro and in PD cell culture studies. For example, in a recent study by Zhou and Lim, 
H2O2 treatment of mouse mesencephalic MN9D dopaminergic cells acted to inhibit 
proteasome activity. It also sensitized these cells to MG-132 and resulted in cell toxicity 
(495).   
These findings suggest that oxidative stress may be a causal stimulus for 
degeneration in PD.  Thus, it will be beneficial to determine what specific factors can act 
to mitigate oxidative insults that may occur with respect to the disease. 
 
1.17 MPTP parkinsonism syndrome and mitochondrial dysfunction in PD 
 In a report in 1979, Davis et al. described a 23 year old male who presented with 
acute parkinsonism following self-administration of home-made 4-propyloxy-4-phenyl-
N-methylpiperidine (MPPP). MPPP is an opiate which has similar effects as the 
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analgesic, Demerol (meperidine). While synthesizing MPPP, the patient also accidentally 
generated a toxic byproduct, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
which contaminated his illegal drug preparations. Following self administration of this 
preparation, the patient developed, “a state of muteness, severe rigidity, weakness, 
tremor, flat facial expression, and altered sensorium” (87).   In a later report, Langston et 
al. described four heroin addicts who also developed severe parkinsonism subsequent to 
only one week of illegal MPPP/MPTP contaminated drug use (237). Other similar reports 
later followed (20;236;473). The agent responsible for the onset of disease symptoms was 
concluded to be the MPTP contaminant (237).  
Interestingly, the MPTP-induced parkinsonism syndrome was remarkably similar 
to that of idiopathic PD. Further, post mortem histological analyses of four affected 
patients revealed dramatic degeneration of nerve cells within SNpc as well as associated 
gliosis and microglial activation (87;237;239). However, distinct from sporadic PD, no 
MPTP-induced neuronal effects were detected in other brain regions such as locus 
coeruleus, basal ganglia, hypothalamus, thalamus, cortex, cerebellum, or nucleus basalis 
of Meynert. Further, traditional Lewy bodies were not apparent (239).     
 Following these reports, aggressive studies were conducted to understand the 
mechanism by which MPTP induced cell toxicity. It was discovered that MPTP can 
rapidly diffuse across lipid bilayer membranes into the brain where it can be metabolized 
by the MAO type B (MAO-B) enzyme to form 1-methyl-4-phenylpyridnium (MPP+). 
This reaction is thought to occur in glia since appreciable levels of MAO-B enzyme 
localize particularly to glial cells and serotonergic neurons in the brain (466;467). The 
20 
 
MPP+ metabolite is the chemically active form of MPTP, but since it is not as lipophilic 
as the MPTP parent compound, to enter cells quickly, the MPP+ metabolite requires 
active transport. Incidentally, MPP+ is a substrate for the dopamine transporter (DAT) 
and can thereby selectively enter dopaminergic neurons.  Once inside the cell, MPP+ 
accumulates in mitochondria where it can bind at two distinct sites in mitochondrial 
complex I and thus disrupt complex I catalytic activity (363).  Inhibition of complex I can 
cause cellular dysfunction by the production of ROS (363;365;398). Discoveries of the 
inhibition of mitochondrial complex I by MPTP/MPP+ and its specific effects on 
dopaminergic neurons in humans provided the first line of evidence for the role of 
mitochondrial impairments in PD pathogenesis. 
 
1.18 Mitochondrial impairments in sporadic PD 
Shortly thereafter, it was discovered that PD patients exhibited reduced activity in 
mitochondrial complex I when compared to normal individuals (273;380) and that this 
deficiency was specifically observed in the substantia nigra brain region (273;381). In 
comparison to controls, some PD patients were also deficient in mitochondrial complex I 
subunits in striatal tissues (302). It was also reported that PD patients demonstrated 
reduced activities of mitochondrial complexes I, II, and IV in skeletal muscle (40), 
although this finding has not been supported by other studies (10;273). Additionally, 
reduced activity in mitochondrial complex I can be detected in platelets of PD patients 
(145;223;223), although this idea may also be controversial (273). Taken together, these 
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findings suggest that mitochondrial dysfunction is the link that connects MPTP-induced 
parkinsonism to sporadic PD. 
 
1.19 MPTP and parkinsonism animal models 
 Interestingly, the effects of MPTP on animal models also resemble features that 
are common to idiopathic PD. When administered to nonhuman primates or mice, 
MPTP/MPP+ selectively and irreversibly damages dopaminergic neurons of the SNpc and 
markedly reduces striatal dopamine content (48;50;111;238). Additionally, protein 
inclusion formation can result from chronic MPTP exposure in mouse models of PD, 
though these inclusions are not necessarily reminiscent of LBs (111;192;295). Exposure 
to MPTP can also lead to protein aggregation in primates (113;114;220).  
In addition, MPTP can be a valuable tool for in vitro studies. For example, 
Pavlovic et al. show that although mouse Neuro-2A (N2A) neuroblastoma cells do not 
express the plasma membrane DAT, MPP+ is able to enter these cells by passive 
diffusion, albeit relatively slowly (346). Following N2A cell entry, MPP+ can decrease 
mitochondrial membrane potential, increase ROS, activate caspases, and induce apoptosis 
(346). Thus MPTP is widely used in studies to model mitochondrial dysfunction.   
1.20 Rotenone models of PD  
Another commonly used mitochondrial inhibitor is rotenone. For centuries prior 
to 1924, rotenone had been harvested from indigenous plants in South American 
countries and was used by natives as a fish poison (225). Rotenone was later discovered 
22 
 
to act as a potent insecticide and became widely used in the United States for this purpose 
(225). Investigations into the physiological mechanism of the rotenone toxin determined 
that it can tightly bind to mitochondrial complex I and thereby block electron transfer 
along the ETC (168;258;259;322).  Rotenone is lipophilic and thus it can ubiquitously 
and indiscriminately enter brain cells to exert its inhibitory effects on mitochondria (240).  
Rotenone is actually proven to be a more potent complex I inhibitor than MPP+ 
(363) and thus it is often used to induce mitochondrial stress in various experimental 
paradigms. Interestingly, while chronic systemic rotenone exposure in rats depletes 
complex I enzyme levels throughout the entire brain, this can result in specific 
degeneration in nigrostriatal tissues as well as intracellular inclusion formation and 
associated parkinsonian behavioral traits (38;54;390). While rotenone may preferentially 
affect nigral dopaminergic neurons for degeneration, other studies have shown that 
neuronal loss can also be detected in rat locus coeruleus, cerebellum and mildly in frontal 
cortex tissues (165). It is thought that the particular toxicity of rotenone on nigrostriatal 
dopaminergic neurons may be due to the increased levels of oxidative stress that arise 
secondary to mitochondrial complex I inhibition (429). Supporting this idea, a recent 
study by Pan-Montojo et al. showed that chronic intragastric rotenone administration in 
mice resulted in decreased motor activity and intracellular protein inclusion formation in 
spinal cord, brainstem, and substantia nigra (336). It also resulted in nigral dopaminergic 
neurodegeneration. This was likely due to secondary effects of rotenone exposure in 
these animals since rotenone was not detected in systemic blood or in the central nervous 
system (336). Other studies also confirm that rotenone has a toxic effect on mouse 
nigrostriatal tissues following chronic oral administration (179;180). Together, these 
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findings suggest that nigral dopaminergic neurons are vulnerable to mitochondrial 
complex I inhibitors and this may further implicate a role for mitochondrial dysfunction 
in PD pathogenesis.   Nevertheless, more work must be done to determine what factors 
may act to modulate this. 
1.21 Genetic causes of PD 
 Discoveries of inherited forms of PD have increased awareness about 
physiological mechanisms that may be implicated in the etiology of the disease. To date, 
at least 14 chromosomal loci and 9 genes have been identified which cause monogenic 
forms of PD (Table 1-2) (152;250). Although familial forms of the disease only comprise 
~ 5% of all PD cases, studies of the gene products encoded by PD-linked genes have 
given insights into the factors that may be relevant to understanding sporadic PD 
(152;250). The roles of the PD-linked genes PARK1/4 (SNCA), PARK2 (parkin), and 
PARK6 (DJ-1) will be the subject of the following sections. 
Table 1-2 
Locus Chromosome Year of 
discovery 
Gene Inheritance 
PARK1/PARK4 4q21-q23 1997 (357) SNCA/α-synuclein  Dominant 
PARK2 6q25.2-27 1997 (284) parkin (208) Recessive 
PARK3 2p13 1998 (125) Unidentified Dominant 
PARK5 4p13 1998(249) UCHL1 Dominant 
PARK6 1p36.12 2001 (442) PINK1 (441) Recessive 
PARK7 1p36 2001(446) DJ-1 (47) Recessive 
PARK8 12q12 2002 (118) LRRK2 (333;497) Dominant 
PARK9 1p36 2005 (468) ATP13A2 (364) Recessive 
PARK10 1p 2002 (161) Unidentified Unknown 
PARK11 2p37.1 2008 (241) GIGYF2  Unknown 
PARK12 Xq21-q25 2002 (337) Unidentified X-linked 
PARK13 2p13.1 2005 (412) Omi/HtrA Dominant 
PARK14 22q13.1 2009 (332) PLA2G6 Recessive 
PARK15 22q11.2 2009 (96) FBXO7 Recessive 
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1.22 PARK1/4 (SNCA)/α-syn 
 In 1990, Golbe and colleagues released reports about an endemic of PD within a 
large family from Contursi village in southern Italy (134). The affected individuals 
developed early-onset disease at ~47 years of age and had relatively rapid courses of less 
than 10 years from disease onset to death. At the time of the report, it was concluded that 
a single gene was causal of this form of PD, though no putative gene candidates had yet 
been identified (134). Years later, a genome wide scan in the affected Italian family 
identified loci at chromosome 4q21-q23 that linked to the disease phenotype (357). SNCA 
or alternatively PARK1/4 was among many genes that mapped to this particular 
chromosomal region. Further sequence analysis of the SNCA gene in the Contursi kindred 
revealed a single nucleotide (G209A) missense mutation which resulted in the A53T α-
synuclein (α-syn) amino acid substitution (357). The pathogenic A53T α-syn mutation 
showed an autosomal dominant pattern of inheritance and this finding provided the first 
solid evidence for a monogenic cause of PD. 
 α-syn immediately became a hot topic of discussion in the field of PD research. 
Human α-syn had been previously cloned in 1993 by Ueda and colleagues as an 
“unrecognized component of amyloid in Alzheimer disease” (438). In the initial report by 
Ueda and colleagues, α-syn was detected in diffuse, primitive and mature amyloid 
plaques but was absent in neurofilbrillay tangles. Thus it was called non-Aβ component 
of AD amyloid (NACP) (438). The identified NACP species was later coined “α-
synuclein” by Jakes and colleagues (188) based on its close sequence homology to 
previously described synuclein proteins (277). 
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 α-Syn is a small protein of 140 amino acid residues which is predominantly 
expressed in the brain and which localizes to presynaptic nerve terminals (187;188;277). 
It is largely a hydrophilic protein with the exception of a central hydrophobic core which 
is designated as the “NAC” region (187). The amino terminus of α-syn contains repeat 
motifs consisting of the residues, K-T-K-E-G-V (277), and the carboxyl terminus is 
acidic due to prevalent Glu residues (187).  
In the same year following the report of the Contursi kindred, it was discovered 
that α-syn protein localized to LBs in idiopathic PD brains (405). Full-length, partially 
truncated and insoluble forms of α-syn were detected in these pathologies and it was 
eventually concluded that, “α-syn is the building block of LBs” (18;119;182;396).  These 
findings were the first to implicate a fundamental role for α-syn in the etiology of both 
inherited and sporadic forms of PD.  
To date, several mutations in the SNCA gene are known to cause autosomal 
dominant PD. In addition to the initial report of the Italian Contursi kindred (357), the 
A53T α-syn mutation has been identified in many PD patients of European descent 
(17;276;338;406). In addition, a missense mutation resulting in the A30P amino acid 
substitution in α-syn was shown to be causal of PD in a German family (224).  In a 
Spanish kindred, severe parkinsonism phenotypes are also associated with another α-syn 
amino acid substitution, E46K (488). Furthermore, short chromosomal duplications and 
triplications that include the SNCA gene are associated with clinical phenotypes that 
resemble idiopathic PD (61;107;176;400). Taken together, these findings implicate α-syn 
protein as an important player in parkinsonism-associated diseases. 
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Although the physiological role for α-syn has yet to be identified, years of 
extensive analyses point towards several putative functions.  Some studies suggest that α-
syn may normally behave in a protective capacity (76;368). For example, α-syn may act 
to regulate synaptic vesicle integrity since it can co-localize with the vesicle membrane 
protein, synaptophysin (187), and is also known to be in close proximity or in association 
with synaptic vesicles (187;277). α-Syn also exhibits chaperone-like activity 
(5;205;206;343;403) and may even act as an auxiliary molecular chaperone for synaptic 
vesicle proteins (59). Additionally, α-syn may act to protect against dopamine induced 
oxidative stress. For instance, α-syn may down-regulate dopamine synthesis by 
modulating the tyrosine hydroxylase (TH) or aromatic L-amino acid decarboxylase 
enzymes (7;348;351;427;70). 
  Though α-syn may exhibit protective features under certain experimental 
conditions, it is thought that α-syn mutations contribute to PD by a gain-of-function. For 
instance, studies suggest that α-syn may induce and/or enhance oxidative stress which 
acts to promote cell toxicity (27;95;169;191;197;339;340;413). It is also known that α-
syn can polymerize into filaments and aggregate into amyloidogenic inclusions, and that 
this ability is enhanced by A53T and E46K mutations (464). Further, α-syn  inclusion 
formation may be lethal in vivo due to associated impairments of the proteasome 
(34;410;425;432). Alternatively, α-syn may exert its detrimental effects by inducing 
mitochondrial impairments (95;103;169;256;261;264;279;329;339;340;388;425;447;448;474).  
An array of α-syn animal models has been developed for the purpose of 
understanding the physiological role of α-syn in vivo. α-Syn null mice were generated in 
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order to determine the effect of α-syn loss-of-function (1). However, although subtle 
alterations in DA neurotransmission were reported, α-syn null mice exhibited normal life 
spans, did not display nigrostriatal deficits, and appeared to be normal as it related to 
synaptic nerve terminal integrity (1). Alternatively, gain-of-function, transgenic mouse 
models expressing human α-syn protein have yielded more provocative findings. In brain 
tissues of transgenic mice expressing wild-type (WT) human α-syn protein, α-syn was 
phosphorylated and exhibited reduced biochemical extractability (315). This was 
interesting since both biochemical features are common to human LB diseases 
(11;117;375;463). Transgenic mice expressing pathogenic mutant A30P human α-syn 
developed phosphorylated, aggregated, proteinase K-resistant LB-like deposits of α-syn 
in various regions of the central nervous system (CNS) (199;315) and this was associated 
with the onset of fatal motor impairments in an age-dependent manner (315). Similarly, 
when expressed in mice, pathogenic mutant A53T human α-syn aggregated into Lewy-
like inclusions that could be detected throughout the neuroaxis (131;247;444). This 
resulted in marked axonal degeneration (131;279;444) and the induction of progressive, 
severe motor abnormalities (131;444;247). These mouse studies suggest that the onset of 
disease phenotypes directly correlate to the propensity for α-syn to aggregate in vivo; 
however it remains to be determined what cellular mechanisms may act to modulate this, 
especially as it relates to how other gene products may be implicated.  Identifying such 
factors would be insightful.  
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1.23 PARK 2 (Parkin) 
 Evidence of autosomal recessive types of juvenile parkinsonism (AR-JP) were 
first reported by Yamamura and colleagues in 1973 (481).  AR-JP was described as an 
insidious disease with juvenile to early-onset (before 40 years of age) (481;184;420) that 
was clinically characterized by progressive typical parkinsonism, superb levodopa 
responsiveness, and a slow and protracted disease course (481). Neuropathological 
analyses of AR-JP cases showed highly selective degeneration of neurons in SNpc but 
without evidence of LB formation. Additionally, degeneration could be detected to a 
lesser degree in the locus coeruleus. Gliosis was also prominent in the affected brain 
regions (420). In 1997, Matsumine and colleagues identified a gene for AR-JP which 
mapped to chromosome 6q25.2-27 (284). This gene, which was designated as PARK2 
(285), was later cloned by Kitada et al. and was discovered to encode a protein product 
that was called “Parkin” (208).  
 The parkin protein is 465 amino acids in length (208). It is expressed in many 
tissues with highest expression in skeletal muscle, heart, testis and brain (208). In 
general, parkin can be detected throughout the brain (84;226) and can be localized to 
neurons, astrocytes, and microglia (172;391;411). It is most abundant in cell soma 
(84;411) but can also localize to processes and presynaptic terminals (84;172;411).   
Based on sequence homology studies, it was determined that parkin shows 
similarity to ubiquitin protein at the N-terminus (208). It was also originally thought that 
parkin had one Really Interesting New Gene (RING) finger motif at the C-terminus 
(208), but it was later determined that parkin actually contains two C-terminal RING 
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finger domains separated by an In-Between-Ring (IBR) finger domain (308). Many 
proteins with this RING1-IBR-RING2 signature are found in nature (445), and it was 
known that some RING finger proteins could act as E3 ligases in the UPS (194). 
Together, this knowledge provoked several studies which aimed to determine whether 
parkin could act as an E3 ligase. Subsequently, it was determined that parkin could 
interact with the E2 enzymes UbcH7, UbcH8, Ubc7, and Uev1/UbcH13 
(100;178;283;325;392;490) and that this association could result in parkin 
autoubiquitination (283;490) as well as polyubiquitylation of unidentified cellular protein 
substrates (178;392). Thus, it was concluded that parkin can function as an E3 ligase; 
however, the physiological relevance for this function has yet to be fully established. 
The parkin gene consists of 12 exons and large intron regions spanning a total of 
1.38 Mega bases in size, making it one of the largest known genes (16). Genes of large 
size, such as parkin, may be particularly susceptible to mutations.  To date, it is known 
that a variety of parkin exonic deletion, duplication, triplication, splice site, missense, and 
nonsense mutations result in juvenile to early-onset PD (26;155;270;282;359;416). In 
fact, parkin mutations are the leading cause of recessive juvenile PD (478). Thus, there 
has been much focus on understanding the role of parkin protein, especially as it relates 
to how parkin mutations may be causal of PD. 
 It is thought that parkin mutations cause disease by a loss-of-function. Supporting 
this idea, it has been reported that many pathogenic parkin missense mutants show 
reduced or impaired E3 ligase activities when analyzed in vitro (72;283;392;407;490). It 
is also known that several pathogenic parkin mutants have a tendency to form 
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intracellular aggregates when expressed in cultured cells (81;143;148;407;460) and that 
this may be due to improper folding of mutant protein (383). Based on these findings, one 
would expect for parkin-associated PD patients to exhibit an overabundance of parkin-
positive pathologies in their brains; however such an observation is very uncommon. In 
fact, to the contrary, most parkin-associated PD patients seemingly resist inclusion 
formation since neither LBs nor other pathological inclusions are typically detected 
during postmortem analyses (4). However, it should be mentioned that α-syn and/or 
parkin positive pathologies have been observed in the brains of a few patients with parkin 
mutations (106;361;378;384).  
The absence of Lewy inclusions in parkin-associated PD brains led some to 
speculate that functional parkin protein must be required for LB formation (72;384). In 
agreement with this notion, parkin has been shown in some studies to localize to LBs in 
sporadic and inherited forms of PD (22;384;391) and may act to ubiquitinate O-
glycosylated forms of α-syn as a substrate in vivo (393). Additionally, parkin may 
ubiquitinate α-syn positive LB-like inclusions in cultured cells (72). Further, the α-syn 
interacting protein, synphilin-1 (104;317;202), was identified as a putative parkin 
substrate by Chung and colleagues in 2001 (72). This is interesting since synphilin-1 can 
localize to LBs in sporadic PD brains (458;312;22) and can promote the formation of 
cytosolic α-syn-positive inclusions in cultured cells (104;72). Though the physiological 
role for synphilin-1 is not clear, it is known to be polyubiquitylated in the presence of 
parkin and to co-immunoprecipitate with parkin in vivo (72). Additionally, although it is 
thought that parkin may facilitate polyubiquitylation of synphilin via Lys-63-linked 
chains and that this may regulate synphilin in a proteasome-independent manner, it is 
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known that parkin can mediate proteasome degradation of synphilin under certain 
experimental conditions (257). 
It should also be mentioned that to date, a growing number of other putative 
parkin substrates has been identified. Among them are included the synaptic vesicle 
associated protein, CDCrel-1 (490); the parkin-associated endothelin receptor-like receptor, 
Pael-R (177); cytoskeletal proteins α/β-Tubulin (370); the  synaptic vesicle protein, 
synaptotagmin XI (173); the aminoacyl-tRNA synthetase cofactor, p38/JTV-1 (83;217); 
the cell division control-related protein, SEPT5_v2/CDCrel-2 (68); the cell cycle protein, 
cyclin E (409); and the p38/JTV-interacting protein, far upstream element-binding 
protein 1 (FBP1; 216). Determining the authenticity of these proposed substrates remains 
to be confirmed in vivo since studies in parkin deficient animals and AR-JP brains have 
been somewhat limited. More work must be done to determine the effects of parkin on 
putative substrates especially as it relates to how these effects may contribute to PD 
pathogenesis. 
 Studies suggest that parkin acts to protect against a multiplicity of toxic insults. It 
is known that parkin actively decreases ROS formation (190) and can also mitigate the 
effects of harmful protein aggregation (311;262). When overexpressed in cultured cells, 
parkin can protect against noxious agents such as ONOO-, H2O2, MPP+, DA, 6-OHDA, 
and MG-132 (174;175;440;190;71;151). It can also assuage the deleterious effects 
following MPTP or 6-OHDA exposure in vivo (345;450). It is thought that parkin may 
prevent cell death by activating protective signaling pathways (156;386) and also by 
down-regulating classical apoptotic signaling molecules (85;151;190;56). Additionally, 
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parkin may have a specific role at protecting cells by maintaining mitochondrial 
homeostasis (373;314;126;230;229;75;342;485;358;93;341;268;141;35). 
Parkin deficient animals are known to be particularly vulnerable to certain types 
of stressors and this is likely due to a loss of protective parkin function. For example, 
transgenic parkin null worms and mice exhibit selective vulnerability to rotenone 
exposure (447;55). Parkin deficient Drosophila are highly sensitive to paraquat (353). 
Systemic exposure of aged parkin deficient mice to the inflammatory stimulus, 
lipopolysaccharide (LPS), can result in selective nigral dopaminergic neurodegeneration 
(116). Taken together, this evidence supports the notion that loss of parkin function can 
have detrimental consequences within certain confines. However, in the absence of 
stressful stimuli, determining the in vivo effects of parkin loss-of-function has proven to 
be difficult, especially in mouse models. Parkin deficient mice appear to be 
phenotypically normal as it relates to lifespan, body weight, brain size, brain morphology, 
and nigrostriatal neuronal integrity (135;186;211;350;379;496). Some labs report mild 
motor or learning deficits in parkin null mice (135;186;350;454;496); however these 
observations are not confirmed in other studies (379). Parkin deficient mice also show 
slight alterations in nigrostriatal dopamine neurotransmission and/or turnover (186;496) 
(135;379), although this finding is inconsistent with other reports (116;349;350). 
Interestingly, von Coelln and colleagues observed a loss of locus coeruleus neurons in 
parkin null mice (454), but this finding was not reported by other groups. Additionally, 
some studies suggest that parkin deficient animals suffer from mitochondrial 
impairments, oxidative stress, and glial dysfunction (335;372;401) while others show that 
parkin null mice are resilient against stressors like MPTP and 6-OHDA (349;431), and 
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the latter findings seem contradictory to the former. Thus, the reported inconsistencies 
regarding the effects of parkin loss-of-function in mice make it very difficult to conclude 
what physiological role parkin may play in PD pathogenesis.   
 
1.24 PARK7(DJ-1) 
In 2001, a report was published by van Duijn and colleagues about 4 individuals 
in a Dutch family who presented with early-onset parkinsonism (446). The affected 
individuals developed symptoms prior to 40 years of age, were responsive to levodopa 
and dopamine agonist therapies, showed severe abnormalities consistent with 
nigrostriatal dopaminergic system dysfunction, and had slow disease progression (446). 
The affected patients did not harbor mutations in the other known PD-linked genes, and a 
novel locus at chromosome 1p36 was identified and linked to the disease phenotype with 
an autosomal recessive pattern of inheritance (446). The new locus was called PARK7 
(446). In later studies, Bonifati et al. sequenced the candidate genes at the PARK7 locus 
and identified an exonic deletion in the affected Dutch family which mapped to the DJ-
1gene (46). Interestingly, in the same report, Bonifati and colleagues also discovered a 
homozygous missense mutation in the DJ-1 gene that was causal of early-onset PD in an 
Italian family (46). Together, these discoveries sparked new interest in DJ-1 as a novel 
PD-linked gene.  
To date, a variety of pathogenic DJ-1 mutations have been reported (Table 1-3) 
and are thought to cause disease by a loss of DJ-1 function (46). While most affected 
34 
 
patients clinically exhibit the cardinal symptoms of PD, autopsy tissues are not yet 
available to determine the neuropathological features associated with causative DJ-1 
mutations (200). These mutations are rare (433;66;214), perhaps only contributing to 1-
2% of all early-onset PD cases (154).   
Table 1-3 
Mutation Inheritance Average Age of 
disease onset 
Ethnic group 
affected 
Year reported 
(Reference) 
L166P Homozygous 30 Italian 2003(45;47) 
M26I Homozygous 39 Ashkenazi Jesish 2003 (2) 
E64D Homozygous 34 Turkish 2004 (157) 
E163K Homozygous 31.6 Italian 2005 (14) 
L10P Homozygous 18.5 Chinese 2008 (144) 
P158DEL Homozygous 33.8 Dutch 2009 (270) 
14 kb deletion Homozygous 32.6 Dutch 2003 (47;446) 
R98Q Heterozygous < 50 European descent 2003 (146;263) 
A104T Heterozygous 35 Latino 2003(146) 
c.253-322  deletion Heterozygous 45 Serbian 2004 (98) 
A179T Heterozygous 47 Dutch 2009 (270) 
Exon1-5 duplication Heterozygous 46 Dutch 2009 (270) 
c.C56DEL 
c.G57A 
c. intron6, G1C 
Compound 
Heterozygous 
24 Latino 2003 (146) 
D149A 
G78G 
Compound 
Heterozygous 
36 Afro-Caribbean 2003(2) 
 
 The DJ-1 gene is comprised of 7 exons and 8 introns that span 16-24 kilobases, 
and exons 2-6 encode DJ-1 protein (419). DJ-1 had originally been discovered in 1997 by 
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Nagakubo et al. in a yeast two-hybrid study to identify proteins that interacted with the 
known cancer gene, c-myc (313). In this study, the nucleotide and amino acid sequences 
determined for one of the isolated clones was designated as “DJ-1”.  DJ-1 was later found 
to be a false-positive clone that actually did not interact with c-myc directly. 
Nevertheless, Nagakubo and colleagues knew that DJ-1 was a novel protein and reported 
that it could function as an oncogene (313). Later studies to clarify the role for DJ-1 
identified it as a protective protein component in rat sperm (457), a modulator for 
androgen-receptor mediated transcription (421), as well as a regulatory component of 
RNA-binding protein complexes (163).  
 It is known that DJ-1 is a 189 amino acid protein (313) that is ubiquitously 
expressed in the brain and peripheral tissues (47;228;489). It can be detected in neurons 
(309;476;218;371;316;324), astrocytes (21;218;324;316), reactive astrocytes (309;316), 
and microglia (181). It exhibits a diffuse cellular localization pattern (313;163) and can 
be redistributed to cell nuclei and mitochondria during stressful conditions 
(489;53;253;196), though neither nuclear nor mitochondrial localization signals have yet 
been identified for the protein.  
Crystallization studies reveal that DJ-1 is composed of eight α-helices and 11 β-
strands that are arranged into a helix-strand-helix sandwich (170).  These structural 
features are common to the ThiJ/PfpI superfamily of enzyme proteins (167;170;469).  
Like other members of the ThiJ/PfpI superfamily, DJ-1 conserves a catalytic cysteine 
residue, Cys-106 (469); however, DJ-1 lacks the other coordinating residues required to 
form a catalytic active site, and this distinguishes DJ-1 from its structural homologues 
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(167;170;469).  Further, it is known that DJ-1 exists as an obligate homodimer (469) 
(170) which may be able to associate into filaments (57).  
Extensive analyses reveal that DJ-1 exhibits a diversity of protective functions. 
For instance, DJ-1 acts as a molecular chaperone in vitro (389;494). It has also been 
shown to protect against cell toxicity that is induced by proteasome inhibition and/or 
toxic protein aggregation (260;479;487;493). DJ-1 may also act to maintain 
mitochondrial homeostasis (43;196) since it can protect against mitochondrial toxins such 
as MPTP/MPP+ and rotenone (204;8;418;53;253;43;345;310) and has specifically been 
shown to bind and maintain the activity of mitochondrial complex I (153). Several studies 
also support a role for DJ-1 in regulating the transcription of specific mRNA targets 
(163;395;421;479;491;443) such as pro-survival genes (43).  DJ-1 can also protect 
against ischemia-induced insults (482) and inflammatory stimuli (456). 
  Following the discovery of oxidized forms of DJ-1 in human umbilical vein 
endothelial cells, it was proposed that DJ-1 may play a role in maintaining cell redox 
homeostasis (299). It is known that oxidative stress can upregulate the DJ-1 promoter 
(203). This may explain why DJ-1 protein is often increased both in vitro and in vivo 
following oxidative insult (251-253;294;418;185).  DJ-1 protein levels are also elevated 
and/or oxidized in various human diseases (21;29;65;251;374;428). 
 The oxidation state of DJ-1 is thought to be regulated by a major oxidation site at 
amino acid residue Cys-106 (13;43;207;327;455;494). Oxidation of Cys-106 to cysteine 
sulfinic acid is thought to facilitate the protective functions of DJ-1 protein  (53); 
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however, further oxidation of DJ-1 to cysteine sulfonic acid functionally inactivates the 
protein (301;494).  
DJ-1 is known to protect against a variety of toxic oxidative agents such as DA 
(252), 6-OHDA (181;418;253;27), H2O2 (204;418;479;253;482;27;196) and paraquat 
(137). It is possible that DJ-1 may not directly quench ROS since it has been shown in 
many studies to mediate cell viability by modulating other protein targets. For instance, 
DJ-1 may exert its protection by upregulating chaperones such as Hsp70 (27;260;255) 
(493) or by modulating signaling proteins such as extracellular related kinases 1 and 2 
(ERK1 and 2) (252;142), apoptosis signal-regulating kinase 1 (ASK1) (198;455), 
phosphatidylinositol 3-kinase (Akt) (8;129;484), homeodomain interacting protein kinase 
(HIPK1) (385), or c-Jun N-terminal Kinase (JNK1) (303;498). Alternatively, DJ-1 may 
ameliorate harmful oxidation by acting to upregulate other known antioxidant proteins 
(13;77;271;492). On account of these factors, it is reasonable to understand why the loss 
of DJ-1 function may have detrimental consequences in vivo. 
Surprisingly, genetically altered DJ-1 null mice do not exhibit phenotypes that 
model disease. Ablation of DJ-1 in mice does not result in nigrostriatal degeneration or 
obvious neuropathology (13;60;63;136;211;274). However, subtle alterations have been 
detected in some animals. For example, in a study by Andres-Mateos et al., DJ-1 
deficient mice exhibited reduced brain mitochondrial peroxidase enzyme activities and 
this resulted in increased mitochondrial H2O2 production (13).  Chandran and colleagues 
detected abnormal gait, decreased grip strength, and hypokinesia in DJ-1 null animals but 
this was not due to any apparent nigrostriatal abnormalities (60).  Some studies suggest 
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that DJ-1 may regulate DA neurotransmission since the loss of DJ-1 in mice results in 
subtle defects. For instance, age-dependent motor abnormalities, increased stimulated DA 
release, and higher striatal DA levels resulted from the lack of DJ-1 in one mouse model 
(63). Additionally, nigral neurons in DJ-1 deficient mice were less responsive to D2 
autoreceptor stimulation (136). DJ-1 null mice also demonstrated increased levels of 
striatal cell surface DAT protein (274).   
Although DJ-1 deficient mice do not display overt parkinsonian phenotypes, 
several studies suggest that they may be particularly vulnerable to stressful stimuli. 
Paraquat induces behavioral and biochemical deficits in DJ-1 deficient animals that are 
not observed in WT mice (483). Rotenone alters the firing pattern of nigral neurons in 
mice lacking DJ-1 but does not affect WT mice to the same extent (354). DJ-1 null 
animals are also hypersensitized to the MPTP neurotoxin (204), although this is thought 
to be due to enhanced DAT-mediated uptake (274). Future studies to assess for the 
effects of stress on DJ-1 deficient mice may give insights into the biochemical and 
cellular functions of DJ-1 protein. 
Alternatively, approaches to investigate the effects of pathogenic DJ-1 mutations 
on protein function may also prove to be beneficial in understanding the role of DJ-1 in 
the etiology of PD.  
1.25 Hypotheses and Organizational Overview 
The focus of this thesis was to analyze the biochemical and cellular properties of 
mutant DJ-1, α-syn, and parkin proteins using cultured cell and mouse models.  
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Little is known about the effects of recently reported pathogenic DJ-1 mutations, 
E163K, L10P, or P158DEL, on protein function. Since it is thought that DJ-1 mutations 
cause disease by a loss of function, it was hypothesized that mutants would exhibit 
aberrant biochemical properties in comparison to WT DJ-1 protein and would also cause 
other secondary effects related to such functional deficits. In chapter two, it is shown that 
pathogenic E163K mutant DJ-1 is similar to WT DJ-1 protein when assessed for protein 
stability, solubility, and dimerization. However, E163K mutant DJ-1 renders stably 
expressing mouse Neuro-2A neuroblastoma cells to be selectively vulnerable to oxidative 
insults. Additionally, following oxidative stress, E163K mutant DJ-1 shows aberrant 
subcellular localization in comparison to WT protein. Interestingly, since both WT and 
E163K mutant DJ-1 proteins are protective against proteasomal and mitochondrial 
stressors, it suggests that the E163K DJ-1 mutation specifically abolishes the antioxidant 
properties of the protein and may implicate a role for DJ-1 in multiple biochemical 
pathways.   
In chapter three, the pathogenic DJ-1 mutants, L10P, P158DEL and L166P, are 
characterized biochemically in comparison to WT protein. It is discovered that all 3 
pathogenic DJ-1 mutants exhibit reduced protein stabilities. Additionally, all mutants can 
be partially stabilized in the presence of proteasome inhibitors, though the effects of this 
on L10P are most provocative. Further analyses reveal that unlike L166P DJ-1, the L10P 
and P158DEL DJ-1 mutants can form dimers. Interestingly however, all of the 
pathogenic DJ-1 mutants show aberrant folding patterns in comparison to WT protein. 
Further, under normal cellular conditions, P158DEL mutant DJ-1 demonstrates reduced 
solubility in comparison to all other DJ-1 variants. Insoluble pools of L10P and L166P 
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are also accumulated in response in proteasome inhibition. Immunocytochemistry 
analyses reveal that L10P and P158DEL mutant proteins can associate into inclusions 
under normal culturing conditions. Further, proteasome inhibition results in the formation 
of atypical intracellular protein inclusions in cells expressing L10P, L166P, or P158DEL 
DJ-1 while these inclusions are not detected in cells expressing WT DJ-1 under the same 
conditions.  Together, these findings suggest that the aberrant folding patterns adopted by 
L10P, P158DEL and L166P DJ-1 protein mutants result in rapid degradation of the 
respective protein variants and that this could thereby have deleterious effects on 
downstream cellular targets.   
It has been previously shown that transgenic mice expressing human pathogenic 
mutant A53T α-syn (M83 mice) develop an age-dependent severe motor impairment 
phenotype associated with the formation of cytoplasmic α-syn inclusions throughout the 
neuroaxis (131).  While reports by other labs suggest that DJ-1can chaperone misfolded 
α-syn in vitro (389;494), it is not known whether DJ-1 regulates α-syn in vivo. Thus it is 
of interest to better understand the physiological role of DJ-1 especially as it relates to its 
effects on α-syn aggregation. Chapter four describes the generation of homozygous Ala-
53-Thr α-syn transgenic mice on a DJ-1 null background (M83-DJnull mice). If DJ-1 
normally acts to modulate α-syn in vivo, it is hypothesized that M83-DJnull mice should 
exhibit an exacerbated phenotype in comparison to M83 mice.  M83-DJnull mice were 
analyzed and compared to M83 mice as it relates to survival rate, distribution of α-syn 
pathologies, nigrostriatal integrity, biochemical properties of the α-syn protein, and the 
secondary effects of expressing mutant α-syn. These analyses revealed that there were no 
significant differences between mouse genotypes, suggesting that DJ-1 may not directly 
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modulate α-syn, nor protect against the harmful effects that result from α-syn aggregation 
in vivo.    
There are few studies to assess for the effects of pathogenic parkin mutations in 
vivo. Analyses of genetically altered parkin deficient mice demonstrate that these animals 
do not recapitulate the key features of PD. Studies using more suitable approaches to 
model parkin deficiency in vivo would be very useful. In chapter five, we describe the 
discovery of a novel homologous endogenous mutation in the C3H mouse strain which 
results in the E398Q parkin amino acid substitution. Characterization of E398Q parkin in 
cultured cells reveals that it may be functionally inactive in comparison to WT parkin 
protein as the mutant shows aberrant biochemical properties. Mutant parkin also exhibits 
reduced interactions with UbcH7 and UbcH8 E2 enzymes. Additionally, C3H mice 
display age-dependent alterations in the steady-state levels of synphilin-1. Together, these 
findings suggest that C3H (E398Q) parkin may be functionally inactive and that C3H 
mice may serve as natural parkin loss-of-function models, similar to PD patients 
harboring missense parkin mutations.  
In chapter six, I conclude by discussing the implications of these findings in the 
realm of the field. Additionally, I propose outstanding questions and future directions for 
these studies. 
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2.1 Abstract 
 Recent discoveries of genetic mutations linked to familial forms of PD, including 
mutations in DJ-1, have provided insights into the pathogenesis of sporadic PD. 
Recently, a novel homozygous missense mutation in the gene encoding human DJ-1 
protein resulting in the E163K amino acid substitution has been reported. This mutation 
is associated with early-onset and clinical presentations that include parkinsonism, 
cognitive decline, and amyotrophic lateral sclerosis. The specific effect of this mutation 
on the function of DJ-1 protein as it relates to disease pathogenesis is currently unknown. 
Herein we show that the E163K pathogenic mutant retains similar properties to WT DJ-1 
protein as it relates to protein stability, solubility, and dimerization. However, we show 
that the E163K mutant loses the ability to protect against oxidative stress while 
demonstrating a reduced redistribution towards mitochondria, but retains the ability to 
mitigate toxicity due to mitochondrial stress and proteasomal impairment. These findings 
suggest that DJ-1 influences several neuroprotective pathways and that the E163K 
mutation impairs the mechanism that is more specific to oxidative stress.   
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2.2  Introduction 
   Although the majority of PD cases are idiopathic, a growing number of mutations 
have been found to be associated with familial forms of the disease (110;213;305). Mutations 
in genes at multiple loci, designated PARK1 through PARK 13, result in parkinsonian 
phenotypes with distinct features (32;80;213). Various mutations in PARK7 (DJ-1), including 
truncation, missense, splice-site, and large deletions have been discovered (2;47). Mutations in 
DJ-1 cause autosomal recessive PD with early to mid age of onset, and these may contribute to 
1-2% of early onset PD cases (154;263).  
DJ-1 encodes a 189 amino acid protein which is a member of the ThiJ/PfPI 
superfamily based on its structure (170;248;313;469). It is expressed in both neurons and 
astrocytes in the brain (19;21;218;325;387), but it is also expressed in many other organs 
(121;170;248;324;324;469;489). A number of studies have shown that DJ-1 can have 
protective functions against oxidative, proteasomal and mitochondrial stresses 
(53;181;204;281;418;483;487;493).  
Interestingly, a novel missense E163K DJ-1 mutation was reported for a family in 
southern Italy which results in a severe phenotype as early as 24 years. Subjects 
homozygous for this E163K mutation develop symptoms that include parkinsonism, 
dementia, and amyotrophic lateral sclerosis (14). Characteristics include weakness and 
muscle atrophy in the upper and lower extremities, speech deficits, cognitive impairment, 
and parkinsonism.  Because of the early onset and more extensive phenotype associated 
with this mutation, its analysis and an understanding of how it can lead to disease may 
provide new insights into the function of DJ-1.  In this study, we explore the properties of 
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human E163K mutant DJ-1 protein as it relates to its solubility, dimerization, stability, 
subcellular localization, and effects on cell viability as compared to WT protein.   
2.3  Results 
 Neuro-2A (N2A) mouse neuroblastoma cell lines (Figure 2-1a) and Chinese 
Hamster Ovary (CHO) cell lines (data not shown) stably expressing WT and E163K DJ-1 
were generated as described in “Material and Methods”. The studies on solubility, 
dimerization, and protein stability were reproduced in both types of cells, but toxicity 
studies were conducted exclusively on N2A cell lines (see below).   
Figure 2-1 
 
 
Assessment of the solubility, dimerization and stability of E163K human DJ-1 in N2A cells.               
(A) Western blot analysis with DJ5 antibody, specific for human DJ-1, showing the expression of WT 
human DJ-1 in two stable N2A cell lines (clones 11 and 12) and E163K human DJ-1 in three stable N2A 
cell lines (clones 16, 47 and 52). An immunoblot with an anti-Actin antibody is shown as a loading control.  
(B) Biochemical fractionation was performed on N2A cells and stable cell clones of N2A cells expressing 
WT (clone 11) or E163K (clone 16) human DJ-1.  Cellular proteins were extracted with buffers of 
increasing solubilization strengths as described in “Experimental Procedures”.  Each fraction was analyzed 
by western blotting with the anti-human DJ-1 antibody, DJ5, and an anti-ERK 1/2, ERK1, antibody to 
verify equal protein loading. (C) Size-exclusion chromatography was performed to analyze the native size 
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of E163K human DJ-1 compared to WT human DJ-1 and endogenous murine DJ-1. Soluble extracts from 
N2A cells and stable cell clones of N2A cells expressing WT (clone 11) or E163K (clone 16) human DJ-1 
were loaded on a precalibrated Superose 6 column as described in “Experimental Procedures”. The total 
cell lysates ("Start") and fractions were collected and analyzed by western blot analysis with DJ5 antibody 
to detect human DJ-1 or 691 antibody to detect endogenous murine DJ-1. Fractions 20-30 are shown. The 
elution profile of known molecular mass standards [BSA (66 kDa), ovalbumin (44 kDa), carbonic 
anhydrase (29kDa) and cytochrome C (12kDa)] are indicated above. (D) Pulse-chase turnover assay of 
E163K human DJ-1 compared to WT human DJ-1. N2A stable cell clones expressing WT (clone 11) or 
E163K  (clone 16) human DJ-1 were pulsed with 35S-methionine for 30 minutes and chased for 0, 3, 6, 12, 
or 25 hours. Experiments were conducted in quadruplicates. The results are plotted as percentage of protein 
over time standardized to the 0 hrs time point. The error bars show standard deviation.  
 
The E163K mutation does not lead to changes in solubility. 
 Protein aggregation is known to be a key component in the disease pathogenesis 
of many neurodegenerative disorders (245) and reduced solubility of DJ-1 has been 
reported in some diseased brains (227;296;304;316;371). To assess whether the E163K 
mutation may lead to changes in solubility, N2A cells stably expressing WT and E163K 
DJ-1 were sequentially extracted with buffers of increasing solubilization strengths. The 
WT and the E163K mutant form of human DJ-1 both were extracted most abundantly in 
the soluble Triton X-100 fractions (TX1 and TX2) (Figure 2-1b) and to a lesser extent in 
the RIPA fractions. Additionally, neither E163K mutant nor WT DJ-1 were detected in 
the SDS fractions, and there were no differences between the distribution of WT and 
E163K DJ-1 across any of the biochemical fractions.  
Biochemical fractionation experiments also were performed in CHO cells stably 
expressing the human WT or E163K mutant DJ-1 protein and no differences in protein 
solubility between the WT and E163K variants were observed in these cells (data not 
shown). 
The E163K mutation does not alter the ability of DJ-1 to dimerize. 
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DJ-1 has been previously shown to form a homodimer in vitro which may be 
essential to its function (139;248;324). Some mutations like L166P have previously been 
shown to affect protein folding such as to prevent dimer formation, resulting in rapid 
degradation (28;42;139;158;171;298;324). Crystal structure analysis of DJ-1 protein 
shows that the L166P mutation occurs in helix 7, which is one of the helices in the dimer 
interface of DJ-1 (167;170;426;469). Since the E163K mutation also occurs in helix 7, it 
is possible that a similar effect could occur. To assess whether E163K DJ-1 dimerizes 
under native conditions, size exclusion chromatography was performed on soluble 
extracts from N2A cells expressing endogenous DJ-1 alone or expressing WT or E163K 
human DJ-1. The elution of purified proteins with known molecular masses was used to 
standardize this assay. Both the WT DJ-1 and the E163K mutant DJ-1 exclusively eluted 
in fractions 24 through 26 (Figure 2-1c), which corresponds to a molecular mass of ~42 
kDa, the proposed molecular mass for the DJ-1 dimer.  Endogenous DJ-1 protein 
expressed in N2A cells also eluted in the same fractions.  
Size exclusion chromatography was also performed in CHO cells stably 
expressing either the WT or the E163K mutant form of DJ-1 protein in order to confirm 
the protein dimerization results. In the CHO cells, both the WT and the E163K mutant 
DJ-1 protein eluted in fractions 24 and 25 (data not shown), corresponding to the mass of 
a dimer. 
The DJ-1 E163K mutant shows comparable stability to WT. 
It has been previously shown that some pathogenic mutants of DJ-1 like M26I are 
structurally similar to WT DJ-1 in the ability to form a homodimer, but can demonstrate 
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reduced stability compared to the WT protein (42;324;422;479). Therefore, the effect of 
the E163K mutant on protein stability was assessed by pulse-chase experiments with 35 S-
methionine and comparison to the WT protein. Both the E163K mutant and WT DJ-1 
proteins showed similar turnover in N2A cells (Figure 2-1d), indicating that the E163K 
mutation does not result in reduced stability. These experiments were also performed in 
CHO cells (data not shown) and both protein variants also showed similar turnover rates 
in this alternate cell type. 
The E163K mutant DJ-1 does not show altered subcellular localization by western 
blot. 
 DJ-1 is normally diffusely expressed in cells (21), but WT DJ-1 as well as 
pathogenic mutants may localize to the mitochondria (489) and the latter localization may 
increase in response to mitochondrial stress (37;42). However, the subcellular 
localization of the E163K pathogenic mutant form of DJ-1 has not been previously 
investigated. To determine a possible effect of this mutation on altering the localization 
of DJ-1, subcellular fractionation was performed by differential centrifugation as 
previously used by others (298).  Untransfected N2A cells and N2A cells stably 
expressing either human WT DJ-1 or human E163K DJ-1 were homogenized in triplicate 
in subfractionation buffer. Cytosolic and mitochondrial fractions were collected. Cell 
lysates were resolved by SDS-PAGE and analyzed by western blot analysis with DJ5 
(human specific monoclonal DJ-1 antibody), 691 (polyclonal DJ-1 antibody that reacts 
with mouse and human protein), Tim23 (translocases of the inner mitochondrial 
membrane) as a mitochondrial marker, and ERK1/2 as a cytoplasmic marker. 
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Endogenous DJ-1 protein in N2A cells and both human WT and E163K DJ-1 expressed 
in these cells demonstrated similar predominant cytoplasmic distributions (Figure 2-2).  
Figure 2-2 
 
The E163K mutant does not show altered subcellular localization. N2A cells and stable cell clones of 
N2A cells expressing WT (clone 11) or E163K (clone 16) human DJ-1 were subjected to subcellular 
fractionation by differential centrifugation as described in “Experimental Procedures”. Cellular fractions 
were analyzed by western blot with the monoclonal anti-human DJ-1 antibody, DJ5, the polyclonal anti-
DJ-1 antibody, 691, anti-Tim 23 antibody (used as a mitochondrial marker), and anti-ERK1/2 antibody 
(used as a cytoplasmic marker). Experiments are shown in triplicates.  
 
The E163K mutant protein fails to rescue under conditions of oxidative stress. 
 Many studies have reported that WT DJ-1 can serve in a protective capacity when 
overexpressed in various cells lines (53;389;447;487;493). To investigate the ability of 
human E163K DJ-1 to protect N2A mouse neuroblastoma cells from mitochondrial 
stress, proteasomal stress, and oxidative stress, cells expressing WT or E163K human DJ-
1 were challenged with various specific stressors.   
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 Native N2A cells or N2A cells stably expressing WT DJ-1 or E163K mutant DJ-1 
were treated with either fresh DMEM/FBS or DMEM/FBS containing MG-132 (a 
proteasome inhibitor) or MPP dihydrochloride (a mitochondrial complex I inhibitor) at a 
range of concentrations. N2A cells demonstrated reduced cell viability to MG-132 
treatment at all concentrations used (10-30 uM). Additionally, N2A cells were vulnerable 
to MPP dihydrochloride concentrations that exceeded 10 uM and WT DJ-1 protein was 
able to protect against both of these stressors at all toxic concentrations tested (Figure 2-
3A). Expression of E163K DJ-1 was also able to protect against MG-132 and MPP 
dihydrochloride toxicity.  
 To further assess the specific effect of the E163K mutation, other specific 
mitochondrial complex inhibitors were analyzed (Figure 2-3B). Antimycin, an inhibitor 
of mitochondrial complex III, resulted in a ~40% decrease in viability in N2A cells at the 
100 nM concentration and a ~60% decrease in viability at the 200 nM concentration 
while expression of either WT or E163K DJ-1 had a protective effect at these 
concentrations (Figure 2-3B). The irreversible inhibitor of mitochondrial complex II, 3-
nitropropionic acid (3-NP), did not have a significant effect on the viability of any of the 
three cell lines at the 5 uM or 10 uM concentrations tested. However, N2A cells showed a 
slight vulnerability to 15 uM 3-NP and expression of either the E163K mutant DJ-1 or 
WT DJ-1 was protective. 
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Figure 2-3 
 
The E163K mutant fails to rescue under 
conditions of oxidative stress. 
(A) N2A cells and stable cell clones of N2A 
cells expressing WT (clone 11) or E163K 
(clone 16) human DJ-1 were treated with 
various chemical stressors and the Trypan 
Blue Exclusion Assay was used to assess 
viability. Results were plotted as the 
percentage of viable cells over time of 
chemical treatment. The error bars show 
standard deviation. In A, cells were treated for 
20 hrs with either fresh DMEM/FBS or 
DMEM/FBS containing 10-30 uM MG-132, 
or 7.5-20 uM MPP dihydrochloride. In B, 
cells were treated for 96 hours with either 
fresh DMEM/FBS or DMEM/FBS containing 
50-200 nM Antimycin or 5-15 uM 3-
nitropropionic acid. (C) Several N2A stable 
clones expressing either WT human (clones 
11 and 12) or E163K human mutant DJ-1 
(clones 16, 47 and 52) were treated for 20 
hours with either fresh DMEM/FBS or 
DMEM/FBS containing 10-30uM H2O2.  
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Native N2A cells or stable clones expressing WT or E163K DJ-1 protein were 
challenged with H2O2 ranging from 10-30 uM in order to induce oxidative stress.  We 
found that challenging the cell line expressing E163K mutant DJ-1 (E163K clone #16) 
that had been used in all of the aforementioned toxicity experiments not only 
demonstrated a lack of protection against H2O2 oxidative stress, but furthermore showed 
increased  vulnerability to H2O2 exposure at all of the concentrations used (Figure 2-3C). 
To determine whether enhanced sensitivity to oxidative stress was due to expression of 
the E163K DJ-1 mutant, two additional N2A cell lines (clone #47 and clone #52) stably 
expressing the human E163K mutant DJ-1 were tested for H2O2 toxicity (Figure 2-3C).  
Both of these clones also revealed increased vulnerability to H2O2 oxidative stress when 
compared to native N2A cells. In contrast, two N2A cell lines stably expressing human 
WT DJ-1 (clones #11 and #12) demonstrated protection against H2O2 stress. These 
results indicate that the E163K mutation selectively compromises the protective role for 
DJ-1 on oxidative stress.  
Human exogenous DJ-1 protein does not co-immunoprecipate with endogenous DJ-
1 in N2A cells. 
   One plausible explanation for the selective vulnerability of N2A cell lines 
expressing E163K mutant DJ-1 to oxidative stress is that the mutant protein may behave 
as a dominant negative by forming a heterodimer with endogenous murine DJ-1 protein, 
inactivating the antioxidant capacity of the endogenous protein. Size exclusion 
chromatography analysis demonstrated that endogenous and human DJ-1 formed dimers, 
but these studies do not ascertain whether these proteins could form heterodimers (Figure 
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2-1).  Coimmunoprecipitation experiments were performed to test the interaction between 
human WT and E163K DJ-1 with endogenous DJ-1. Since mouse and human DJ-1 
migrate with the same mobility on SDS-PAGE, transfections with N-terminal flagged 
human DJ-1 constructs were used for these studies. Cell extracts from N2A cells or 
extracts from N2A cells transiently expressing either WT Flag-DJ-1 or E163K Flag-DJ-1 
were immunoprecipitated with a mouse anti-flag monoclonal antibody. 
Immunoprecipitates were resolved by SDS-PAGE and analyzed by western blot with the 
polyclonal DJ-1 antibody, 691.  Endogenous DJ-1 protein was not pulled downed by 
immunoprecipitation with either WT-flag tagged or E163K-flag tagged DJ-1 (Figure 2-
4), indicating that there is no detectable formation of heterodimers between the 
endogenous DJ-1 and exogenous human DJ-1 protein. 
Figure 2-4 
 
 
 
 
 
 
 
 
Human exogenous DJ-1 protein does not co-immunoprecipate with N2A endogenous DJ-1. N2A cells 
were mock transfected or transiently transfected with either flag-tagged human WT or E163K mutant DJ-1 constructs. 
Soluble protein extracts were immunoprecipitated with anti-flag antibody. Fractions were resolved by SDS-PAGE and 
immunoblotted with the polyclonal DJ-1 antibody, 691. The “Start” fraction represents the total soluble extracts before 
IP and the “Unbound” fraction represents the protein remaining in the protein lysates after the IP. 
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Immunofluorescence microscopy reveals an altered localization for E163K mutant 
DJ-1 protein in response to oxidative stress. 
 To further understand the effect of the E163K mutation, quantitative 
immunofluorescence studies were conducted comparing untreated cells and cells 
challenged with oxidative stress.  Under normal conditions, DJ-1 exhibited a diffuse 
staining pattern throughout the cell and co-immunofluorescence experiments with the 
mitochondrial marker, MitoTracker ® Red CMXRos, revealed some overlap with both 
WT and E163K DJ-1 (Figure 2-5a). However, after treating with hydrogen peroxide, 
cells expressing WT DJ-1 showed a 5-fold increase in staining overlap of the human DJ-1 
protein with the mitochondrial marker as compared to untreated cells. In striking contrast, 
under the same oxidative conditions, cells expressing the E163K mutant DJ-1 showed a 
6-fold decrease in the overlap with mitochondrial marker (Figure 2-5b). To try to assess 
whether these alterations in DJ-1 distributions were due to changes in the presence of DJ-
1 in the mitochondria, subcellular biochemical fractionation of cells treated with 
oxidative stress was performed. However, no biochemical mitochondrial localization was 
observed under harsh conditions of oxidative stress (Figure 2-5c). These results suggest 
that under oxidative stress, WT human DJ-1 in N2A cells can relocate in close proximity 
to the mitochondria, but does not enter these organelles, while E163K DJ-1 is impaired in 
this property, which may play a role in its inability to protect against oxidative stress. 
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Figure 2-5 
  
Immunofluorescence microscopy reveals an altered mitochondrial localization for E163K mutant DJ-1 protein 
in response to oxidative stress. 
(A) N2A cells stably expressing WT (clone 11) or E163K (clone 52) human DJ-1 were treated either DMEM/FBS containing 20uM 
H2O2 or with DMEM/FBS. Cells were stained with Mitotracker (red), DJ5 (green), and DAPI (blue) and visualized by confocal 
microscopy. Representative images are shown. Bar = 13.5μm (B) The confocal microscopy images were quantified using MetaMorph 
6.0. The graph represents the average of the relative pixel intensity for DJ-1 per mitochondrial area. The error bars show the standard 
deviation between replicate images. (C) N2A cells and N2A cells stably expressing WT (clone 11) or E163K (clone 52) human DJ-1 
were either untreated (lanes labeled with “U”) or treated with 350uM H2O2 (lanes  labeled with “T”) for 1.5 hrs and then fractions 
enriched for mitochondria were isolated by differential centrifugation as described in “Material and Methods”. Cellular fractions were 
analyzed by western blot with the monoclonal anti- human DJ-1 antibody, DJ5, the polyclonal anti-DJ-1 antibody, 691, anti-Tim 23 
antibody (used as a mitochondrial marker), and anti-ERK1/2 antibody.  Experiments are shown in duplicates. 
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2.4  Discussion 
 DJ-1 mutations are associated with early-onset parkinsonism. The E163K 
mutation is also causal of early-onset disease, but clinical presentations are more 
extensive and diverse than for other DJ-1 disease-causing mutations (14).   In this study, 
the properties and effects of this mutant were assessed in cultured cells. Under normal 
conditions, the E163K mutant had properties similar to WT DJ-1 in terms of subcellular 
localization, dimerization abilities, stability, and solubility. These findings are consistent 
with recent findings by Lakshminarasimhan and colleagues that showed that in vitro 
E163K DJ-1 was able to form stable dimers (233).  
 Many groups have shown that WT DJ-1 protein can act to mitigate the deleterious 
effects of various insults including oxidative stress both in cell culture and in animal 
models (181;242;281;297;418;487). While the E163K mutant retains the ability to protect 
N2A cells against proteasome inhibition as well as mitochondrial stress through 
mitochondrial complex I and III inhibition, this mutation compromises the ability of DJ-1 
to protect against oxidative stress and even increases sensitivity to oxidative insult. A 
number of studies demonstrated that the DJ-1 pathogenic mutant, L166P, insufficiently 
protects against oxidative stress (139;181;198;281;418;493), but in contrast to the E163K 
mutation the L166P mutation impairs the ability of DJ-1 to form stable dimers resulting 
in a dramatic instability of the mutant protein and  loss of expression that can explain the 
loss of protective function  (138;269;298;324). The M26I mutant also displays reduced 
protection against oxidation stress (422) despite the ability to form stable dimers 
(42;304;422), but this mutation appears to reduce protein stability, albeit much less than 
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the L166P mutation (42;304;422;479). However,  it is unclear if the reduced protection 
against oxidative stress by the M26I mutation is simply associated with reduced half-life 
or perhaps with an increased propensity for the M26I mutant protein to aggregate as 
recently reported (171).   
In contrast to these other mutations in DJ-1, the effect of the E163K mutation on 
impairing DJ-1 function is specific to oxidative stress and it does not impair dimerization, 
protein stability or increase aggregation.  E163 is in close proximity of L166, and both 
residues are located in α-helix G7 which is critical in forming stably folded protein 
(139;170). The E163K mutation clearly does not cause the dramatic structural changes of 
the L166P mutation which introduces a helix-breaking residue, but the fact that E163 is 
highly conserved in DJ-1 across species underscores the importance of this residue (139). 
The E163K mutation appears to result in subtle structural changes and recent biophysical 
studies by Lakshminarasimhan et al. demonstrated that E163 can form a salt bridge with 
R145 and that the disruption of this interaction by the E163K mutation results in 
increased mobility of R145 (233).   
Our findings that oxidative stress promoted the redistribution of DJ-1 towards 
mitochondria but without evidence of mitochondrial import are consistent with the 
studies of Canet-Aviles and colleagues that reported that oxidative stress can increase the 
amount of DJ-1 on the cytoplasmic side of this organelle without resulting in import (53). 
It is shown in the present studies that under conditions of oxidative stress, the E163K 
mutant demonstrated a paucity of localization towards mitochondria. It is possible that 
simply the change from a negatively to positively charged residue and/or the subtle 
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structural effects discussed above may prevent the interaction of DJ-1 with other proteins 
that may be involved in the redistribution of DJ-1 under conditions of oxidative stress. 
Identifying such mechanisms may be important to further understand the function of DJ-
1.  The toxicity studies demonstrate that DJ-1 influences several neuroprotective 
pathways but that the E163K mutation specifically impairs the oxidative stress protective 
mechanism. The findings that this mutation appears to exacerbate the response to 
oxidation and diminish the redistribution of DJ-1 towards the mitochondria suggest that 
both processes may be related, but further studies will be needed to substantiate a direct 
association.  
 Our results reveal that the loss of DJ-1 protective function can occur without overt 
biochemical changes on the protein and demonstrate that alterations to specific residues 
in this protein can specifically affect individual functions indicating that DJ-1 is likely 
involved in multiple cellular pathways. A more detailed understanding of the mechanism 
by which DJ-1 can protect against stresses is still needed to better understand the 
activities of this protein and its role in neurodegenerative diseases.   
2.5  Experimental Procedures 
Antibodies 
DJ-5 is a mouse monoclonal antibody specific for human DJ-1 protein (296). 691 is a 
rabbit polyclonal antibody raised against recombinant human DJ-1 protein but that reacts 
with DJ-1 from various species (296). 
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 Anti-Tim23 is a purified mouse monoclonal antibody to Tim23 (BD Transduction 
Laboratories, San Jose, CA). Anti-extracellular signal related kinase-1 (ERK-1) (C-16) is 
an affinity purified rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) that reacts with both ERK-1 and -2. Anti-Flag-tag mouse monoclonal antibody 
(GenScript Corporation, Piscataway, NJ) is a purified antibody that reacts with proteins 
with the amino acid sequence, DYKDDDDK . Anti-Actin is a purified mouse 
monoclonal antibody (Millipore Corporation, Billerica, MA 01821) that reacts with all 
six isoforms of vertebrate Actin. 
Cloning of human DJ-1 constructs 
Human full-length WT DJ-1 cDNA was cloned into the mammalian expression 
vector pZeoSV2 (Invitrogen, Carlsbad, CA) at the Not I and Hind III restriction sites to 
create the plasmid pZeoWThDJ. Using the pZeoWThDJ construct, the QuickChange® 
Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used in order to generate 
the E163K mutant form of human DJ-1 in the pZeoSV2 vector. The sequences of the 
oligonucleotides used for mutagenesis were as follows: Forward- 5’-GGG CCT GGG 
ACC AGC TTC AAG TTT GCG CTT GCA ATT GTT-3’  and  Reverse- 5’- AAC AAT 
TGC AAG CGC AAA CTT GAA GCT GGT CCC AGG CCC-3’.  The sequence of the 
plasmid with E163K mutant DJ-1 was verified by DNA sequencing as a service offered 
by the DNA Sequencing Facility of the University of Pennsylvania, and the construct was 
named pZeoEKhDJ. 
 Sequential restriction digestions with Not I and Apa I were performed on both 
pZeoWThDJ and pZeoEKhDJ. The DNA fragments containing the full-length DJ-1 
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sequences were ligated into the pcDNA3.1 (Invitrogen, Carlsbad, CA) mammalian 
expression vector in order to generate the human WT and E163K mutant DJ-1 constructs 
named pc3.1WThDJ1 and pc3.1EKhDJ1, respectively. 
An N-terminal flag-tagged WT DJ-1 construct was generated by PCR, using the 
pZeoWTDJ-1 construct as a template. The sequences for the oligonucleotides used were 
as follows: Forward-5’- GAT CGC GGC CGC CAC CAT GGA TTA CAA GGA TGA 
CGA CGA TAA GGC TTC CAA AAG AGC TCT GGT CAT CCT -3’ and Reverse-5’-
GAT CAA GCT TCT AGT CTT TAA GAA CAA GTG GAG CCT TC-3’. The tagged 
insert was cloned into the pCR 2.1 TOPO vector (Invitrogen, Carlsbad, CA) and 
subsequently cloned into the pcDNA3.1 (-) vector at the Hind III and Not I restriction 
sites. The construct was named pc3.1WThDJ1-Nflag. The sequence of the plasmid was 
verified by DNA sequencing as described above. The E163K N-terminal flag-tagged DJ-
1 construct was generated by performing site directed mutagenesis using the 
pc3.1WThDJ1-Nflag construct as a template. The same oligonucleotides were used as 
described above for mutagenesis. The plasmid was named pc3.1E163KhDJ1-NFlag. 
Cell culture 
 N2A and CHO cells were cultured in Dulbecco-modified Eagle medium (DMEM) 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma, St.Louis, 
MO), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA). 
Cells were incubated at 37ºC and 95% air/5% CO2 atmosphere.  
Generation of stable cell lines expressing WT and E163K DJ-1 
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The pc3.1WThDJ and pc3.1EKhDJ constructs were used to transfect N2A cells 
using FuGENE reagent following the manufacterer’s protocol. Stably expressing clones 
were isolated and selected with G418 (Invitrogen, Carlsbad, CA) at 200-500 μg/mL and 
screened by Western blotting for the expression of DJ-1 using the antibody DJ5 that is 
specific for human DJ-1. Stably expressing clones expressing WT (clone #11 and clone 
#12) or E163K (clone #16, #47 and #52) human DJ-1 were used in the studies (See 
Figure 1A). 
The pZeoWThDJ and pZeoEKhDJ constructs were used to transfect CHO cells 
using FuGENE (Roche, Basel, Switzerland) transfection reagent according to the 
manufacturer’s protocol. Stably expressing clones were isolated following selection with 
Zeocin (Invitrogen, Carlsbad, CA) at 50 ug/mL. 
Biochemical fractionation 
 Native N2A and CHO cells or stable clonal lines expressing WT or E163K human 
DJ-1 were cultured in 10 cm dishes as described above. Cells were grown to confluency, 
rinsed and scraped in PBS, and harvested by centrifugation at 13,000 x g. Cells were 
vortexed vigorously in 2 pellet volumes of PBS/0.1% Triton, sedimented, and the 
supernatant was collected as the TX1 fraction. This was repeated on the remaining pellet 
and the supernatant was collected as the TX2 fraction. The pellet was resuspended in 2 
volumes of RIPA buffer, vortexed vigorously, sedimented, and the supernatant was 
collected as the RIPA fraction. The remaining pellet was solubilized in 2%SDS/17mM 
Tris, pH 8.0 and kept as the SDS fraction. 
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Gel filtration chromatography 
 Gel filtration chromatography was performed by calibrating a Superose 6 column 
(Amersham Biosciences) attached to a fast performance liquid chromatography (FPLC) 
system with standards of known molecular mass using 10 mM Tris, pH 7.5, 100 mM 
NaCl as the mobile phase. Molecular mass standards [BSA (66 kDa), ovalbumin (44 
kDa), carbonic anhydrase (29 kDa) and cytochrome C (12 kDa)] were resolved separately 
to calibrate the column. The elution of the standards was monitored by protein 
absorbance at 280 nm.  N2A or CHO cells and stable cell lines thereof were cultured in 
10 cm dishes and grown to confluency. Cells were rinsed and scraped in phosphate 
buffered saline, pH 7.4. After recovery by centrifugation, cells were lysed in PBS/0.1% 
Triton and the cell debris was sedimented at 13,000 x g for 5 min. The extracts were 
filtered through a 0.45 µm filter and loaded onto the column. Fractions were analyzed by 
immunoblotting with anti-DJ-1 antibodies, DJ5 (1:1000) and 691 (1:1000). 
Pulse-chase protein turnover experiments 
 N2A or CHO cells stably expressing WT or E163K DJ-1 were cultured in 6-well 
dishes. Cells were methionine-deprived for 15 minutes by incubation in methionine-free 
DMEM (Invitrogen, Carlsbad, CA)/ 10% dialyzed FBS before adding 100 μCi [35S]-
methionine (Invitrogen, Carlsbad, CA) per ml of methionine free DMEM/10% dialyzed 
FBS for 30 min.   Chase experiments were conducted in quadruplicates with normal 
DMEM/FBS for 0, 3, 6, 12, and 25 hours. Cells were then rinsed with PBS and harvested 
in CSK buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 % Triton X-100) 
containing 1 % SDS and boiled at 100 ºC for 5 minutes. CSK buffer was added to the 
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lysates in order to bring the final concentration of SDS to 0.25%. Lysates were frozen on 
dry ice and kept frozen at -20 ºC until the last time point was harvested. The radiolabelled 
protein extracts were pre-cleared with a rabbit serum pre-incubated with protein A-
agarose (Santa Cruz Biotechnologies, Santa Cruz, CA)  for 3 hours at 4ºC and 
radiolabelled extracts were then immunoprecipitated overnight at 4ºC with anti-DJ-1 
polyclonal antibody 691 pre-incubated with protein A-agarose (Santa Cruz 
Biotechnologies, Santa Cruz, CA). The antibody-protein complexes were washed 3 times 
with 10 volumes of CSK buffer, resuspended in 2 volumes of 2X SDS sample buffer and 
boiled at 100 ºC for 5 minutes. The beads were removed by centrifugation and the 
samples were loaded on 12 % polyacrylamide gels. Following electrophoresis, gels were 
fixed with 50% methanol/5% glycerol, dried and exposed to a PhosphorImager plate and 
the signal was quantified using ImageQuant software (Molecular Dynamics, Inc., 
Sunnyvale, CA). 
Subcellular fractionation 
 The subcellular fractionation procedures used were similar to those previously 
described (298) with some changes. Native N2A, or N2A cells stably expressing WT or 
E163K DJ-1 were cultured in 10 cm plates. Cells were rinsed and scraped in phosphate-
buffered saline, pH 7.4 (Invitrogen, Carlsbad, CA) and pelleted at 13,000 x g. Cells were 
resuspended in 3 pellet volumes of subfractionation buffer (0.25 M sucrose, 10 mM 
HEPES/NaOH, pH 7.5, 1 mM DTT, and protease inhibitors). Cells were homogenized 
with 20 strokes of a Dounce homogenizer (Kontes Glass Co;Vineland, NJ). The nuclei 
and unlysed cells were pelleted by sedimentation at 489 x g for 10 minutes at room 
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temperature (RT). The supernatants were further cleared at 1585 x g for 10 minutes. The 
supernatants (S1) were removed to fresh tubes and sedimented for 10 minutes at 1585 x g 
at RT. The supernatants (S2) were removed to fresh tubes and pelleted for 17 minutes at 
22000 x g at 4º C. The supernatants (S3) were removed as the crude cytoplasmic fraction 
and incubated on ice. In the mean time, the pellet (mitochondrial enriched fraction) was 
rinsed with 3 pellet volumes of subfractionation buffer and centrifuged again at 22000 x g 
for 17 minutes at 4ºC. The supernatant from this rinse was discarded and the 
mitochondrial pellet was solubilized in 3 pellet volumes of 2% SDS/17mM Tris and 
boiled at 100 ºC for 5 minutes. The tube containing the crude cytoplasmic supernatant 
(S3) was then sedimented at 103,000 x g for 25 minutes at 4 ºC in order to pellet small 
organelles and cell debris, and the resulting supernatant (S4) was collected as the 
cytosolic fraction. The protein concentrations were determined in each fraction using the 
bicinchoninic acid protein (BCA) Assay (Pierce, Rockford, IL) with and bovine serum 
albumin as a standard. Fractions were analyzed by immunobloting with antibodies DJ5 
(1:1000), 691 (1:1000), Tim23 (0.5ug/mL), and ERK1 (0.2ug/mL). 
For subcellular fractionation experiments that followed oxidative stress, N2A 
cells or cells stably expressing human WT or E163K mutant DJ-1 were cultured in 10 cm 
plates and were treated for 1.5 hours with DMEM/FBS or DMEM/FBS containing 
350uM H2O2. Cells were treated with H2O2 in duplicate. Cells were rinsed and scraped in 
PBS. Subcellular fractionation by differential centrifugation was performed as described 
above. 
Cell viability assay 
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 Native N2A or N2A cell lines expressing WT or E163K DJ-1 were cultured 
separately into 48 well plates. Each cell type was treated for 20 hours in sextuplicates 
with DMEM/FBS containing either 10, 20 or 30 uM H2O2, 7.5, 10, or 20 uM MPP 
dihydrochloride (Sigma, St.Louis, MO ), 10, 20, or 30 uM MG-132 (Sigma, St.Louis, 
MO), or fresh DMEM/FBS. In separate experiments, these cell lines were treated for 96 
hours in sextuplicates with either 50, 100, or 200 nM Antimycin A (Sigma, St.Louis, 
MO) or 5, 10, or 15 uM 3-nitropropionic acid (Sigma, St.Louis, MO). After treatment, 
the media from each well was collected into separate 1.5 mL microfuge tubes. The cells 
remaining in the wells were trypsinized, and harvested in corresponding microfuge tubes. 
Cells were pelleted and resuspended in fresh DMEM/FBS, and then 3-fold volumes of 
Trypan Blue solution (Sigma, St.Louis, MO ) was added. Live and dead cells were 
counted manually using a hemacytometer and an Olympus CKX41 microscope. The 
percentage of live cells relative to the total number in each well was calculated. 
Co-immunoprecipitation and heterodimer studies 
 N2A cells were cultured in 10 cm plates. Cells were mock transfected or 
transiently transfected with pc3.1E163KhDJ1-NFlag, or pc3.1WThDJ1-NFlag constructs 
using Lipofectamine reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol. After 24 hours, cells were rinsed and scraped in PBS and lysed into 500 uL of 
1X CSK buffer by vortexing. Cell debris was sedimented at 13,000 x g for 5 minutes and 
supernatants were removed to fresh tubes. 30 uL of each supernatant was saved as the 
“Start” fraction. The remainders of the supernatants were incubated at 4 ºC with a mouse 
anti-flag antibody preabsorbed to protein A/G PLUS Agarose beads (Santa Cruz 
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Biotechonogy, Inc., Santa Cruz, CA). The beads were sedimented, repeatedly rinsed with 
1X CSK buffer, resuspended in sample buffer, heated to 100 oC and saved as the “IP” 
fractions. The supernatants remaining after the immunoprecipitation were saved as the 
“Unbound” fractions. Sample buffer was added to the “Start” and “Unbound” fractions 
and then they were heated to 100 oC for 5 minutes. 
Immunofluorescence and confocal microscopy 
 Native N2A, or N2A cells stably expressing WT or E163K DJ-1 were treated with 
DMEM/FBS or DMEM/FBS containing 20 uM H2O2 for 3 hours. The media was 
removed and replaced with warmed DMEM/FBS containing 100 nM Mitotracker ® Red 
CMXRos (Invitrogen, Carlsbad, CA). The cells were allowed to respire for 20 minutes 
and then were fixed with neutral buffered formalin according to the manufacturer’s 
protocol. The cells were rinsed with PBS for 5 minutes and then blocked for 30 minutes 
at room temperature in PBS/2% FBS/0.1% Triton. Cells were then incubated at 4ºC with 
DJ5 antibody diluted into PBS/2% FBS at a concentration of 1:500 overnight, washed 3 
times with PBS at 10 minutes each, and then incubated at room temperature with a goat 
anti-mouse secondary antibody conjugated to Alexa Fluor ® 488 (Invitrogen) diluted into 
PBS/2% FBS at a concentration of 1:500 for 2 hours. Cells were rinsed for 10 minutes 
with PBS, incubated at room temperature with DAPI (Pierce, Rockford, IL) diluted into 
PBS at a concentration of 1ug/mL for 5 minutes, and then rinsed 3 times with PBS at 10 
minutes each. Cells were coversliped with CytosealTM 60 mounting media (Richard-Allen 
Scientific, Kalamazoo, MI). The images were visualized with a Zeiss LSM-510 Meta 
confocal microscope. For each sample, five 143 x 143 μm images were taken from a 
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single plane using the 63x /1.4 oil objective. The images were then quantified using 
MetaMorph 6.0 software (Molecular Devices, Sunnyvale, CA). The relative integrated 
staining for DJ-1 per mitochondrial area was calculated by measuring the integrated pixel 
intensity for DJ5 signal that overlapped with pixels positive for Mitotracker Red 
CMXRos divided by total mitochondrial area. Integrated pixel intensity is defined as 
pixel intensity times the area of pixels positive for the signal. The average values for the 
replicate images were calculated. 
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3.1    ABSTRACT 
A variety of mutations in the gene encoding DJ-1 protein are causal of autosomal 
recessive early-onset parkinsonism. Recently, a novel pathogenic homozygous DJ-1 
missense mutation resulting in the L10P amino acid substitution was reported. In a 
separate study, a novel homozygous mutation resulting in the deletion of DJ-1 residue 
P158 was also reported to be causative of disease. The specific effects of the novel L10P 
and P158DEL mutations on protein function have not been studied. Herein, L10P and 
P158DEL DJ-1 proteins were assessed for protein stability, dimerization, solubility, and 
subcellular localization in comparison to WT and the L166P DJ-1 pathogenic variant. It 
was discovered that in comparison to WT protein, L10P, L166P, and P158DEL DJ-1 
variants exhibited dramatically reduced protein stabilities. Degradation of each of the 
respective pathogenic mutants appeared to be mediated in-part by the proteasome. 
Interestingly, unlike L166P DJ-1, the L10P and P158DEL DJ-1 variants retained the 
ability to dimerize and thus it was concluded that the observed decreases in protein 
stability were due to aberrations in protein folding. Supporting this idea, the L10P, 
L166P, and P158DEL DJ-1 variants exhibited altered profiles on size-exclusion 
chromatography and reduced solubilities in comparison to WT protein, and the latter 
aberration could be exacerbated in the presence of MG-132. Taken together, these 
findings suggest that DJ-1 mutations may cause disease by distinct mechanisms and 
indicate that the pathogenicity of the L10P and P158DEL variants are related to 
aberrations in protein stability and protein folding. 
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3.2    INTRODUCTION 
 Several genes, designated PARK1-PARK13, that can cause Parkinson disease 
(PD) have been indentified  (124;250).   A variety of mutations in PARK7/DJ-1, 
including large genetic deletions, splice-site alteration and missense mutations, are also 
known to be causal of autosomal recessive early-onset parkinsonism (200). Recently, two 
novel recessive mutations in the PARK7/DJ-1 gene have been reported which result in 
early-onset parkinsonian phenotypes in the affected patients (144;270). A homozygous 
missense mutation resulting in the  DJ-1 amino acid substitution L10P was identified in a 
consanguineous Chinese family (144). The affected patients presented with disease 
symptoms at 19 years of age which is the earliest age of onset reported for any PD case 
specifically linked to DJ-1 mutations. Following this report, another DJ-1 mutation 
carrier was identified in a genetic study conducted on early-onset PD patients from the 
Netherlands (270).  The affected individual harbored a small homozygous deletion in DJ-
1 exon 7 which resulted in the deletion of the highly conserved DJ-1 residue, P158DEL 
(270).  
 Although the first causative PARK7/DJ-1 mutations were reported nearly a 
decade ago (47) and DJ-1 has been implicated in many biological pathways (200 and the 
references therein;109), the specific role of DJ-1 in disease pathogenesis is still unclear. 
DJ-1 is a relatively small 189 amino acids protein that is evolutionarily conserved across 
many species (23;47;313). It is ubiquitously expressed in most tissues and is present in 
cell nuclei and cytoplasm (28;47;313). Crystallization studies reveal that DJ-1 is 
composed of eight α-helices and eleven β-strands that are arranged into a helix-strand-
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helix sandwich (12;170).  These structural features are common to members of the 
ThiJ/Pfp superfamily of proteins (167;170;469). Further, it is known that DJ-1 tightly 
associates into a homodimer and that the dimer interface is composed of  α-helices 1, 7, 
and 8 and β-strands 3 and 4  (12;170;167;469).  DJ-1 dimer formation may be required 
for the protein to function properly, though this hypothesis has never been proven. It is 
well known that the pathogenic DJ-1 mutant L166P fails to dimerize and that this deficit 
is likely caused by structural perturbations of the dimer interface 
(12;42;139;139;269;298;324;469). Such conformational abnormalities target L166P DJ-1 
protein for rapid degradation by the proteasome, and the associated reductions in mutant 
protein abundance may be causative of disease phenotypes (139;263;298). Studies to 
assess for the effects of pathogenic DJ-1 mutations on protein function will give insights 
into the cellular mechanisms that may be implicated in the etiology of PD. 
In the current study, the biochemical properties of the novel pathogenic DJ-1 
mutants, L10P and P158DEL are explored.  The novel mutants are assessed for protein 
stability, dimerization, solubility, and subcellular localization in comparison to WT and 
L166P DJ-1. These analyses reveal that L10P, L166P and P158DEL DJ-1 mutants are 
dramatically destabilized in comparison to WT protein. Interestingly, since L10P and 
P158DEL mutants retain the ability to dimerize, it suggests that enhanced turn-over of 
mutant proteins may be related to aberrant protein folding and not necessarily to 
dimerization.  Taken together, the studies herein suggest that L10P, L166P, and 
P158DEL DJ-1 mutations may be causative of disease by distinct mechanisms.  
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3.3   RESULTS 
Pathogenic DJ-1 mutants demonstrate reduced protein stabilities and are partially 
regulated by the proteasome.  
It has been previously shown that L166P mutant DJ-1 demonstrates dramatically 
reduced protein stability in comparison to WT protein (42;138;139;269;298;307;324) and 
that this aberration is due in part to rapid degradation of mutant protein by  the 
proteasome (138;139;298;307;324;422). To determine the effects of the recently reported 
L10P and P158DEL DJ-1 mutations on protein stability, protein turn-over pulse-chase 
experiments were performed with 35 S-methionine. The turn-over rates of WT, L10P, 
L166P, and P158DEL DJ-1 protein were compared.  Following these analyses it was 
determined that the half-life of WT DJ-1 was ~8 hours (Figure 3-1A). As expected, the 
half-life of L166P mutant DJ-1 was ~1 hour, which is consistent with previous reports 
(307;324). L10P and P158DEL DJ-1 mutants exhibited half-lives of ~2.5 hours and ~4 
hours respectively, demonstrating that both of these mutants also destabilize DJ-1. 
 To determine the effects of the proteasome complex on the turn-over rates of 
WT, L10P, L166P, and P158DEL DJ-1 protein variants, protein pulse-chase experiments 
were performed in the presence of 20μM MG-132. The ratio of DJ-1 protein remaining 
with the addition of MG-132 to that without the addition of MG-132 after 6 hours of 
chase was calculated and the results were compared for each DJ-1 variant. The turn-over 
rate for WT DJ-1 was not significantly affected by proteasome inhibition (Figure 3-1B). 
Conversely, treatment of cells with MG-132 partially stabilized all of the DJ-1 mutants 
analyzed, though the effect was most striking for the L10P DJ-1 mutant.   Interestingly, 
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proteasome inhibition slowed the decay of L10P, L166P, P158DEL DJ-1 mutant proteins, 
but it did not completely block the degradation of these mutants. This observation has 
been previously reported for the L166P DJ-1 mutant (139;298;324), suggesting that in 
addition to proteasome-mediated degradation, turn-over of L10P, L166P, and P158DEL 
DJ-1 mutant proteins can also be regulated by proteasome-independent mechanisms. 
Figure 3-1 
 
 Pathogenic DJ-1 mutants 
demonstrate dramatically reduced 
protein stabilities that are partially 
due to proteasome degradation.  
CHO cells were transfected with full-
length WT, L10P, L166P, or P158DEL 
human DJ-1 pZeoSV2 “(+)” 
constructs. At 48 hours post 
transfection, cells were labeled with 
35S-methionine for 30 mins and chased 
for 0, 1, 3, 6, or 10 hours. A) The graph 
represents the protein turnover results 
for the respective DJ-1 variants. The 
results are plotted as percentage of 
protein remaining over time 
standardized to the 0 hrs time point. 
The error bars show standard deviation 
(n=6).  The inset shows representative 
pulse-chase experiments. B) The ratio 
of DJ-1 decay in the presence of 20 μM 
MG-132 added at 0 hrs to that in the 
absence of MG-132 at 6 hours of chase 
was calculated for each sample. The 
graph depicts the average of the ratios 
between replicate samples for each DJ-
1 variant. The error bars indicate 
standard deviation (n=3). The inset 
image represents the DJ-1 signal 
remaining after 6 hours of chase for 
each of the DJ-1 variants in the 
absence and presence of MG-132. 
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The L10P and P158DEL DJ-1 mutations do not disrupt dimer formation but may 
alter protein folding. 
Previous studies reveal that in comparison to WT DJ-1 protein, L166P mutant DJ-
1 displays aberrant folding (12;139;324;469) that impairs the dimerization of this mutant 
and that is associated with a dramatic instability of this mutant protein 
(12;42;139;269;298;307;324). Thus, it is possible that L10P and P158DEL DJ-1 mutants 
are destabilized due to disrupted dimerization and/or improper protein folding. To assess 
the ability of L10P and P158DEL DJ-1 variants to form dimers, co-transfection and co-
immunoprecipitation experiments were conducted. Experiments with WT and L166P DJ-
1 were also conducted for comparison. CHO cells were transiently co-transfected with 
human HA-tagged full-length WT DJ-1 and human untagged full-length WT, L10P, 
L166P, or P158DEL DJ-1. Cells extracts were immunoprecipitated with an anti-HA 
antibody followed by immunoblot with antibody DJ5. These analyses revealed that the 
untagged WT, L10P, and P158DEL DJ-1 variants were all co-immunoprecipitated with 
HA-tagged WT DJ-1 protein (Figure 3-2A). However, L166P DJ-1 was not co-
immunoprecipitated with HA-tagged WT DJ-1. This indicates that L10P and P158DEL 
DJ-1 variants retain the ability to dimerize. 
To further analyze the consequences of DJ-1 mutations on protein structure, size 
exclusion chromatography experiments were conducted. Soluble lysates were 
fractionated from CHO cells expressing WT, L10P, P158DEL, or L166P human DJ-1.  
The assay was standardized by elution of purified proteins of known molecular masses. 
Fractions were resolved by SDS-PAGE and analyzed by immunoblot with the anti- 
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Figure 3-2 
 
The L10P and P158DEL DJ-1 mutations do not disrupt dimer formation but appear to alter protein folding 
patterns. A) CHO cells were co-transfected with HA-tagged full-length WT DJ-1 and pZeoSV2 (+) mock vector 
(“mock”) or with untagged full-length WT, L10P, P158DEL, or L166P human DJ-1 pZeoSV2 (+) constructs. At 24 
hours post transfection, cells were harvested and soluble protein lysates were extracted (“Start”). The cell lysates were 
then immunoprecipitated using anti-HA polyclonal antibody (“IP”). Equal amounts of the start, IP, and unbound 
supernatant (Unbound) fractions were resolved by SDS-PAGE and analyzed by western blot (“WB”) with the 
monoclonal DJ-1 antibody, DJ5. B) CHO cells were transiently transfected with full-length WT, L10P, L166P, or 
P158DEL human DJ-1 pZeoSV2 (+) constructs. Soluble extracts from CHO cells expressing the respective exogenous 
human DJ-1 proteins were loaded on a precalibrated Superose 6 column as described in the “Materials and Methods” 
section. The total cell lysates ("total") and fractions collected from the size-exclusion column were analyzed by western 
blot analysis with DJ5 antibody to detect human DJ-1. Fractions 20-32 are shown. The elution profile of known 
molecular mass standards [BSA (66 kDa), ovalbumin (44 kDa), carbonic anhydrase (29kDa) and cytochrome C 
(12kDa)] are indicated above.   
human specific DJ-1 antibody DJ5. The peak elution fraction for WT human DJ-1 was 
fraction 26 (Figure 3-2B), consistent with dimer formation. It has been previously 
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reported that L166P DJ-1 forms high molecular weight complexes which increase its 
apparent molecular weight when analyzed by gel filtration analyses (269;324). In the 
studies herein, L166P DJ-1 eluted in peak fraction 24, suggesting that it also forms high-
molecular weight complexes in CHO cells. Interestingly, L166P DJ-1 that would elute in 
fractions that would be consistent with monomeric forms of DJ-1 was not detected in 
these analyses.  Surprisingly, the peak elution for L10P DJ-1 was fraction 25, indicating 
that the L10P mutant adopts an apparent larger conformation than WT DJ-1 protein. 
Conversely, P158DEL DJ-1 primarily eluted into fractions 27 and 28, suggesting that it 
adopts a smaller conformation than WT DJ-1 protein.  
L10P, L166P and P158DEL DJ-1 mutants show reduced protein solubilities. 
Protein misfolding and aggregation is a prominent feature of many 
neurodegenerative disorders (402) and reduced solubility of DJ-1 is correlated with 
human disease (227;296;304;316;371). L166P DJ-1 is known to be misfolded 
(12;139;324) and this may result in reduced solubility of the mutant in comparison to WT 
DJ-1 (394). Gel filtration analyses revealed that the L10P and P158DEL DJ-1 variants 
may adopt abnormal folding patterns (Figure 3-2B); however, it is unknown whether 
protein solubility is affected by these mutations. To assess for changes in solubility, CHO 
cells expressing full-length WT, L10P, L166P, or P158DEL human DJ-1 were harvested 
and cell lysates were extracted into buffers of increasing solubilization strengths. The 
lysates were then analyzed by western blot with antibody DJ5.  WT, L10P, L166P, and 
P158DEL DJ-1 variants were all predominantly extracted in the soluble PBS/0.1% Triton 
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(TX) (Figure 3-3A). However, a significant fraction of P158DEL DJ-1 protein was 
extracted in the RIPA and SDS fractions.  
Figure 3-3 
 
L10P, L166P and P158DEL DJ-1 mutants show reduced protein solubilities. CHO cells were transfected with full-
length WT, L10P, L166P, or P158DEL human DJ-1 pZeoSV2 (+) constructs. At 24 hours post transfection, cells were cultured for an 
additional 18 hours in fresh DMEM with or without the addition of either 20μM MG-132 or 1μM Epoxomicin. A) Cells were 
harvested and sequentially extracted into PBS/0.1% Triton (TX) buffer, RIPA buffer, and 2% SDS/17mM Tris (SDS) buffer. Equal 
amounts (10ug) of each sample were loaded onto 13% polyacrylamide gels and analyzed by western blot for DJ-1 distribution with the 
DJ5 antibody. Blots were also probed with an actin antibody to assess equal protein loading. The mobility of molecular mass markers 
is indicated on the left. B) Cells were harvested and extracted using the Qproteome Cell Compartment Kit (Qiagen), following the 
manufacturer’s instructions. Equal amounts (10ug) of each sample were loaded onto 13% polyacrylamide gels and analyzed by 
western blot with antibody DJ5 to assess the distribution of human DJ-1, GAPDH monoclonal antibody as a cytoplasmic marker, 
histone H3 polyclonal antibody as a nuclear marker, and vimentin polyclonal antibody as a cytoskeletal marker.  “CE2” represents the 
cytoplasmic fractions, “CE3” represents the nuclear fractions and “CE4” represents the cytoskeletal/insoluble fractions. “1” lanes were 
loaded with extracts from cells treated with fresh DMEM only. “2” lanes were loaded with extracts from cells treated with fresh 
DMEM + epoxomicin.  “3” lanes were loaded with extracts from cells treated with fresh DMEM +MG-132.  
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Proteasome inhibitors have been shown to stabilize insoluble forms of L166P DJ-
1 protein when assessed in cell culture studies (307;325); however, it is not known 
whether L10P and P158DEL DJ-1 protein mutants display similar biochemical 
properties. To analyze the effects of proteasome inhibitors on DJ-1 solubility, CHO cells 
expressing WT, L10P, L166P, or P158DEL human DJ-1 were treated for 18 hours with 
20μM MG-132 or 1μM epoxomicin followed by harvesting and extraction into buffers of 
increasing solubilization strengths. The extracts were then assessed by immunoblot with 
antibody DJ5. Treatments with either MG-132 or epoxomicin resulted in only trace 
amounts of WT DJ-1 detected in the RIPA or SDS-soluble fractions (Figure 3-3A). Both 
MG-132 and epoxomicin dramatically promoted the accumulation of RIPA and SDS-
soluble forms of L10P DJ-1, though the effects were more provocative with MG-132. 
Similarly, MG-132 and epoxomicin resulted in the buildup of Triton-insoluble pools of 
L166P DJ-1. Interestingly, however, neither MG-132 nor epoxomicin treatments affected 
the amount of Triton-insoluble P158DEL DJ-1 protein. 
To expand on these biochemical fractionation results and to assess for possible 
changes in cellular localization, protein fractionation experiments were performed using 
the Qproteome Cell Compartment Kit.  CHO cells expressing WT, L10P, L166P, or 
P158DEL human DJ-1 were compared when untreated or challenged with 20μM MG-132 
or 1μM Epoxomicin for 18 hours.  Cytoplasmic (CE2), nuclear (CE3), and 
cytoskeletal/insoluble (CE4) protein fractions were generated. Cell extracts were 
analyzed by western blot with the antibodies to human DJ-1 (DJ-5), GAPDH, histone-
H3, and vimentin. These analyses revealed that under normal conditions, WT DJ-1 
protein primarily localized to cytoplasmic biochemical fractions and to a much lesser 
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extent into nuclear fractions (Figure 3-3B). WT DJ-1 protein was absent from 
cytoskeletal/insoluble protein fractions. As expected, MG-132 and epoxomicin treatments 
had little effect on WT DJ-1 protein. Under normal conditions, L10P DJ-1 was 
predominantly detected in both cytoplasmic and cytoskeletal/insoluble protein fractions. 
Following treatments with MG-132 or epoxomicin, L10P DJ-1 accumulated in the 
nucleus and cytoskeletal/insoluble fractions, suggesting that inhibition of the proteasome 
may act to stabilize insoluble forms of the L10P DJ-1. Under normal conditions, L166P 
DJ-1 was predominantly observed in the cytoplasmic fraction; however, following 
treatments with MG-132 or epoxomicin, L166P DJ-1 dramatically accumulated in 
cytoplasmic and cytoskeletal/insoluble protein fractions, and to a much lesser extent in 
nuclear fractions.  In the absence of proteasome inhibitors, the P158DEL DJ-1 variant 
was extracted in all three fractions and treatments with either MG-132 or epoxomicin had 
no significant effect on the biochemical extractability of P158DEL DJ -1 protein as 
detected by this method (Figure 3-3B). This finding further implies that this mutant 
exhibits reduced solubility even in the absence of induced proteasome challenge. 
L10P, L166P, and P158DEL DJ-1 form intracellular inclusions following 
proteasome inhibition. 
Olzmann et al. showed that MG-132 induced the recruitment of L166P DJ-1 into 
aggresomes (325). To determine whether a similar effect would be observed for the L10P 
and P158DEL DJ-1 mutants, co-immunofluorescence studies were conducted comparing 
untreated and treated CHO cells expressing WT, L10P, L166P, or P158DEL human DJ-1 
challenged for 12 hours with 20μM MG-132.  Cells were co-labeled with DJ5 and 
82 
 
vimentin antibodies to assess for DJ-1 staining and inclusion formation, respectively. 
Under normal culturing conditions, WT and mutant DJ-1 proteins exhibited diffuse 
staining (Figure 3-4A). However, nuclear and cytoplasmic DJ-1 positive inclusions were 
detected in a small percentage of L10P and P158DEL DJ-1 expressing cells (Figure 3-
4A and C and data not shown).  MG-132 treatment induced the formation of 
intranuclear and cytoplasmic DJ-1 positive protein inclusions in cells expressing L10P, 
L166P, and P158DEL DJ-1 but had little effect on cells expressing WT DJ-1 (Figure 3-
4B and C). Interestingly, co-immunofluorescence analyses with DJ5 and vimentin 
antibodies did not reveal any accumulation or redistribution of vimentin surrounding 
L10P or P158DEL DJ-1 protein inclusions, although vimentin was co-localized with 
these inclusions on rare occasions, suggesting that the observed DJ-1 positive inclusions 
are not classical aggresomes.  MG-132 caused inclusion formation most provocatively in 
cells expressing L10P DJ-1 since ~74±15% of these cells had inclusions. P158DEL DJ-1 
formed inclusions in 59±19% of cells, while L166P DJ-1 formed inclusions in 45±7% of 
cells.  
3.4 DISCUSSSION 
A short nucleotide deletion resulting in P158DEL DJ-1 and a missense mutation 
resulting in the L10P DJ-1 amino acid substitution are novel recently reported 
PARK7/DJ-1 mutations causative of autosomal recessive early-onset parkinsonism 
(144;270). In the current study, the effects of these mutations on DJ-1 protein stability, 
dimerization, solubility, and localization were assessed in cultured cells. Additionally, the 
previously extensively characterized pathogenic L166P DJ-1 mutant was also analyzed in 
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Figure 3-4A 
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Figure 3-4B 
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Figure 3-4C 
 
L10P, L166P, and P158DEL DJ-1 form intracellular inclusions following proteasome inhibition. CHO cells were 
transfected with full-length WT, L10P, L166P, or P158DEL human DJ-1 pZeoSV2 (+) constructs. At 48 hours post 
transfection, cells were cultured for an additional 12 hours in fresh DMEM with or without the addition of 20μM MG-
132. Cells were stained with the mouse monoclonal anti-DJ-1 antibody DJ5 (green), a rabbit polyclonal anti-vimentin 
(red) and Hoechst 33342 (blue) and visualized by microscopy. Representative images are shown for cells that were not 
treated with MG-132 in A) and cells that were treated with MG-132 in B). Bar = 50μm (C) The proportion of  cells 
depicting DJ-1 inclusions  was quantified as the  percentage of the total cells expressing full-length WT, L10P, L166P, 
or P158DEL human DJ-1 with or without MG-132 challenge. The graph represents the percentage of cells with 
inclusions averaged between replicate images. The error bars show standard deviation. 
 
parallel. In comparison to WT DJ-1 protein, the L10P, L166P, and P158DEL DJ-1 
mutants all exhibited reduced protein stabilities when assessed by pulse-chase protein 
turn-over analyses; however, the extent of the effects of the respective mutations on 
protein stability was variable. The L10P and P158DEL mutants were relatively less 
unstable than L166P. To begin to explain these findings, and because  it was previously 
reported that the instability L166P DJ-1was at least partially mediated by the proteasome 
(138;139;298;307),  pulse-chase analyses were conducted in the presence of the 
reversible proteasome inhibitor, MG-132. As previously shown by others (138;139), MG-
132 only partially stabilized L166P DJ-1 protein in the studies herein. Similarly, MG-132 
failed to completely block degradation of L10P and P158DEL DJ-1 mutants, though turn-
over was dramatically slowed for both variants. Noteworthily, in comparison to the other 
mutants, MG-132 most effectively slowed the degradation of L10P DJ-1, suggesting that 
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this mutation renders DJ-1 to be more susceptible to degradation by the proteasome. 
Based on the findings herein, is it also likely that proteasome-independent mechanisms 
can act to degrade L10P, L166P, and P158DEL DJ-1 mutant proteins. It is worth 
mentioning that autophagy inhibitors did not impede the degradation of any of the DJ-1 
protein variants analyzed in these studies (data not shown). This observation has also 
been reported by other groups (42;324). Though a recent paper by Giaime and colleagues 
supports a role for caspase-6 mediated cleavage of DJ-1, it is not clear what additional 
proteases may act to regulate DJ-1 protein (129). The current findings suggest that 
reduced DJ-1 protein stability resulting from the L10P and P158DEL mutations may at 
least be partially responsible for DJ-1 loss-of-function.  
It has been previously shown that the L166P mutation causes DJ-1 to unfold and 
it is believed that this disconformity effectively disrupts dimer formation, which may be 
associated with rapid degradation  (12;139;298;307;324). Interestingly, it was determined 
that unlike L166P DJ-1, L10P and P158DEL DJ-1 mutants were able to dimerize with 
WT DJ-1 protein. A similar finding has been reported for another pathogenic DJ-1 
mutant, M26I, which also exhibits decreased stability without associated dimerization 
impairments (42). This indicates that the ability for DJ-1 to form dimers may not 
necessarily correlate to protein stability. However, improper protein folding may be 
causal of the decreased stability observed for some pathogenic DJ-1 mutants. Supporting 
this idea, the studies herein revealed that L10P and P158DEL DJ-1 variants adopted 
altered structural conformations in comparison to WT DJ-1 protein as determined by size 
exclusion chromatography. Though it is believed that L166P DJ-1 cannot dimerize, 
monomeric forms of L166P DJ-1 of the expected ~21 kDa size were not detected in the 
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current study. This may be due to the unstable nature of monomeric L166P DJ-1.  
Instead, the observed L166P DJ-1 eluted with an apparent molecule mass greater than 
that of WT DJ-1. This finding is consistent with a previous report showing that L166P 
DJ-1 forms higher-order protein complexes (269), and this suggests that L166P DJ-1 may 
also form such complexes in CHO cells. The elution of WT DJ-1 was primarily 
consistent with dimer formation, although the broad elution profile would also suggest 
equilibrium with a monomeric pool. Surprisingly, the L10P DJ-1 mutant exhibited an 
apparent elution profile that is consistent with a slightly larger conformation than WT 
protein. The L10P mutation is located in the first β-strand of DJ-1, which is not directly 
involved in the dimer interface (167;170;469). Therefore, this mutation is not predicted to 
affect dimerization, but would have a significant effect on disrupting the first β-strand.  
Conversely, P158DEL DJ-1 exhibited an elution profile that suggests that it is slightly 
smaller than WT protein. Residue P158 is also outside of the DJ-1 dimer interface; 
however it located  right before the beginning of DJ-1 α-helix 7 which is required for 
dimer formation (167;170;469). Additionally, P158 is a highly conserved residue in the 
DJ-1 protein family (23). Thus, it is possible that deletion of residue P158 shifts the 
conformation of DJ-1 in such a way as to allow for tighter packing of the monomer or the 
dimer and this could in turn result in apparent decreased protein size.   
Without proper regulation, misfolded proteins can accumulate and aggregate with 
each other, and this can eventually lead to impaired cellular processes (291;323).  Since 
our data indicate that the L10P, L166P, and P158DEL mutations can alter protein folding, 
it was of interest to determine the effects of these mutations on protein solubility.  The 
respective solubilities of WT, L10P, L166P, and P158DEL DJ-1 proteins were assessed 
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by two different biochemical fractionation methods. When expressed in CHO cells under 
normal culturing conditions, P158DEL DJ-1 and to a lesser extent L10P DJ-1 
demonstrated reduced solubilities.  Interestingly, when biochemical fractionation 
experiments were performed following treatments with MG-132 or epoxomicin, L10P 
and L166P DJ-1 proteins demonstrated dramatic accumulations of insoluble proteins  
while WT  DJ-1 was unaffected by these treatments. This indicated that L10P and L166P 
DJ-1 protein variants, which are inclined to misfolding and being degraded, accumulate 
as aggregates when degradation is impaired.  The finding that more L10P accumulates in 
the insoluble fractions compared to L166P in the presence of MG132 suggests that the 
ability of the former variant to still form dimers may also promote this process.  
Surprisingly, while P158DEL formed insoluble aggregates under native conditions, 
proteasome inhibition did not enhance the accumulation of insoluble species. These 
findings suggest that P158DEL DJ-1 can spontaneously accumulate as misfolded 
aggregates that are largely regulated by proteasome-independent mechanisms.   
Aggregation of DJ-1 mutant proteins also was studied at the microscopic level. 
Under normal conditions, only a small percent of cells expressing L10P and P158DEL 
DJ-1 depicted DJ-1 inclusions. Such a finding has not been reported for other pathogenic 
DJ-1 mutants, suggesting that these mutants may be more prone to aggregation.  MG-132 
treatments induced the formation of L10P, L166P, and P158DEL DJ-1 intranuclear and 
intracytoplasmic protein inclusions that were not detected in cells expressing WT DJ-1 
protein under the same conditions. Most of the observed inclusions did not co-localize 
with common aggresome markers, suggesting that they likely represent deposits of 
aggregated DJ-1. The formation of these inclusions did not correlate with formation of 
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insoluble DJ-1 observed biochemically. For example, biochemical analysis demonstrated 
that P158DEL DJ-1 forms an intrinsic insoluble pool of protein and this is not 
significantly altered by MG132 treatment. It is possible that MG132 treatment induced 
this pool of P158DEL DJ-1 to coalesce into inclusions.  Remarkably, inclusions were 
most prominent in cells expressing L10P DJ-1 following MG132 challenge. Biochemical 
analysis demonstrated that MG132 resulted in a dramatic accumulation of insoluble L10P 
DJ-1 and it is possible that such a pool is required for inclusion formation. Similarly, 
MG132 treatment resulted in the accumulation of insoluble L166P DJ-1 and inclusion 
formation. Olzmann and colleagues showed that L166P DJ-1 formed perinuclear 
aggresomes in cultured cells following treatments with MG-132; however it was 
determined that this phenomenon only occurred in the presence of the E3 ubiquitin-
protein ligase, parkin (325). Interestingly, no interactions between parkin and L10P or 
P158DEL DJ-1 variants were discovered in the studies herein (data not shown), thus it is 
likely that L10P and P158DEL DJ-1 inclusion formation is regulated by alternative 
mechanisms.  
In conclusion, these studies demonstrate that the pathogenic L10P and P158DEL 
mutants result in the destabilization of DJ-1 and that proteasome degradation is at least 
partially involved in this process. Additionally, the L10P and P158DEL mutations do not 
prevent dimer formation, indicating that that the observed decreases in protein stability 
may be caused by limited and localized perturbations in protein folding. These alterations 
in protein structure are likely responsible for reduced protein solubilities and intracellular 
protein inclusion formation. These properties of L10P and P158DEL mutants may 
collectively contribute to DJ-1 loss-of-function by depleting the pool of functional 
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protein. In addition, these novel findings indicate that different pathogenic DJ-1 mutants 
can display diverse altered biochemical properties. Future studies to assess for specific 
effects of pathogenic DJ-1 mutations on biological pathways in vivo and studies in 
patients would give insights into the physiological role for DJ-1 protein especially as it 
relates to the etiology of PD. 
3.5 MATERIALS AND METHODS 
Antibodies 
DJ-5 is a mouse monoclonal antibody that is specific for human DJ-1 protein (296). 
Affinity purified mouse anti-actin (clone C4) monoclonal antibody reacts with all forms 
of vertebrate actin (Millipore, Billerica, MA).  The affinity purified polyclonal antibody, 
HA.11 (Covance, Emeryville, CA), reacts with proteins with the amino acid sequence, 
YPYCVPVYA. Vimentin (C-20) is an affinity purified polyclonal antibody that reacts 
with vimentin (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Anti-histone H3, CT, 
pan (Millipore, Temecula, CA) is a polyclonal antibody that recognizes histone H3 
protein. Affinity purified glyceraldehyde-3-phosphate dehydrogeanase (GAPDH) (clone 
6C5) monoclonal antibody reacts with GAPDH from various species (Advanced 
Immunochemical, Long Beach, CA). 
Cloning of Human DJ-1 Constructs 
Human full-length WT DJ-1 cDNA was cloned into the pZeoSV2 (Invitrogen, 
Carlsbad, CA) mammalian expression vector at the HindIII and Xho I restriction sites. 
Using the WT DJ-1 construct, the QuickChange® Site Directed Mutagenesis Kit 
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(Stratagene, La Jolla, CA) was used in order to generate L10P, L166P, and P158DEL 
mutant forms of DJ-1 in the pZeoSV2 vector. The sequences of the oligonucleotides used 
for mutagenesis are listed in Table 1. The respective DJ-1 plasmid sequences were 
verified by DNA sequencing as a service offered by the DNA Sequencing Facility of the 
University of Pennsylvania. 
A human N-terminal HA-tagged WT DJ-1 construct was generated by PCR, using 
the human full-length WT pZeoSV2 construct as a template. The sequences for the 
oligonucleotides are listed in Table 3-1. The tagged insert was cloned into the pCR 2.1 
TOPO vector (Invitrogen) and subsequently cloned into the pZeoSV2 vector at the Hind 
III and Xho I restriction sites. The sequence of the plasmid was verified by DNA 
sequencing as described above. 
Cell Culture 
 Chinese Hamster Ovary (CHO) cells were cultured in Dulbecco-modified Eagle 
medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (Hyclone, 
Logan, UT), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Cells were 
incubated at 37ºC and 95% air/5% CO2 atmosphere.  
Pulse-chase Protein Turnover Analysis 
 CHO cells were cultured in 100 mm dishes. Cells were transfected with pZeoSV2 
full-length WT, L10P, L166P, or P158DEL human DJ-1 constructs using Lipofectamine 
Reagent (Invitrogen), following the manufacturer’s protocol. At 24 hours post 
transfection, cells were split into 35 mm dishes and cultured in complete DMEM for an 
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additional 24 hours. At 48 hours post transfection, cells were methionine-deprived for 15 
minutes by incubation in pre-warmed methionine-free DMEM (Invitrogen)/10% dialyzed 
FBS (Hyclone)  before adding 100μCi [35S]-methionine (Perkin-Elmer, Waltham, MA) 
per ml of methionine free DMEM/10% dialyzed FBS for 30 min.   Chase experiments 
were conducted in triplicates with normal DMEM/FBS with or without 20μM MG-132 
for 0, 1, 3, 6, and 10 hours. Cells were then rinsed with PBS and harvested in 
cytoskeleton (CSK) buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 % 
Triton X-100) containing 1 % SDS and boiled at 100 ºC for 5 minutes. CSK buffer was 
added to the lysates in order to bring the final concentration of SDS to 0.25%. Lysates 
were frozen on dry ice and kept frozen at -20 ºC until the last time point was harvested. 
The radiolabelled protein extracts were pre-cleared with a rabbit serum pre-incubated 
with protein A-agarose (Santa Cruz Biotechnology, Inc.)  for 3 hours at 4ºC and 
radiolabelled extracts were then immunoprecipitated overnight at 4ºC with antibody DJ5 
pre-incubated with protein A/G PLUS-agarose (Santa Cruz Biotechnology, Inc). The 
antibody-protein complexes were washed 3 times with 10 volumes of CSK buffer, 
resuspended in 2 volumes of 2X SDS sample buffer and boiled at 100 ºC for 5 minutes. 
The beads were removed by centrifugation and the samples were loaded onto 13 % 
polyacrylamide gels. Following electrophoresis, gels were fixed with 50% methanol/5% 
glycerol, dried and exposed to a PhosphorImager plate and the signal was quantified 
using ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA). 
Western Blot Analysis 
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Protein samples were resolved by SDS-PAGE followed by electrophoretic transfer onto 
nitrocellulose membranes.  Membranes were blocked in Tris buffered saline (TBS) with 
5% dry milk, and incubated overnight with primary antibodies diluted in TBS/ 5% dry 
milk. Each incubation was followed by goat anti-mouse conjugated horseradish 
peroxidase (HRP) (Amersham Biosciences, Piscataway, NJ) or goat anti-rabbit HRP 
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA), and immunoreactivity was detected 
using chemiluminescent reagent (NEN, Boston, MA) followed by exposure onto X-ray 
film.  
Size Exclusion Chromatography 
Gel filtration chromatography was performed as previous described (366). CHO cells 
transiently expressing human full-length WT, L10P, L166P, or P158DEL DJ-1 were 
cultured in 100 mm dishes, grown to confluency, and harvested. To harvest cells, the 
cells were rinsed and scraped in PBS. After recovery by centrifugation, cells were lysed 
in PBS/0.1% Triton and the cell debris was sedimented at 13,000 x g for 5 min. The 
extracts were filtered through a 0.22 µm filter and loaded onto the column. Fractions 
were analyzed by immunoblotting with anti-human DJ-1 specific antibody DJ5.  
Experiments were repeated at least 3 times and similar results were obtained. 
Co-Immunoprecipitation and Heterodimer Analysis 
CHO cells were cultured in 100 mm plates. Cells were transfected with N-
terminal HA-tagged full-length WT human DJ-1 construct (HA-WThDJ/pZeoSV2) or co-
transfected with HA-WThDJ/pZeoSV2 and pZeoSV2 full-length untagged WT, L10P, 
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L166P, or P158DEL human DJ-1 constructs.  After 24 hours, cells were rinsed and 
scraped in PBS and lysed by vortexing into 500 uL of ice-cold 1X CSK buffer with 
protease inhibitors. Cell debris was sedimented at 13,000 x g for 1 minute and 
supernatants were removed to fresh tubes. 50 uL of each supernatant was saved as the 
“Start” fraction. The remainders of the supernatants were incubated for 3 hours at 4 °C 
with anti-HA tag antibody, HA.11 (Covance) preabsorbed to protein A-Agarose beads 
(Santa Cruz Biotechonogy, Inc.). The beads were sedimented, repeatedly rinsed with ice-
cold 1X CSK buffer, resuspended in 2X SDS sample buffer, heated to 100 oC and saved 
as the “IP” fractions. The supernatants remaining after immunoprecipitation were saved 
as the “Unbound” fractions. Sample buffer was added to the “Start” and “Unbound” 
fractions and then they were heated to 100 oC for 5 minutes. The Start, IP, and Unbound 
fractions were resolved by SDS-PAGE and immunoblotted with DJ5 antibody.  
Biochemical Fractionation and Cell Compartment Fractionation 
CHO cells were cultured in 100 mm dishes and transfected with pZeoSV2 full-length 
WT, L10P, L166P, or P158DEL DJ-1 constructs using Lipofectamine transfection 
reagent. At 24 hours post transfection, the cells were cultured for an additional 18 hours 
in fresh DMEM with or without the addition of either 20μM MG-132 or 1μM 
Epoxomicin.  For biochemical fractionation, cells were scraped into PBS, sedimented, 
and lysed into buffers of increasing solubilization strengths using previously described 
methods (366). The respective biochemical fractions were analyzed by western blot with 
the monoclonal antibodies DJ5 and anti-actin.  
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For cell compartment fractionation, cells were scraped into ice-cold PBS and fractionated 
into cellular compartments using the Qproteome Cell Compartment Kit (Qiagen, 
Valencia, CA) following the manufacture’s protocol.   Cell lysates were quantified using 
the BCA assay and analyzed by western blot with the monoclonal antibodies DJ5 and 
GAPDH and the polyclonal antibodies anti-histone H3 and vimentin (C-20).  
 Double-immunofluorescence Analyses  
CHO cells were cultured in 35 mm dishes and transfected with pZeoSV2 full-
length WT, L10P, L166P, or P158DEL DJ-1 constructs using Lipofectamine transfection 
reagent. At 48 hours post transfection, the cells were cultured for an additional 12 hours 
in fresh DMEM with or without the addition of 20μM MG-132. Cells were rinsed in PBS 
and fixed by incubation in ice-cold acetic-methanol (1 part acetic acid to 20 parts 
methanol) at -20 °C for at least 30 minutes. Cells were rehydrated with water, rinsed with 
PBS, and blocked in PBS/1% FBS/1% skin fish gelatin (Sigma)/1% milk/0.1% Triton for 
30 minutes. Primary antibodies were diluted into blocking solution and cells were labeled 
for 1-2 h at room temperature.  Following PBS washed, coverslips were incubated with 
anti-mouse IgG antibody secondary conjugated to Alexa 488 and anti-rabbit IgG 
antibody conjugated to Alexa 594.  Nuclei were counterstained with Hoechst 
trihydrochloride trihydrate 33342 (Invitrogen), and coverslips were mounted using 
Fluoromount-G (Southern Biotech, Birmingham, AL).  Images were captured using an 
Olympus BX51 fluorescence microscope mounted with a DP71 digital camera (Olympus, 
Center Valley, PA). For quantification of cells with DJ-1 inclusions, images were 
captured with a 20x objective and all cells in the field were counted. 
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Table 3-1 
Human DJ-1 
Variant 
Forward Oligonucleotide 
sequence 
Reverse Oligonucleotide 
Sequence 
L10P 5’-GCT CTG GTC ATC CCG 
GCT AAA GGA GCA GAG-
3’ 
5’-CTC TGC TCC TTT 
AGC CGG GAT GAC 
CAG AGC-3’ 
L166P 5’-TTC GAG TTT GCG CCT 
GCA ATT GTT GAA-3’ 
5’-TTC AAC AAT TGC 
AGG CGC AAA CTC 
GAA-3’ 
P158DEL 5’-CTT ACA AGC CGG GGG 
GGG ACC AGC TTC GAG-3’ 
5’-CTC GAA GCT GGT 
CCC CCC CCG GCT TGT 
AAG-3’ 
HA-tagged WT 5’-AAG CTT GCC ACC ATG 
TAC CCA TAC GAT GTT 
CCA GAT TAC GCT ATG 
GCT TCC AAA AGA GCT 
CTG GTC ATC-3’ 
5’-CTC GAG CTA GTC 
TTT AAG AAC AAG-3’ 
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4.1 ABSTRACT 
PD is the most common neurodegenerative movement disorder.  A pathological hallmark 
of PD is the presence of intraneuronal inclusions comprised of fibrillized α-syn in 
affected brain regions.  Mutations in the gene, PARK7, which encodes DJ-1, can cause 
autosomal recessive early-onset PD. Although DJ-1 has been shown to be involved in 
diverse biological processes, several in vitro studies suggest that it can inhibit the 
formation and protect against the effects of α-syn aggregation. We previously established 
and characterized transgenic mice expressing pathogenic A53T human α-syn (M83 mice) 
that develop extensive α-syn pathologies in the neuroaxis resulting in severe motor 
impairments and eventual fatality.  In the current study, we have crossbred M83 mice on 
a DJ-1 null background (M83-DJnull mice) in efforts to determine the effects of the lack 
of DJ-1 in these mice.  Animals were assessed and compared for survival rate, 
distribution of α-syn inclusions, biochemical properties of α-syn protein, demise and 
function of nigral dopaminergic neurons, and extent of gliosis in the neuroaxis. M83 and 
M83-DJnull mice displayed a similar onset of disease and pathological changes, and none 
of the analyses to assess for changes in pathogenesis revealed any significant differences 
between M83 and M83-DJnull mice. These findings suggest that DJ-1 may not function 
to directly modulate α-syn nor does DJ-1 appear to play a role in protecting against the 
deleterious effects of expressing pathogenic A53T α-syn in vivo. It is possible that α-syn 
and DJ-1 mutations may lead to PD via independent mechanisms. 
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4.2 INTRODUCTION   
In 1997, the seminal identification of a missense mutation (A53T) in α-syn in 
several kindred with PD (357) lead to subsequent studies showing that α-syn is a major 
component of several types of brain amyloidogenic pathological inclusions 
(133;320;405;464). For example, it is now established that Lewy bodies, characteristic 
neuronal inclusions of PD, are predominantly comprised of α-syn polymerized into 10-15 
nm fibrils (133;320;464).  The spectrum of  neurodegenerative disorders  with α-syn 
pathological inclusions are termed synucleinopathies  (122;133;320;405;464). α-Syn is a 
140 amino acid protein that is predominantly expressed in the brain and which localizes 
to presynaptic nerve terminals (76;133;320). The physiological role for α-syn is not fully 
understood, but several functions including the abilities to act as an auxiliary molecular 
chaperone and to play a role in maintaining synaptic nerve terminal integrity have been 
suggested (33;59;76;464). Although there is substantial evidence supporting the toxic 
nature of aberrant α-syn aggregation, mutations (missense or gene multiplication) in the 
α-syn gene (SNCA) provide the most direct evidence for a pathogenic role of α-syn 
(133;320;357;405;464). 
  PD is the most common neurodegenerative movement disorder (90;465). The 
clinical features of PD include bradykinesia, postural instability, resting tremor, and 
rigidity, which result from the progressive loss of dopaminergic neurons in the substantia 
nigra pars compacta (86;112;127;164;334), as well as a range of nonmotor symptoms 
(62;355). While for most patients the cause for PD is idiopathic, mutations in genes at 
multiple loci, designated PARK1 through PARK 13, result in parkinsonian phenotypes 
with distinct features (32;80;124;213). DJ-1 was initially associated with PD 
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pathogenesis when homozygous recessive mutations in the PARK7 gene encoding DJ-1 
protein were identified in patients with early-onset PD (46). Since this initial report,  
various autosomal recessive mutations in DJ-1, including, missense, splice-site, 
frameshift and large deletions have been discovered (2;14;46;144;146;157;270)  in 1-2% 
of PD patients with early to mid age of onset (144;154;263). DJ-1 mutations are thought 
to cause PD due to a loss of functional DJ-1 protein, though the natural role for DJ-1 as it 
relates to sporadic PD is not known (41;109;365;486).  In addition, no autopsies have 
been performed on individuals with DJ-1 mutations; therefore, the exact 
neuropathological manifestations of disease in patients harboring DJ-1 mutations remains 
to be determined.  
DJ-1 encodes a 189 amino acid protein which is a member of the ThiJ/PfPI 
superfamily based on its structure (170;248;313;469). It is expressed in both neurons and 
astrocytes in the brain (19;21;218;325;387), but it is also expressed in many other organs 
(121;324;489).  DJ-1 has been shown to protect against a variety of insults including 
oxidation, inflammation, mitochondrial inhibition, and proteasome dysfunction 
(139;260;310;366;418;422;456;487;498). More specifically, in vitro studies have 
suggested that DJ-1 may act to directly prevent α-syn aggregation (389;494) and several 
groups have reported that  DJ-1 can ameliorate the harmful effects of mutant α-syn in 
vitro and in cell culture studies (27;389;493). Interestingly, elevated levels of oxidized 
DJ-1 protein are present in the brains of patients with sporadic PD (65) and DJ-1 
associates with inclusions in various other synucleinopathies (296;316). Thus, it is 
plausible to hypothesize that DJ-1 may physiologically act to protect against the 
formation or the harmful effects of aggregated α-syn.    
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We previously reported a transgenic mouse of synucleinopathies that was 
generated by expressing human A53T α-syn in the nervous system using the mouse prion 
protein (PrP) promoter (131). These mice developed an age-dependent severe movement 
disorder which is associated with abundant neuronal α-syn inclusions in the neuraxis and 
axonal degeneration (131). Since DJ-1 has been postulated to have several protective 
functions, including anti-α-syn aggregation properties, we sought to study the effects of 
the lack of DJ-1 in these mice. We hypothesize that the loss of DJ-1 may exacerbate the 
extent or promote the onset of disease in these mice, either by promoting α-syn 
aggregation or the consequences of α-syn inclusions. In the current study, transgenic 
mice homozygotically expressing human A53T α-syn (“M83 mice”) were crossed with 
genetically altered null DJ-1 mice in order to generate homozygous A53T α-syn 
transgenic mice on a DJ-1 null background (“M83-DJnull mice”). M83-DJnull mice were 
analyzed and compared to M83 mice as it relates to survival rate, distribution of α-syn 
pathologies, biochemical properties of the α-syn protein, and extent of gliosis in the 
neuroaxis.  
  
4.3 RESULTS 
Generation of DJ-1 null mice 
DJ-1 null mice were generated as described in detail in “Materials and Methods” 
in order to create a loss-of-function DJ-1 mouse model. The disruption of DJ-1 
expression was demonstrated with several DJ-1 antibodies by western blot analysis of 
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total protein lysates that were extracted from the brain cortices of DJ-1 null, heterozygous 
(Het), and WT mice (Fig. 4-1C).  The protein signal for DJ-1 in DJ-1 Het mice was ~0.6 
fold the intensity compared to WT mice and was completely absent in samples from DJ-1 
null mouse tissues. Similar results were obtained using other tissues including 
cerebellum, brainstem, spinal cord, liver and lung (data not shown).  As reported by 
others for other DJ-1 null mice, extensive histological analyses did not demonstrate any 
evidence of degeneration in the nervous system (data not shown and see Fig. 3C) 
(13;60;63;136;274).  
 
M83-DJnull mice display a similar motor phenotype and age of onset as M83 mice. 
In attempts to understand the role for DJ-1 in modulating α-syn pathology in vivo, 
the previously established transgenic mouse line M83 expressing human A53T α-syn 
(131) was cross-bred with the DJ-1 deficient mouse line described above in order to 
generate mice homozygous for both the α-syn transgene and the DJ-1 null allele (“M83-
DJnull” mice). The double homozygous transgenic genotype was confirmed as described 
in the “Materials and Methods” section. The lack of DJ-1 was confirmed by western blot 
analysis that also demonstrated that the deficiency of DJ-1 did not alter the expression 
levels of human α-syn (Fig. 4-1D). It is known that M83 mice exhibit a severe motor 
impairment with mid to late age of onset and which eventually results in fatality (131). 
To determine whether a DJ-1 deficiency would alter the disease motor phenotype and 
onset of disease, a cohort of M83-DJnull mice and M83 mice were housed in parallel. It 
was observed that the M83-DJnull mice presented symptoms of weight loss, neglect of 
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grooming, decreased mobility, paralysis, and eventual fatality, symptoms similar to those 
characterized for the M83 mice described 
Figure 4-1 
 
Generation of DJ-1 null mice.       
A) Schematic of the DJ-1 gene (419) 
showing the inserting of the β-geo 
trap (gray box) in the intron between 
exon 6 and 7 resulting in disruption of 
the gene. The β-geo trap includes a 
splice acceptor (SA), a selectable 
marker β-Geo, which is a fusion of β-
galactosidase and neomycin 
phosphotransferase II, followed by a 
stop codon and a polyadenylation 
signal. B) Image showing the 
analyses from 3 individual 6-month 
old DJ-1 null (DJ null), DJ-1 het (DJ 
het), and wild-type (WT) mice. Tail 
DNA was extracted and analyzed by 
PCR with primers specific for the neo 
gene. An agarose gel stained with 
ethidium bromide is shown.  The 
arrow indicates the predicted PCR 
product for the neo cassette insert 
used to disrupt DJ-1 expression. C) 
Cerebral cortical tissues were 
harvested and total protein lysates 
were extracted.  Equal amounts (12 
ug) of protein extracts were loaded 
onto 13% polyacrylamide gels and 
analyzed by western blot analysis 
with the polyclonal anti-DJ-1 
antibodies, 691 and N-20 as well as a 
monoclonal anti-actin antibody to 
confirm equal protein loading. Three 
samples were loaded, each from the 
same mice depicted in B. D) The 
brainstem and spinal cord tissues 
were harvested from 2 individual DJ-
1 null (DJnull), M83-DJnull, M83, 
and WT mice and HS protein lysates 
were extracted. 4 ug of protein 
extracts were loaded onto 13% polyacrylamide gels and analyzed by immunoblot with antibody 691 to assess DJ-1 
expression. Blots were also analyzed with the human specific monoclonal anti-α-syn antibody, LB509, as well as a 
monoclonal anti-actin antibody to assess protein loading. 
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 previously (131). The severity of disease symptoms was comparable between M83-
DJnull mice and M83 mice. Further, while the age range for the onset of disease in the 
M83-DJnull mice was 4-16 months of age (Fig. 4-2), this was not significantly different 
from the age of disease onset in M83 mice, which was 8-17 months of age. To confirm 
this observation, statistical analyses comparing the survival rates between mice revealed 
that the median age of disease onset for both mouse genotypes was 11 months of age.   
Figure 4-2 
 
The lack DJ-1 does not affect 
the survival of M83-DJnull 
mice. The graph depicts the 
onset of motor phenotype in M83 
mice (n=77) and M83-DJnull 
mice (n=26).  
 
 
 
 
 
The distribution and extent of α-syn pathologies is similar between M83-DJnull and 
M83 mice.   
 Although M83-DJnull mice did not exhibit enhanced motor impairment or 
decreased survival rate in comparison to M83 mice, it is possible that DJ-1 deficient 
animals may display an altered distribution of α-syn inclusions, perhaps affecting areas of 
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the nervous system that were not previously observed in M83 mice. Certain neuronal 
populations, including the hippocampus, the olfactory bulb, dopaminergic neurons of the 
substantia nigra, and Purkinje cells of the cerebellum are completely devoid of α-syn 
inclusions in the M83 mouse (131). Thus, post mortem immunohistochemical and 
immunofluorescence analyses were conducted on brain and spinal cord tissues from sick 
M83-DJnull mice in order to assess the distribution of α-syn inclusions.  These analyses 
revealed that affected M83-DJnull mice demonstrate the same distribution of 
somatodendritic α-syn neuronal inclusions and dystrophic α-syn neurites throughout the 
neuraxis as seen in M83 mice. A high density of inclusions was observed in the spinal 
cord, throughout the brainstem, the deep cerebellar nuclei, and some regions of the 
thalamus, such as the medioventral, ventromedial and paracentral nuclei (Fig. 4-3A and 
data not shown). In the cortex, α-syn inclusions were predominantly observed in the 
motor cortex. Conversely, regions that were devoid of pathology in M83 mice, such as 
the olfactory bulb, hippocampus, or Purkinje neurons were also spared of inclusions in 
M83-DJnull mice (Fig. 4-3A and data not shown). In representative images showing the 
similarities between the mouse genotypes, inclusions were immunoreactive with antibody 
Syn 514 which detects pathological α-syn (Fig. 4-3A). Ubiquitin, which is known to 
modify α-syn in the inclusions in M83 mice (131;376), also localized to most of the α-syn 
inclusions in M83-DJnull animals (Fig. 4-3A). It was previously shown that α-syn 
inclusions that are present in the diseased tissues of M83 mice are highly phosphorylated 
at Ser129 in α-syn (463). Similarly, the majority of the α-syn inclusions in M83-DJnull 
mice were immunoreactive for an antibody specific for this modification (Fig. 4-3A).  
Notably, while α-syn inclusions were present in a few of the tyrosine hydroxylase (TH)-
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positive neurons of the locus coeruleus (Fig. 4-3B), none were present in the TH-positive 
neurons of the substantia nigra in M83-DJnull animals (Fig. 4-3B), a phenomenon which 
was also previously observed in M83 mice (131).  Further, stereological analyses of the 
substantia nigra in WT, M83, DJ-1 null and M83-DJnull animals did not reveal any 
significant differences in the total number of dopaminergic neurons between mouse 
genotypes when animals were analyzed at 6 and 12 months of age (Fig. 4-3C).  However, 
similar to M83 mice, a significant number of the α-syn inclusions in M83-DJnull mice 
were positive for the amyloid binding dye Thioflavin-S (Fig. 4-3D)(131). 
Figure 4-3 
Neither the distribution of α-syn pathologies 
nor the numbers of TH positive neurons in 
substantia nigra are altered in M83-DJnull 
mice compared to M83 mice. A) 
Immunohistochemical analyses were performed 
as described in “Materials and Methods”. M83 (1, 
3, 5, and 7) and M83-DJnull tissues (2, 4, 6, and 
8) were stained with the anti-ubiquitin antibody (1 
and 2); anti-pSer129 antibody (3 and 4), or anti-α-
syn antibody Syn 514 (5-8). The representative 
images depict the pons (1-6) and CA2 region of 
the hippocampus (7 and 8). B) Double 
immunofluorescence analysis of the locus 
coeruleus and substantia nigra from a 10 month 
old sick M83-DJnull mouse. Tissues were double 
labeled with anti-α-syn antibody Syn303 (green) 
and anti-TH (red). The overlay is shown on the 
right. C) Stereological analysis of TH positive 
neurons in substantia nigra of WT, M83, DJ-1 
null, and M83-DJnull mice at ages 6 and 12 
months. The graph represents the mean value of 
the total number of TH positive neurons for each 
mouse strains as indicated. The error bars indicate 
standard deviation (n=3).  D) Spinal cord tissues 
were double labeled with antibody Syn303 (red) 
and Thioflavin S staining (green). The image 
shows amyloidogenic α-syn inclusions in a 12 
month old diseased M83-DJnull mouse. The bar = 
100μm in A and B and 10μm in C. 
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The α-syn in M83-DJnull mice does not display altered abundance or biochemical 
properties compared to M83 mice. 
  Previous studies of M83 mice revealed that the formation of α-syn inclusions is 
reflected by the accumulation of insoluble α-syn protein in the respective tissues analyzed 
(131). While M83-DJnull mice did not reveal histological differences in comparison to 
M83 mice, biochemical studies may reveal more subtle differences. Western blot 
analyses were performed using extracts from brain cortical, cerebellar, and 
brainstem/spinal cord (BS/SC) tissues which had been fractionated into buffers of 
increasing solubilization strengths. Analyses between age-matched sick M83-DJnull and 
M83 mice were compared.  These analyses revealed that the abundance and biochemical 
distribution of human α-syn was similar between the M83-DJnull and M83 mice in all of 
the tissues analyzed. In the cerebral cortex, human α-syn was most abundantly extracted 
into the HS, HS-TX and RIPA fractions for both mouse genotypes (Fig. 4-4A). In the 
cerebellum of M83 and M83-DJnull mice, α-syn was distributed in a similar manner 
(Fig.4-4B). However, α-syn exhibited slightly reduced solubility into SDS fractions in 
cerebellar tissues of some of the mice analyzed (Fig. 4-4B). This observation was not due 
to a DJ-1 deficiency, however, since it was variable from mouse to mouse, irrespective of 
genotype (data not shown).  In the BS/SC regions of affected M83 and M83-DJnull mice, 
biochemical analysis revealed a similar accumulation of RIPA-insoluble/SDS-soluble 
human α-syn (Fig. 4-4C). Additionally, while there were no differences in the abundance 
or extractability of the α-syn  present in the BS/SC tissues of the predicted ~17 kDa size, 
when comparing between M83 and M83-DJnull mice, several insoluble, higher molecular 
weight α-syn species were detected on some immunoblots (Fig. 4-4C). These species 
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were previously shown to represent ubiquitinated forms of α-syn (376). However, this 
phenomenon was not due to a DJ-1 deficiency since it was variable and independent of 
DJ-1 expression (data not shown)(376).  
M83-DJnull mice do not display increased levels of Ser 129 specific α-syn 
phosphorylation. 
In a previous report, diseased M83 mice exhibited increased levels of insoluble α-syn 
protein which was highly phosphorylated specifically at amino acid residue Ser129 (463). 
To determine whether a DJ-1 deficiency could alter the levels of the Ser129-specific 
phosphorylation of α-syn in brain cortical, cerebellar, and BS/SC tissue extracts from 
age-matched diseased M83 and M83-DJnull mice were compared by western blot 
analysis with the antibody pSer129.  α-Syn that was extracted from  BS/SC tissues from 
M83-DJnull mice was highly phosphorylated in the SDS-soluble fraction but barely 
detectable in the HS, HS-TX, or RIPA fractions in all of the mice analyzed (Fig. 4-4C).  
However, there were no differences between M83 and M83-DJnull mice when the levels 
of phosphorylated α-syn were compared.    
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Figure 4-4 
The paucity of DJ-1 does not affect the 
levels or biochemical distribution of α-syn 
nor does it affect Ser 129 specific α-syn 
phosphorylation. Age-matched (10 month 
old) diseased M83-DJnull (“1” and “2”) and 
M83 (“3”) mice were analyzed for the 
abundance and solubility of α-syn protein. The 
levels of Ser 129 specific α-syn 
phosphorylation were also compared between 
mice. The brain cortex (A), cerebellum (B) 
and BS/SC (C) were harvested and 
sequentially extracted into HS extraction 
solution, HS-Tx extraction solution, RIPA 
extraction solution, and 2% SDS/8M urea 
extraction solution (SDS). Equal amounts 
(5ug) of each sample were loaded onto 15% 
polyacrylamide gels and analyzed for α-syn 
distribution by western blot analysis with the 
monoclonal human specific α-syn antibody, 
LB509 (in A-C). Ser 129 specific α-syn 
phosphorylation in the BS/SC was assessed 
with the monoclonal antibody, pSer129 (in C). 
Additionally, blots were probed with antibody 
691 to assess DJ-1 and an actin antibody to 
confirm equal protein loading. The mobility of 
molecular mass markers is indicated on the 
left.  
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M83-DJnull mice do not show increased gliosis. 
It is well known that reactive gliosis can follow brain tissue damage and is 
typically accompanied by inflammation (123). A recent study by Waak et al. showed that 
the disruption of DJ-1 expression in astrocytes resulted in enhanced neurotoxcity which 
was due to an elevated neuroinflammatory response (456). Diseased M83 mice exhibit 
astrocytic gliosis in the brain regions where α-syn inclusions are the most abundant (131).   
It is possible that a DJ-1 deficiency in M83-DJnull mice would result in an aberrant 
inflammatory response in these animals.  To test this hypothesis, M83 and M83-DJnull 
mouse brain tissues were evaluated by immunohistochemistry analysis with the reactive 
microglial antibody marker, IBA-1 as well as the astrocyte marker, GFAP. The 
distributions of the microglia and astrocytes present in the mouse tissues were compared. 
While these analyses revealed that reactive microglia were primarily localized to the 
brainstem and spinal cord tissue regions, the distribution and abundance of microglia was 
similar in M83 and M83-DJnull mouse tissues (Fig. 4-5A and data not shown). 
Astrogliosis also was observed in areas of the neuroaxis such as the brainstem and spinal 
cord where abundant α-syn pathological inclusions were present; however, the prevalence 
was similar in M83 and M83-DJnull mice (Fig. 4-5A and data not shown). This 
observation was further confirmed by biochemical fractionation/western blot analysis for 
IBA-1 (Fig. 4-5B) and GFAP (Fig. 4-5C). 
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Figure 4-5 
Gliosis in M83-DJnull mice 
does not differ from M83 
mice.                                    
A) Immunohistochemical 
analyses were performed 
using brain tissues harvested 
from diseased M83 and M83-
DJnull mice. The distribution 
of microglia was assessed 
between mice using the 
polyclonal antibody, IBA1, 
which is specific for reactive 
microglia. Analyses to 
determine the presence of 
astrocytes were conducted 
using the polyclonal antibody, 
GFAP. The representative 
images show staining in the 
pons. The scale bar = 100μm. 
In B) and C), age-matched 
diseased M83-DJnull (“1” and 
“2”) and M83 (“3”) mice were 
analyzed biochemically for 
changes in gliosis. The 
representative images show 
the analyses from 10 month 
old mice. Brainstem and 
spinal cord tissues were 
harvested, pooled together and 
sequentially extracted as 
described in “Materials and 
Methods”. Equal amounts 
(5ug) of each sample were 
loaded onto 13% 
polyacrylamide gels and 
analyzed by western blot 
analysis with antibody IBA1 
in B) and antibody GFAP in 
C). In B) and C), the mobility 
of molecular mass markers is 
indicated on the left. 
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M83-DJnull mice do not have elevated levels of Peroxiredoxin 6. 
During the course of previous proteomics analysis, we discovered that affected 
M83 mice display increased levels of peroxiredoxin (Prx) 6 that is substantiated by 
western blot analysis (Fig. 4-6A) and this may reflect an attempt to activate a protective 
mechanism. In addition, DJ-1 is thought to be able to act as an atypical Prx-like 
peroxidase (13) and to protect against oxidative insults 
(13;53;181;196;253;366;455;493). It is possible that the disruption of DJ-1 expression 
may induce further reactive stress in M83-DJnull mice. Therefore, the effect of the 
paucity of DJ-1 on the levels of Prx6 induced by α-syn pathology was assessed. 
However, no major differences between M83 and M83-DJnull mice were detected as it 
related to the extent of Prx6 expression or biochemical distribution. 
M83-DJnull mice do not exhibit changes in the levels of dopamine or its metabolites. 
 Since some studies suggest that DJ-1 and α-syn may modulate TH and L-3,4-
dihydroxyphenylalanine (L-DOPA) decarboxylase enzyme activities (185), it is possible 
that M83-DJnull mice could display altered levels of dopamine (DA) and its metabolites. 
To test this hypothesis, striatum tissues were dissected from WT, M83, DJ-1 null, and 
M83-DJnull mice at 6 and 12 months of age. Tissues were analyzed by high performance 
liquid chromatography-electrochemical detection (HPLC-ECD) to quantify and compare 
the total levels of L-DOPA, DA, and 3,4-dihydoxyphenylacetic acid (DOPAC) between 
mouse genotypes. However, there were no significant differences between animals for 
either of the age groups analyzed (Fig. 4-7), indicating normal dopamine-related 
biochemical activities in M83-DJnull mice. 
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Figure 4-6 
M83-DJnull mice do not 
have elevated levels of Prx 6 
relative to M83 mice.     A) 
The representative 
immunoblots were performed 
with HS-soluble extracts from 
brainstem and spinal tissues 
that were harvested from a WT 
non-transgenic mouse, M83 
mice that were sacrificed 
before the manifestation of a 
motor phenotype at 3 months, 
6 months, and 10 months of 
age, as well as a diseased M83 
mouse. Equal amounts (10 ug) 
of protein extracts were loaded 
onto 15% polyacrylamide gels 
and analyzed by western blot 
analysis with antibody anti-
Prx6 to assess the levels of Prx 
6 in the mice. Blots were also 
probed with the human 
specific α-syn antibody, 
LB509 to verify the expression 
of human α-syn protein as well 
as a β-tubulin antibody to 
assess protein loading. B) 
Age-matched diseased M83-DJnull (“1” and “2”) and M83 (“3”) mice were analyzed for the levels of Prx 6. Brainstem 
and spinal cord tissues were harvested, pooled together and sequentially extracted as described in “Material and 
Methods”. Equal amounts (5ug) of each sample were loaded onto 13% polyacrylamide gels and analyzed by western 
blot for Prx6 as well as actin. The representative images show the analyses from 10 month old mice. The mobility of 
molecular mass markers is indicated on the left.  
 
4.4   DISCUSSION 
 Some in vitro studies and cell culture paradigms indicate that DJ-1 may be able to 
modulate the aggregation of α-syn and/or act to mitigate the toxicity of pathogenic forms 
of α-syn (27;389;493;494). However, these properties of DJ-1 have not been directly 
assessed in vivo. M83 transgenic mice are previously described animals that express 
human A53T α-syn and developed a severe age-dependent motor phenotype 
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Figure 4-7 
Unaltered levels of DA in 
the striatum of M83-
DJnull animals. Striatal 
tissues were dissected from 
WT, M83, DJ-1 null, and 
M83-DJnull mice at ages 6 
months and 12 months. 
Tissues were analyzed by 
HPLC to quantify DA in 
(A), L-DOPA in (B), and 
DOPAC in (C). The graphs 
in A-C depict the mean of 
the levels of the respective 
analytes for each of the 
indicated mouse strains at 
the respective ages. D) The 
ratio of DA/DOPAC was 
calculated. In A-D, errors 
bars indicate standard 
deviation (n=3 for 6 month 
animals and n=5 for 12 
month animals).   
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associated with the formation of α-syn pathological inclusions in the neuroaxis (131). 
These inclusions were demonstrated to be composed of fibrillized aggregates of insoluble 
α-syn protein with a high abundance in  the brainstem and spinal cord while inclusions 
were absent in some regions such as the olfactory bulb, hippocampus, and dopaminergic 
neurons of the substantia nigra (131). In the current study, in efforts to ascertain whether 
DJ-1 modulates α-syn aggregation and pathology in vivo, double homozygous M83-
DJnull transgenic mice were generated which express human A53T α-syn on a DJ-1 null 
background. If DJ-1 normally acts to mitigate α-syn aggregation or has protective 
functions against the deleterious effects of α-syn aggregation, it was hypothesized that the 
DJ-1 deficient M83-DJnull mice would exhibit an exacerbated phenotype in comparison 
to that observed in M83 mice. Statistical analyses comparing the survival rates revealed 
that the disease onset was not earlier in M83-DJnull mice compared to M83 mice. The 
median age of survival for both groups of animals was 11 months of age. This suggested 
that DJ-1 may not play a major role in ameliorating the harmful effects of expressing 
A53T mutant α-syn in vivo. However, to further assess the differences between these 
mice, several analyses were conducted. Nevertheless, no major differences between M83 
and M83-DJnull mice were observed in any of the analyses that were performed. 
Immunohistochemical analyses comparing the distributions of α-syn pathologies 
throughout the neuroaxis failed to detect any overt variations between M83 and M83-
DJnull mice. Both mouse groups consistently exhibited abundant pathologies in the same 
tissue regions while the absence of inclusions in other areas was remarkably similar 
between mice. These analyses also revealed that most of the inclusions in diseased M83-
DJnull animals were composed of ubiquitinated, fibrillized α-syn protein that was highly 
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phosphorylated at amino acid residue Ser129 similar to inclusions in diseased M83 mice 
(131;463) and in patients (117;150;232;404;463). The formation of inclusions in M83 
and M83-DJnull mice was further validated by biochemical and western blot analyses to 
assess the soluble extractability. However, the studies herein did not reveal any changes 
relating to α-syn aggregation in M83-DJnull animals. In addition, these studies did not 
reveal any differences in the levels of the phosphorylation of Ser129. Thus, these findings 
suggest that DJ-1 does not directly alter α-syn in vivo as it relates to protein fibrillization, 
phosphorylation, or aggregation. Neither does DJ-1 appear to directly modulate the 
expression of mutant α-syn since similar levels of the mutant protein were observed 
between mice in the brain regions analyzed. 
While the present study suggests that DJ-1 does not act to directly regulate A53T 
mutant α-syn in vivo, it is possible that DJ-1 can mitigate secondary deleterious effects of 
α-syn aggregation in mice such as inflammation and oxidative stress. It was previously 
established that M83 mice exhibited astrocytic gliosis associated with the formation of α-
syn inclusions (131). Additionally, recent studies using a primary neuron and astrocyte 
co-cultured model reveal that a DJ-1 deficiency is causal of an enhanced 
neuroinflammatory response that results in increased neurotoxicity (456). To determine 
whether DJ-1 modulates the gliosis associated with α-syn aggregation in vivo, diseased 
M83 and M83-DJnull mice were analyzed by immunohistochemistry with astrocyte 
specific and reactive microglia specific markers. However, these analyses did not reveal 
any differences between mouse types relating to the distribution and/or extent of gliosis. 
Additionally, the biochemical and immunoblot assessments of protein extracts from M83 
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and M83-DJnull mouse tissues also did not identify any differences. Thus, since gliosis 
was independent of DJ-1 expression, DJ-1 may not act to regulate gliosis in M83 mice.  
Since DJ-1 and α-syn may regulate TH promoter activation and have an effect on 
TH enzyme activity (189), it was relevant to assess for the levels of striatal DA in M83-
DJnull mice in comparison to WT, DJ-1 null, and M83 animals. However, no differences 
were revealed for any of the genotypes when mice were analyzed for the levels of L-
DOPA, DA, or DOPAC. This supports previous findings in the literature which report 
normal DA levels and its metabolites in DJ-1 null animals (136). Further, in the studies 
herein, stereological analyses revealed no change in the number of nigral dopaminergic 
neurons in both a young and old cohort of M83-DJnull mice. Our finding is also in 
agreement with other reports which do not detect degeneration of these neurons in DJ-1 
null mice (136). 
In a variety of model systems, the expression of mutant A53T α-syn has been 
shown to result in increased levels of oxidative stress (191;197;339).While DJ-1 has been 
shown to be involved in diverse biological processes, several studies demonstrate its 
ability to mitigate the toxic effects of aberrant oxidation 
(13;53;181;200;253;366;455;493). In addition, in some studies DJ-1 was reported to be 
able to act as an atypical Prx-like peroxidase (13). The current study demonstrated that 
when compared to WT mice and healthy M83 mice, sick M83 animals exhibited 
increased steady-state expression of Prx6. This phenomenon specifically occurred in the 
BS/SC tissues of M83 mice where α-syn pathologies were most abundant. 
Comparatively, no alterations in Prx6 were observed in the cortex in diseased M83 
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animals (data not shown). This suggests that the increased levels of Prx6 observed in sick 
M83 mouse BS/SC tissues may be a protective attempt against α-syn aggregation. It is 
known that Prx6 levels are increased in PD and that this increase is associated with the 
recruitment of Prx6 to Lewy body inclusions (360). Additionally, since Prx6 has been 
shown to be up-regulated in response to oxidation (69), it could imply that α-syn 
inclusion formation is accompanied by increased oxidative stress in sick M83 mice.  To 
determine whether these observed alterations in Prx6 were modulated by DJ-1 in vivo, 
BS/SC tissues from sick M83 and M83-DJnull mice were analyzed by western blot 
analysis and compared for immunoreactivity with the Prx6 antibody. However, these 
analyses revealed that diseased M83 and M83-DJnull mice expressed Prx6 at similar 
levels.  
Herein, a loss-of-function DJ-1 mouse model was employed in attempts to 
ascertain the role for DJ-1 in mitigating mutant α-syn in vivo. Many groups have utilized 
DJ-1 deficient animals in efforts to define a physiological role for DJ-1 protein in vivo as 
it relates to PD (13;60;136;204;274;354;480;483). However, while DJ-1 null animals 
have been shown to exhibit mild behavioral changes, these were not associated with any 
observed degeneration in the nervous system (13;60;63;136;480). Neither have DJ-1 null 
mice exhibited increased signs of oxidative stress (63;480). A few studies have shown 
that DJ-1 deficient animals are more vulnerable to paraquat (483), MPTP (204;274), and 
rotenone toxicity (354), suggesting a role for DJ-1 in protecting against oxidative stress 
and mitochondrial impairments. 
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 In the present study, DJ-1 deficient animals were not more vulnerable to the toxic 
effects of mutant A53T α-syn. These studies suggest that DJ-1 may not have a significant 
role in mitigating the formation of α-syn inclusions and their deleterious effects in vivo. 
Alternatively, there may be compensatory mechanisms in the mouse which act to mimic 
the function of the lost DJ-1 protein. For example, recent studies by other groups suggest 
a possible genetic interaction between DJ-1 and other  PD related genes, PINK1 and 
parkin (449;477). It is of interest to note that in the current study, no alterations in the 
steady-state levels of parkin protein were observed in the brains of M83 and M83-DJnull 
mice when they were analyzed by western blot (data not shown). Neither did PINK1 
protein levels appear to be modulated by DJ-1 in the mice analyzed (data not shown). 
Further, triple knockout mice that are deficient for DJ-1, parkin, and PINK1 do not have 
decreased life spans nor do they exhibit phenotypes that are comparable to any of the 
symptoms of PD (211). It is possible that yet unidentified candidate genes may be acting 
to compensate for the loss of DJ-1 in vivo. Identifying such candidate genes would give 
new insights into plausible biochemical mechanisms that underlie the pathogenesis of 
PD. 
4.5  MATERIALS AND METHODS 
Antibodies 
Anti-IBA1 is a rabbit polyclonal antibody raised against ionized calcium-binding adaptor 
molecule 1 (Iba1), a marker for activated microglial cells (Wako Chemicals USA, Inc., 
Richmond, VA). Anti-glial fibrillary acidic protein (GFAP) is a rabbit polyclonal 
antibody against glial fibrillary acidic protein, a specific marker for astrocytes (Promega 
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Corporation, Madison, WI). LB509 is a mouse monoclonal antibody that specifically 
reacts with human α-syn (18;132). Syn 303 and 514 are monoclonal antibodies raised 
against oxidized forms of human α-syn and that preferentially recognize pathological 
forms of the protein (130;462).  pSer129 is a monoclonal antibody that specifically 
recognizes α-syn that is phosphorylated at the Ser129 (463). Anti-ubiquitin (clone 1510) 
is a mouse monoclonal antibody that reacts with conjugated and unconjugated forms of 
ubiquitin (Millipore, Billerica, MA). Anti-actin (clone C4) is an affinity purified 
monoclonal antibody that reacts with all vertebrate isoforms of actin (Millipore). Anti-TH 
antibody (Millipore) is an affinity purified rabbit polyclonal antibody.  An affinity 
purified rabbit polyclonal antibody raised against a synthetic peptide corresponding to 
amino acid residues 196-210 of human Prx6 was obtained from Sigma-Aldrich (Saint 
Louis, MO). 691 is a rabbit polyclonal antibody raised against recombinant human DJ-1 
protein but that reacts with DJ-1 from various species (296). DJ-1 (N-20) is an affinity 
purified goat polyclonal antibody raised against a peptide corresponding to the N-
terminus of human DJ-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Anti-β-
tubulin (clone TUB2.1) is a monoclonal antibody raised against β-Tubulin (Sigma). Goat 
anti-mouse IgG Alexa Fluor 488 conjugated antibody and goat anti-rabbit or anti-mouse 
IgG Alexa Fluor 594 conjugated antibodies were purchased from Molecular Probes 
(Eugene, OR).  
Generation of DJ-1 null mice 
Murine embryonic stem (ES) cells (clone XE726) with a recombination resulting in the 
disruption of the DJ-1 gene were obtained from BayGenomics (San Francisco, CA). This 
cell line was generated by random exon trapping and it was determined by DNA 
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sequencing that the recombination event occurred after exon 6 in the murine DJ-1 gene 
(see Fig. 1A). These ES cells were injected into C57BL/6J blastocysts as a service of the 
University of Pennsylvania Transgenic and Chimeric Mouse Facility and chimeric mice 
were generated. The germ line transmission of the null-gene was determined by breeding 
chimeras with C57BL/6J mice and PCR analyses of tail DNA with primers specific for the 
neomycin gene. Mice homozygous for the null-allele were generated by crossing F1 mice, 
and homozygous null mice were determined by PCR analyses of tail DNA and western 
blot analysis of mouse tail protein samples (dissolved in 4%SDS, 8M urea) using an 
antibody to DJ-1.  
Generation of M83-DJnull mice 
The previously established homozygous transgenic mice line M83 expressing A53T 
human α-syn (131), was bred with the homozygous DJ-1 null mouse line described in the 
previous section. The double heterozygous offspring were mated to generate double 
homozygous transgenic mice. Mouse genotypes were confirmed by Southern blot 
analysis of tail genomic DNA with a probe for human α-syn. Homozygous α-syn 
transgenic lineages were identified by quantitative Southern blot analysis and verified by 
backcrossing. Null DJ-1 homozygosity was determined by PCR against the neo gene and 
western blot analysis of mouse tail protein samples as described in the previous section. 
In some mice, immunoblotting of brain tissue extracts with 691 and LB509 antibodies 
were used to confirm the loss of DJ-1 protein and the expression of human pathogenic α-
syn protein respectively. Mice were sacrificed by CO2 euthanization as approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee. 
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Immunohistochemical Analysis 
 Mice were sacrificed with CO2 euthanization and perfused with PBS/heparin, followed 
by perfusion with either 70% ethanol/150mM NaCl or PBS buffered formalin. The brain 
and spinal cord were then removed and fixed for 24 hours in the respective fixatives used 
for perfusion. As previously described tissues were dehydrated at room temperature 
through a series of ethanol solutions, followed by xylene and then were infiltrated with 
paraffin at 60ºC (434).  The tissues were then embedded into paraffin blocks which were 
then cut into 6μm sections. Immunostaining of the sections was then performed using 
previously described methods (102). 
Double-Labeling Immunofluorescence Analysis  
Paraffin-embedded tissue sections were deparaffinized and hydrated through a series of 
graded ethanol solutions followed by 0.1M Tris, pH 7.6.  The sections were incubated 
simultaneously with the Syn 303 and anti-TH primary antibodies diluted in 5% dry 
milk/0.1M Tris, pH 7.6. After extensive washing, sections were incubated with goat anti-
mouse secondary conjugated to Alexa 488 and goat anti-rabbit secondary conjugated to 
Alexa 594. After washing, the sections were coverslipped with VectaShield-DAPI 
mounting medium (Vector Laboratories, Burlingame, CA) and visualized using an 
Olympus BX51 microscope.  
Unbiased Stereological Determination of Dopaminergic Neurons in the Substantia 
Nigra 
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The number of anti-TH immunoreactive neurons in the entire substantia nigra was 
assessed for WT, M83, DJ-1 null, and M83-DJnull mice at ages 6 months and 12 months 
using similar methods described by Kitada et al. (211) with a few exceptions. Brains were 
fixed in 70% ethanol/150mM NaCl and sectioned at 10μm thickness. Every fifth section 
was stained with anti-TH polyclonal antibody (Millipore). Three brains were analyzed for 
each of the indicated mouse strains at each of the respective ages. 
Thioflavin-S Staining  
Paraffin-embedded tissue sections were incubated with antibody Syn303 followed by 
anti-mouse conjugated Alexa Fluor 594 as described above. Sections were stained with 
thioflavin-S by immersing in freshly made 0.0125% thioflavin-S/40%EtOH/60% PBS 
and differentiated in 50% EtOH/50% PBS. The sections were coverslipped and visualized 
as described above.  
Mouse Protein Analysis 
Cerebral cortical tissues were harvested from 6 month old DJ-1 null, DJ-1 Het, and WT 
mice. Tissues were sonicated in 3 tissue volumes of 2% SDS/8M urea. Total protein 
extracts were then quantified using the bicinchoninic acid (BCA) assay (Pierce 
Biotechnology, Rockford, IL) and bovine serum albumin as the standard. Equal amounts 
of protein extracts were resolved by SDS-PAGE and analyzed by western blot. 
 Sequential Biochemical Fractionation 
The cortex, cerebellum, brainstem and spinal cord were dissected from mice. For each 
mouse, the brainstem and spinal cord were pooled together and then all tissues were 
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weighed and homogenized with a pellet pestle motor in 3 tissue volumes of high-salt 
(HS) buffer (50 mM Tris [pH 7.5], 750 mM NaCl, 5 mM EDTA, with a protease inhibitor 
cocktail at 1:1000 and PMSF at 1:500, and the phosphatase inhibitors, 20 uM NaF, 1 uM 
NaVO4, and 1 uM okadaic acid) followed by sedimentation at 100,000 x g for 20 
minutes. Supernatants were saved as the HS fraction. Pellets were homogenized in 3 
tissues volumes of high salt-triton (HS-TX) buffer (HS buffer with 1% Triton X-100) and 
sedimented at 100,000 x g for 20 minutes. The supernatants were saved as the HS-TX 
fraction. The pellets were subjected to a sucrose myelin float by homogenizing in 3 pellet 
volumes of sucrose buffer (HS buffer/1M sucrose) and after centrifugation, the myelin-
rich supernatants were discarded. Pellets were then homogenized in 2 tissue volumes of 
radioimmunoprecipitation assay buffer (RIPA) buffer (50 mM Tris [pH 8.0], 150 mM 
NaCl, 5 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS with the 
protease and phosphatase inhibitors), sedimented at 100,000 x g for 20 minutes, and the 
supernatants were saved as the RIPA fraction. Pellets were then sonicated in 1 pellet 
volume of 2% SDS/8M urea and were designated to be the SDS fractions. The fractions 
were then quantified using the BCA assay, resolved by SDS-PAGE, and analyzed by 
immunoblot as previously described above. 
Catechol Quantification by HPLC with Electrochemical Detection (ECD)  
Striatal catecholamine content was assessed in WT, M83, DJ-1 null, and M83-DJnull 
mice. Mice were analyzed at 6 months and 12 months of age. In order to isolate the 
striatum, the brains were submerged into ice-cold phosphate buffer and dissected into 1 
mm-thick coronal sections using a vibratome (Series 1000, R.L. Slaughter, Essex, UK). 
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Dissected tissues were weighed and homogenized by sonication in 10 volumes of 1 μM 
3,4 dihydroxybenzylamine (DHBA) in 0.1M perchloric acid. Following centrifugation at 
16,000 × g for 10min at 4oC, 20μl of the supernatants were injected onto an 1100 series 
Agilent HPLC system controlled by Chemstation software (Agilent, Palo Alto, CA).  The 
mobile phase consisted of 72 mM citric acid, 28.4 mM sodium phosphate, 2% methanol, 
pH 2.8. Catechols were resolved at a flow rate of 1 mL/min on a reverse-phase C18 Luna 
column (150 X 4.6 mm, 5um; Phenomenex, Torrance, CA) and detected with a Coularray 
detector (ESA Biosciences, Chemsford, MA) with the following working potentials (in 
mV): -200, +50, +300 and +400.  Chemstation software (version 1.04, ESA Biosciences) 
was used for the quantification by comparing to the peak areas of known concentrations 
of standards.  Acid-precipitated protein pellets were extracted in 2% SDS / 50mM Tris-
Cl, pH 7.4 and the protein concentrations were determined using the microBCA kit 
(Peirce, Rockford, IL). Analyte levels were normalized to DHBA and protein 
concentration. 
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5.1 ASTRACT 
 
Various mutations in the PARK2 gene which encodes the protein, parkin, are 
causal of a disease entity termed autosomal recessive juvenile parkinsonism. Parkin can 
function as an E3 ubiquitin protein ligase, mediating the ubiquitination of specific 
targeted proteins and resulting in proteasomal degradation. Parkin is thought to lead to 
parkinsonism as a consequence of a loss in its function. In this study, immunoblot 
analyses of brain extracts from Balb/c, C57BL/6, C3H, and 129S mouse strains 
demonstrated significant variations in immunoreactivity with anti-parkin monoclonal 
antibodies (PRK8, PRK28, and PRK109). This resulted partly from differences in the 
steady-state levels of parkin protein across mouse strains. There was also a complete loss 
of immunoreactivity for PRK8 and PRK28 antibodies in C3H mice which was due to a 
homologous nucleotide mutation resulting in an E398Q amino acid substitution. In 
cultured cells, parkin harboring this mutation had a greater tendency to aggregate, 
exhibited reduced interaction with the E2 ubiquitin conjugating enzymes, UbcH7 and 
UbcH8, and demonstrated loss of function in promoting the proteasomal degradation of a 
specific putative substrate, synphilin-1. In situ, C3H mice displayed age-dependent 
increased levels of brain cortical synphilin-1 compared to C57BL/6, suggesting that 
E398Q parkin in these mice is functionally impaired and that C3H mice may be a suitable 
model of parkin loss-of-function similar to patients with missense mutations.   
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5.2 INTRODUCTION 
Parkinson disease (PD) is an insidious neurodegenerative disorder that is 
characterized by the selective demise of specific neuronal populations, including 
dopaminergic neurons of the substantia nigra, and is associated with an impairment of 
motor functions. Most cases of PD are sporadic, but several disease-causing genes have 
been identified (44).  In 1998, it was shown that mutations in the parkin gene (also 
known as PARK2) were responsible for a disease entity termed autosomal recessive 
juvenile parkinsonism (AR-JP) (208). To date, a variety of nonsense, missense, exonic 
deletion, splice site, duplication, and triplication mutations in PARK2 have been 
identified in individuals with both early and late-onset PD (155;282;423;452). Since 
several community based reports suggest that parkin mutations may contribute to up to 
15% of the inherited cases of PD and are the major cause of early-onset PD 
(44;144;266;352;475) , much work has been done to understand the role of parkin in the 
pathogenesis of PD.   
 The parkin gene is large, spanning over 1.4 Mega bases with 12 exons and large 
intronic regions (16;208;209). The gene encodes a ~52kDa protein that is 465 amino 
acids in length (208). The protein has an amino terminal ubiquitin-like (Ubl) domain as 
well as two RING finger domains which are separated by an IBR finger domain at the 
carboxyl terminus (208;308). These structural features are common to E3 ubiquitin-
protein ligases (E3 ligases)(424) and parkin can function in this capacity 
(74;148;178;367;392;407). E3 ligases are a class of proteins that work in concert with 
ubiquitin-conjugating enzymes (E2s) to mediate the transfer of ubiquitin to specific 
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protein substrates. This ubiquitin transfer often targets substrates for proteolytic 
degradation by the 26S proteasome (74;194). It is known that parkin can interact with the 
E2 ubiquitin-conjugating enzymes, UbcH7 and UbcH8 (178;392;490). Additionally, 
many groups have shown that under certain experimental paradigms, parkin can facilitate 
the ubiquitination of a variety of substrates and can also aid in the subsequent degradation 
of a subset of these substrates (68;72;83;173;177;216;306;370;393;409;439;490). Thus, it 
is widely accepted that parkin functions as an E3 ligase; however, it is unclear how this 
function may be related to PD (99;109;254).  
Several of the pathogenic mutations in parkin have been shown to impair its E3 
ligase activity. Pathogenic mutations, such as the T240R mutation, have been shown to 
reduce the interactions between parkin and E2 ubiquitin-conjugating enzymes 
(143;178;392;490). Additionally, this disrupted association of parkin with E2 enzymes 
can result in reduced ubiquitination and degradation of parkin substrates 
(72;178;392;407;490). It is also known that parkin can ubiquitinate itself which then 
leads to its degradation by the proteasome (67;490). Pathogenic mutants which do not 
demonstrate the ability to autoubiquitinate often show altered protein solubility (407). 
This altered solubility may be related to decreased protein turnover that is specific to the 
proteasome pathway (490).  
It is hypothesized that parkin mutations may lead to parkinsonism through a loss 
in parkin function since parkin has been shown to play a protective role in a number of 
studies (71;178;201;447). Parkin deficient mice have been generated by several labs in 
efforts to study the effects of parkin loss-of-function in vivo (135;186;212;350;379;454). 
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Several inconsistencies have been reported regarding the effects of abolishing parkin in 
mice. However, in general, parkin loss in mice is not associated with an increased 
morbidity or loss of dopaminergic neurons (135;186;350;379;454;496). Nor has parkin 
loss in mice been shown to have an effect on many of the putative parkin substrates 
(217).  
In this report, the western blot analyses of endogenous brain parkin from four 
different mouse strains, C57BL/6, Balb/c, C3H, and 129S, are described. Dramatic 
variations in the protein levels of endogenous parkin were observed between mouse 
strains. Additionally, a novel endogenous homozygous missense mutation was 
discovered in C3H mice which resulted in the parkin amino acid substitution, E398Q. 
This mutation abolished the PRK8 and PRK28 parkin antibody epitopes in C3H mice 
while immunoreactivity with the PRK109 antibody was retained. Because C3H mice may 
potentially be used in future studies that involved parkin, the impact of the novel 
endogenous parkin mutation on protein function was examined.  Characterization of this 
mutation indicates that C3H mouse parkin is functionally impaired, suggesting that the 
C3H mouse strain may be a suitable in vivo model for endogenous loss-of-function 
parkin studies.  
5.3 RESULTS 
Differential immunoreactivity for parkin protein in various mouse strains 
During the course of analyzing parkin expression by immunoblotting in mice 
from various backgrounds, dramatic differences were observed for immunoreactivity 
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with 3 different monoclonal anti-parkin antibodies (Fig. 5-1).  All three antibodies used 
here (PRK8, PRK28 and PRK109) were previously shown to specifically recognize 
human and mouse parkin and to recognize epitopes within the RING2 domain of parkin 
(amino acids residues 399-465 of human parkin) (347). In brain cortex, PRK109 showed 
the highest level of immunoreactivity in the 129S background, followed by the C3H 
background and lowest, and about equivalent, levels in the Balb/c and C57BL/6 (BL6) 
backgrounds. Immunoblotting with antibodies PRK8 and PRK28 also demonstrated 
equivalent higher immunoreactivity in a 129S background compared to the Balb/c and 
BL6 background.   Surprisingly, the cortical brain extracts from C3H mice were devoid 
of reactivity with both PRK8 and PRK28 antibodies. However, this result was not due to 
a complete loss of parkin expression in C3H mice as the PRK109 antibody recognized 
parkin in C3H tissue extracts. These results suggest that PRK8, PRK28, and PRK109 
antibodies recognize different epitopes and that somehow, in C3H mice, the epitope that 
is specifically recognized by the PRK8 and PRK28 antibodies is altered. 
Figure 5-1  
 
Western blot analysis showing differential levels of 
immunoreactivity with different parkin antibodies 
in various mouse strains. Cerebral cortical tissues 
were harvested from Balb/c, C57BL/6 (BL6), C3H, and 
129S mice and total protein lysates were extracted. 
Equal amounts (18 ug) of total protein extracts were 
loaded on 13% polyacrylamide gels and analyzed by 
western blot analysis with the anti-parkin monoclonal 
antibodies, PRK8, PRK28, and PRK109 as well as an 
actin antibody to confirm equal protein loading. The 
representative blot above shows extracts from 10 week 
old mice. Two samples were loaded, each from separate 
mice of the indicated strains. All experiments were replicated and similar results were obtained for a total of n=4 mice 
from each strain. 
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Similar levels of the parkin mRNA transcript are observed in different mice 
backgrounds.  
To begin to understand the reasons for the differences in immunoreactivity with 
parkin antibodies in the Balb/c, BL6, C3H, and 129S mice backgrounds, the levels of 
parkin mRNA in these mice was determined.  Two-step quantitative real-time reverse-
transcription polymerase chain reaction (qRT-PCR) analyses were performed using total 
RNA extracted from cortical tissues of Balb/c, BL6, C3H, and 129S mice. Analyses were 
performed in duplicate using 3 independent RNA samples for each of the different mouse 
strains. All mouse strains expressed comparable levels of the parkin mRNA transcript 
(Fig. 5-2A and B), indicating that the differences observed in parkin protein 
immunoreactivity levels are not due to differences in the amount of mRNA. 
Figure 5-2 
Similar levels of the parkin mRNA 
between different mice stains.  Total 
RNA was extracted from cerebral cortical 
tissues that were harvested from Balb/c, 
BL6, C3H, and 129S mice. Parkin and actin 
mRNA transcripts were quantified using 
two-step qRT-PCR. Experiments were 
performed in duplicate and 3 separate 
samples were analyzed for each mouse 
strain. A) The parkin and actin qRT-PCR 
products are shown. The image represents 
the products from one of the mice analyzed 
for the indicated strain. B) The ratio of the 
Parkin to Actin CT value was calculated for 
each sample. The graph depicts the average 
of the ratios between replicate samples for 
each mouse strain. The error bars indicate 
standard deviation (n=6).  
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Parkin antibody epitope mapping studies 
To further explain the differences in immunoreactivity observed in various mouse 
strains with different parkin antibodies, the epitopes recognized by these antibodies were 
mapped in greater detail. For these epitope mapping studies, full-length and various N- 
and C-terminal truncated forms of human parkin were expressed in bacteria as N-
terminally GST-tagged recombinant proteins (Fig. 5-3).   Western blotting with an anti-
GST antibody demonstrated similar expression for all proteins. The PRK8 antibody 
recognized GST-parkin(1-408), but not GST-parkin(1-399), indicating that the epitope 
for this antibody includes residues 400-408. PRK8 reacted with both GST-parkin(381-
465) and GST-parkin(399-465), but reactivity for GST-parkin(399-465) was much 
weaker. These data indicate that the epitope of antibody PRK8 require residues 400-408, 
but extends further upstream of this sequence. Antibody PRK28 demonstrated similar 
immunoreactive properties to antibody PRK8, with an additional weak reactivity with 
GST-parkin(1-399). Therefore, the epitope for PRK28 also requires amino acid residues 
400-408 and extends further upstream than PRK8. Antibody PRK109 reacted with GST-
parkin(1-420), but not GST-parkin(1-408) indicating that the epitope for this antibody 
includes residues 409-420.  
An endogenous mutation in the C3H parkin gene is responsible for the loss of PRK 
8 and PRK 28 immunoreactivity. 
 Since genetic alterations can result in differences in the parkin protein that could 
be responsible for some of the differences in immunoreactivity observed in the different 
mouse strain backgrounds, we proceeded to determine the parkin cDNA sequence  
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Figure 5-3 
Parkin antibodies epitope mapping studies. A. Schematic of parkin protein. The numbers indicate the amino acid 
residues that correspond to the respective protein domains. Ubl is the ubiquitin-like domain, Mid is the linker domain, 
R1 is the first RING finger domain, 
IBR is the in-between-ring-finger 
domain, and R2 is the second RING 
finger domain.  B. Full-length 
human parkin cDNA corresponding 
to amino acids 1-465 and various 
truncated cDNA fragments of 
parkin were cloned in the bacterial 
expression vector pDEST15, that 
expresses N-terminal GST-tagged 
recombinant proteins. The 
recombinant proteins were 
expressed in BL21 E. coli cells. The 
cells were harvested and equal 
amounts of total protein lysates 
were analyzed by western blot with 
a GST antibody in order to confirm 
similar expression of the respective 
proteins. Additionally, equal 
amounts of the protein extracts 
were assessed for immunoreactivity 
with the PRK8, PRK28, and 
PRK109 antibodies. The 
experiments were performed in 
duplicate. Representative blots are 
shown for each construct. The identical blot for PRK28 is shown at different exposure times in order to reveal the faint 
immunoreactivity of the 1-399 construct that is not readily detectable at the shorter exposure time. The mobility of 
molecular mass markers is indicated on the left.  
 
 (nucleotides 963-1388) around the region comprising the antibody epitopes for each 
mouse strain. This analysis revealed that the cDNA sequences for Balb/c, BL6 and 129S 
mice was identical to the previously published sequence for Balb/c (210). However, the 
cDNA sequence for the C3H strain revealed 2 homologous nucleotide alterations (c. 1140 
C>T and c. 1192G>C) (Fig. 5-4 and data not shown).  The nucleotide change at 
position 1140 is a silent mutation that does not change the amino acid. The 1192G>C 
substitution results in the missense mutation E398Q. This mutation is equivalent to a 
E399Q mution in human parkin, since mouse parkin has one less residue (Gly 139) than 
human parkin (210). DNA sequencing of genomic tail DNA confirmed that the C3H 
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parkin mutation occurred at the DNA level and was not due to post-transcriptional events 
(Figure 5-4S1). 
Figure 5-4 
Discovery of a novel 
endogenous parkin 
mutation in C3H mice. 
RT-PCR  was performed 
using total RNA that was 
extracted from cerebral 
cortical tissues of BL6, 
Balb/c, C3H, and 129S 
mice. The amplified PCR 
products spanned bases 895-
1395 of the mouse parkin 
cDNA sequence. The PCR 
products were sequenced 
and analyzed for mutations. 
The image shows the 
respective portion 
(nucleotide bases 1177-
1200) of sequencing 
electropherogram for the 
various mouse strains. The 
corresponding amino acid 
sequences are written above 
the respective DNA codons.   
A novel endogenous 
G1192C parkin cDNA 
mutation was identified in 
C3H mice. This mutation 
translates into a missense 
E398Q mutation. The 1192 
cDNA residue is underlined 
in order to highlight the 
location of the novel 
G1192C mutation in the 
mouse parkin cDNA 
sequence. 
 
Since the E399Q mutation is within the epitopes for both PRK8 and PRK28, the 
effects of this mutation on the reactivity of these antibodies was determined. The E399Q 
mutation was introduced into the bacterial vector expressing GST-parkin(380-465) and 
the protein was expressed concurrently with the similar WT protein. Immunoblotting 
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with an anti-GST antibody demonstrated equivalent expression of both proteins (Fig. 5-
5A). Immunoreactivity with PRK109 was not affected by the E399Q mutation, however 
this mutation abolished the reactivity with both PRK8 and PRK28 (Fig 5-5A).  
To confirm these findings in mammalian cells, a construct expressing full-length 
untagged human WT parkin (parkin/pcDNA3.1) was used to overexpress human parkin 
in mouse neuroblastoma Neuro-2A (N2A) cells. In addition, similar vectors expressing 
T240R and E399Q mutant parkin were used. While antibody PRK109 recognized both 
WT and parkin mutants, antibodies, PRK8 and PRK28 did not react with E399Q parkin 
(Fig. 5-5B). These data indicate that the E399Q mutation disrupts the epitopes of the 
PRK8 and PRK28 antibodies and that the equivalent mutation (E398Q) in C3H mice 
explains the lack of immunoreactivity with these antibodies.  
The E399Q human parkin mutant shows reduced solubility without associated 
inclusion formation.  
Several of the reported PD-linked parkin mutations, some in close proximity to 
the E399Q mutation, lead to altered solubility when they are expressed in mammalian 
cells (148;407;460). To investigate whether the E399Q parkin amino acid substitution 
alters these biochemical properties of parkin, solubility assays were performed. 
HEK293T cells were transiently transfected with untagged full-length WT, E399Q, or 
T240R mutant human parkin constructs. Cell lysates were sequentially extracted in 
buffers of increasing solubilization strengths. Extracts were then analyzed by western blot 
with the PRK109 antibody. In comparison to the other fractions, WT Parkin protein was 
mostly extracted into the soluble TX fractions and to a lesser extent into the SDS 
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insoluble fractions (Fig. 5-6A and B). A significant fraction of both E399Q and 
pathogenic T240R human parkin mutants was extracted in the insoluble SDS-fractions 
(Fig. 5-6A and B).  
Figure 5-4S1 
 
DNA sequencing of mouse parkin from genomic tail DNA. Genomic DNA was extracted from the tails of 10 week 
old BL6 and C3H mice using the Wizard SV Genomic DNA Purification System (Promega, Madison, WI) following 
the manufacture’s protocol. Polymerase chain reactions were conducted on the purified DNA in order to amplify 
nucleotides 1167-1273 of the mouse parkin sequence. The primer sequences for the reaction were as follows. Forward: 
5’-CTA CAG GGT GGA CAA AAG AGC CGC -3’ and Reverse: 5’- CAA TTG GCA CGT TGC AGC GAG GAC-3’.  
The reaction products were confirmed by topoisomerase reaction into pCRTopo2.1 vector (Invitrogen Corporation) and 
DNA sequencing. 
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Figure 5-5 
 
Abolishment of the PRK8 and 
PRK28 antibody epitopes due to 
the E399Q human parkin 
mutation.  A) pDEST15/parkin 
380-465 and pDEST15/parkin 380-
465 E399Q constructs were used to 
express the respective proteins in 
BL21 E. coli. Total protein lysates 
were extracted and equal amounts 
of protein (600 ng) were resolved 
on 13% polyacrylamide gels and 
analyzed by western blot with 
GST, PRK8, PRK28, and PRK109 
antibodies. B) Full-length untagged 
wild-type and mutant (T240R and 
E399Q) human parkin cDNA 
cloned in the mammalian 
expression vector pcDNA3.1 were 
used to express these proteins in 
mouse N2A neuroblastoma cells. 
Following transfection with the 
respective constructs, equal 
amounts (4 ug) of total protein 
lysates were resolved on 13% 
polyacrylamide gels and assessed 
by western blot for recognition of 
the indicated parkin antibodies. 
Additionally, the blots were probed with an actin antibody to confirm equal protein loading. The mobility of molecular 
mass markers is indicated on the left. 
 
To determine whether this altered extractability of E399Q mutant parkin is 
associated with the formation of protein inclusions, immunofluorescence studies were 
conducted. HEK293T cells transiently expressing untagged full-length WT, E399Q, or 
T240R human parkin were assessed for parkin localization with the PRK109 antibody. 
Following these analyses, while parkin was found to exhibit similar homogeneous 
cytoplasmic staining for all of the parkin variants, inclusions were not detected in any of 
the cells analyzed (Fig. 5-6C).  
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Figure 5-6 
 
The E399Q human 
parkin mutant shows 
reduced solubility in 
mammalian cells 
without associated 
inclusion formation. 
HEK293T cells were 
transfected in duplicate 
with untagged full-length 
WT, E399Q, or T240R 
human parkin/pcDNA 
3.1 constructs.  A) and B) 
At 48 hours post 
transfection, cells were 
harvested and 
sequentially extracted 
into PBS/0.1% Triton 
(TX) buffer, RIPA 
buffer, and 2% 
SDS/17mM Tris (SDS) 
buffer. Equal amounts 
(16ug) of each sample 
were loaded onto 10% 
polyacrylamide gels and 
analyzed by western blot 
for parkin distribution 
with the PRK109 
antibody. Blots were also 
probed with an actin 
antibody to assess equal 
protein loading. The 
mobility of molecular 
mass markers is indicated 
on the left. The western 
blot images were 
quantified as described in 
“Materials and Methods”. 
The total percentage of 
parkin extracted into SDS 
fractions was calculated 
for each sample. Error 
bars indicate standard deviation (n=4). C) Immunofluorescence analysis of HEK293T cells expressing WT or mutant parkin 
immunostained with PRK109 (red) and counterstained with Hoerscht (blue). The merged images depict the absence of inclusions in 
cells expressing WT, E399Q, or T240R parkin. Scale bar =10um.   
 
The E399Q parkin mutant is functionally impaired.  
Parkin functions as an E3 ubiquitin-protein ligase, acting to promote the 
ubiquitination and subsequent degradation of its substrates (178;367;490). Synphilin-1 
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has been identified as one of the putative substrates for parkin (72;257). Several of the 
pathogenic mutations in parkin, including the T240R mutation, have been shown to 
impair the ability for parkin to promote the degradation of synphilin-1 (72;407). In order 
to ascertain whether the E399Q mutation hinders parkin function, steady-state levels of 
synphilin-1 were analyzed in the presence of WT, T240R, or E399Q parkin. The levels of 
synphilin-1 were compared between parkin variants. In addition, some transfected cells 
were treated with the proteasome inhibitor, clasto-lactacystin β-lactone (Omuralide), to 
assess that the degradation of synphilin-1 promoted by parkin was due to the proteasome.  
HEK293T cells were co-transfected with myc-tagged synphilin-1 and either pcDNA3.1 
mock vector or the respective pcDNA3.1 untagged parkin constructs. Cells were 
transfected with a 4:1 cDNA ratio of parkin to synphilin-1 as under these conditions, it 
has been previously shown that parkin promotes the degradation of synphilin-1 (257). 
Total cell lysates were analyzed by immunoblot with anti-c-Myc and PRK109 antibodies.  
Expression of WT parkin led to a significant decrease in synphilin-1 steady-state levels in 
comparison to the levels for synphilin-1 when it had been co-expressed with mock vector 
(Fig. 5-7A and B). However, neither the T240R nor the E399Q parkin had any effect on 
the steady-state levels of synphilin-1. Additionally, as it has been previously shown, 
parkin-mediated degradation of synphilin-1 occurs via the proteasome pathway (257), 
since it was completely blocked in the presence of a specific proteasome inhibitor. 
 To further determine the effects of WT, T240R, and E399Q  parkin on the 
stability of synphilin-1, HEK293T cells were co-transfected with myc-tagged synphilin-1 
and either pcDNA3.1 mock vector or the respective pcDNA3.1 untagged human parkin 
constructs as described above. Synphilin-1 turnover was assessed by pulse-chase analyses 
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Figure 5-7 
E399Q mutant parkin is 
functionally impaired. 
HEK293T cells were co-
transfected either with mock 
pcDNA3.1 vector “(-)” or 
full length WT, T240R, or 
E399Q human parkin 
pcDNA 3.1 constructs as 
well as the pcDNA3.1 myc-
tagged full-length 
synphilin-1 construct. The 
co-transfection experiments 
were performed using a 
parkin to synphilin-1 cDNA 
ratio of 4:1. At 24 hours 
post transfection, (A and B) 
cells were incubated for 16 
hours with fresh DMEM or 
with DMEM containing 
5uM Omuralide. Cells were 
then harvested and total 
protein lysates were 
extracted. Extracts were 
resolved by 10 % 
polyacrylamide gels and 
immunoblotted with the 
monoclonal antibodies anti-
c-Myc clone 9E10 to assess 
synphilin-1 levels, PRK109 
antibody to confirm parkin 
expression, and anti-actin 
antibody to ensure equal 
protein loading. All 
experiments were 
performed in triplicate and 
repeated at least 3 times. 
The mobility of molecular 
mass markers is indicated 
on the left. The levels of 
synphilin-1 were quantified 
as described in “Materials 
and Methods” and the graph 
in B depicts the percentage 
of synphilin-1 protein 
standardized to that in the 
mock vector samples. The 
error bars indicate standard 
deviation between replicate 
samples (n=4). C) Cells 
were pulsed with 35S-
methionine for 1 hour and 
chased for 0, 1, 3, or 6 
hours. The inset shows 
representative pulse-chase 
experiments. Experiments 
were conducted in triplicates. The results are plotted as percentage of protein over time standardized to the 0 hrs time 
point. The error bars show standard deviation (n=3).  
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with 35 S-methionine and the effects of the respective parkin variants on synphilin-1 
turnover were compared. Synphilin-1 exhibited a half-life of ~6 hours in the absence of 
parkin (Fig. 5-7C). WT parkin enhanced the turn-over of synphilin-1, reducing the half-
life to ~1 hour. However, neither T240R nor E399Q parkin had an effect on synphilin-1 
degradation, suggesting that both mutants are functionally inactive. 
 Synphilin-1 was initially identified as a substrate for parkin in studies 
investigating interacting proteins (72). It is possible that the E399Q mutation disrupts the 
direct interaction between mutant parkin and synphilin-1 that would prevent parkin-
mediated degradation. To determine whether there is a loss in the direct interaction 
between E399Q mutant parkin and synphilin-1, co-transfection and co-
immunoprecipitation experiments were conducted. HEK293T cells were co-transfected 
with myc-tagged synphilin-1 and untagged human WT, E399Q, or T240R mutant parkin 
constructs. At 48 hours post transfection, soluble cells lysates were immunoprecipated 
with an anti-c-Myc antibody followed by immunoblot with the PRK109 antibody. All 
parkin variants, including the E399Q mutant, were co-immunoprecipitated with 
synphilin-1 (Fig. 5-8). Thus, the E399Q Parkin mutation does not disrupt the interaction 
between parkin and synphilin-1. 
It has been previously shown that parkin specifically interacts with the E2 
ubiquitin conjugating enzymes, UbcH7 and UbcH8, in order to exert its function as an E3 
ligase (178;392;490). One plausible explanation for the impaired function exhibited by 
the E399Q parkin mutant could be disrupted binding with E2 enzymes. To test this 
hypothesis, co-transfection and co-immunoprecipitation experiments were conducted. 
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Figure 5-8 
E399Q mutant parkin can 
directly interact with 
synphilin-1. HEK293T cells 
were transiently co-transfected 
with myc-tagged synphilin-1 
and pcDNA3.1 mock vector 
(“none”) or with untagged full-
length WT, T240R, or E399Q 
human parkin pcDNA3.1 
constructs. Cells were 
harvested and soluble protein 
lysates were extracted 
(“Input”). The cell lysat es 
were then immunoprecipitated 
using anti-c-Myc polyclonal 
antibody (“IP”). Equal 
amounts of the input, IP, and 
unbound supernatant 
(Unbound) fractions were 
resolved by SDS-PAGE and 
analyzed by western blot 
(“WB”) with anti-c-Myc monoclonal antibody 9E10 or with anti-parkin antibody PRK109. Experiments were repeated 
at least 3 times. The mobility of molecular mass markers is indicated on the left. 
 
HEK293T cells were co-transfected with HA-tagged UbcH7 or UbcH8 constructs and 
either mock pcDNA3.1 or untagged pcDNA3.1 full-length WT, T240R, or E399Q human 
parkin constructs.  At 48 hours post transfection, cell lysates were immunoprecipitated 
with a polyclonal anti-HA antibody, HA.11, followed by immunoblot with the 
monoclonal antibodies PRK109 and anti-HA (clone 12CA5).  These analyses revealed 
that while UbcH7 recruited similar levels of both WT and T240R parkin, the binding of 
E399Q parkin with UbcH7 was dramatically reduced (Fig. 5-9). Interestingly, in 
comparison to binding with UbcH7, parkin was recruited less effectively by UbcH8 and 
the levels of T240R and E399Q mutant parkin recruited by UbcH8 were modestly 
reduced in comparison to WT parkin. Together, these results indicate a loss of function of 
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the E399Q mutant may be due, at least in part, to reduced interactions with E2 ubiquitin 
conjugating enzymes.  
Figure 5-9 
The E399Q 
parkin mutant 
shows reduced 
binding to UbcH7 
and UbcH8. 
HEK293T cells 
were co-
transfected with 
pRK5-HA-UbcH7 
or pRK5-HA-
UbcH8 and either 
pcDNA3.1 mock 
vector (“mock”) or 
with untagged full-
length WT, 
T240R, or E399Q 
human parkin 
pcDNA3.1 
constructs. Cells 
were harvested 
and soluble protein 
lysates were extracted (“Input”). The cell lysates were then immunoprecipitated using the anti-HA polyclonal antibody, 
HA.11 (“IP”). Input and IP fractions were resolved by SDS-PAGE and analyzed by immunoblot with the monoclonal 
antibodies PRK109 and anti-HA (clone 12CA5). The PRK109 blots are shown at 5 second and 20 second exposure 
times to highlight the differences in signal intensity reflected by the binding of parkin with UbcH7 versus that with 
UbcH8. 
 
Synphilin-1 levels are increased in C3H mice.  
Since E399Q mutant parkin was incapable of down-regulating synphilin-1 expression in 
cultured cells (Fig. 5-7), it is plausible to hypothesize that the parkin in C3H mice, 
harboring the homologous E398Q mutation, may show increased levels of the synphilin-1 
substrate in situ.   To test this hypothesis, total protein extracts from cerebral cortical 
tissues of 10 week old BL6 and C3H mice were analyzed by western blot with the 
affinity purified synphilin-1 antibody, UPN79.  No differences in synphilin-1 were 
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detected between mice at this age (Fig. 5-10A and B). However, it is possible that 
synphilin-1 may accumulate in C3H mice in an age dependent manner.  To determine 
this, cerebral cortical protein extracts from 8 month old BL6 and C3H mice were 
immunoblotted with antibody UPN79. Remarkably, extracts from 8 month old C3H mice 
revealed 2.0 ± 0.18 fold higher synphilin-1 levels than BL6 mice of the same age (Fig 5-
10C and D).  
To confirm that these changes were not due to differences at the transcriptional 
level, qRT-PCR analyses were performed using total RNA extracted from cortical tissues 
of the 8 month old BL6 and C3H mice used for synphilin-1 protein analysis described 
above. Both mouse strains expressed comparable levels of the synphilin-1 mRNA 
transcript (Fig. 5-10D and E), indicating that the differences observed in synphilin-1 
protein immunoreactivity are not due to differences in the amount of mRNA. These 
findings are consistent with the notion that the E398Q mutation impairs the ability of 
parkin to mediate the degradation of synphilin-1, leading to an age-dependent 
accumulation of synphilin-1 in C3H mice.  
5.4 DISCUSSION 
Western blot analyses of brain extracts from Balb/c, C57BL/6, C3H, and 129S mice 
revealed dramatic variations in immunoreactivity with 3 monoclonal parkin antibodies 
(PRK8, PRK28, and PRK109). Notably, immunoreactivity for PRK8 and PRK28 was 
absent in C3H mice. This was especially unexpected since it had been previously 
reported that the epitopes for the PRK8, PRK28, and PRK109 antibodies were similarly 
located around the second RING domain of parkin (347). In efforts to gain insights into 
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Figure 5-10 
 
Synphilin-1 protein levels are increased in C3H mice. Cerebral cortical tissues were harvested from BL6 and C3H 
mice. Protein lysates were extracted from animals at ages 10 weeks (A and B) and 8 months (C and D). Equal amounts 
(18 ug) of high-salt protein extracts were loaded onto 10% polyacrylamide gels and analyzed by western blot analysis 
with the affinity purified polyclonal antibody, UPN79 to assess synphilin-1, as well as an actin antibody to confirm 
equal protein loading. Four samples were loaded, each from separate mice of the indicated strains.  The graphs in B and 
D show the average ratios of the levels of UPN79 to actin normalized to the values in BL6 animals at the respective 
aforementioned ages.  E) Total RNA was extracted from cerebral cortical tissues that were harvested from the same 
BL6 and C3H mice analyzed in C. Synphilin-1 and actin mRNA transcripts were quantified using two-step qRT-PCR.  
Experiments were performed in duplicate and 3 separate samples were analyzed for each mouse strain. The synphilin-1 
and actin qRT-PCR products are shown. The image shows the products from one of the mice analyzed for the indicated 
strains. F) The ratio of the synphilin-1 to actin CT value was calculated for each sample. The graph depicts the average 
of the ratios between replicate samples for each mouse strain. The error bars indicate standard deviation (n=6).  
 
how epitope differences could account for some of these changes in mouse parkin 
immunoreactivity, thorough epitope mapping studies were conducted. The analyses of a 
variety of recombinant N-terminal and C-terminal truncated parkin proteins allowed for 
the PRK8, PRK28 and PRK109 antibody epitopes to be more discretely mapped. The 
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PRK8 antibody epitope requires residues 400-408 of human parkin but also extends 
upstream of these residues. The PRK28 epitope also requires residues 400-408 but 
extends slightly further upstream of the PRK8 epitope. Lastly, the PRK109 epitope is 
further downstream and includes residues 409-420 of human parkin protein.  
Genetic analysis revealed a homologous nucleotide substitution (c. 1192G>C) in 
C3H mice that results in an E398Q missense amino acid change. This alteration is 
responsible for the disruption of the PRK8 and PRK28 epitopes in C3H mice. These 
findings and the epitope mapping are particularly important due to the prevalent use of 
these parkin antibodies in several studies (52;115;156;243;244;347). 
Immunoblotting with antibody PRK109 demonstrated variations in the levels of 
parkin in different mouse strains with the highest level being observed in 129S mice 
followed by C3H and lowest, and about equivalent levels, in the Balb/c and BL6 mice. 
Similar results were obtained when comparing parkin levels in 129S, Balb/c and BL6 
mice with antibodies PRK8 and PRK28. Genetic studies revealed no alterations that 
would affect the PRK109 epitope in 129S, C3H, Balb/c and BL6 mice. Nor were any 
genetic mutations identified that would affect the PRK8 or PRK28 epitopes in 129S, 
Balb/c and BL6 mice. Additionally, the levels of brain parkin mRNA were found to be 
similar between strains, indicating post-transcriptional effects. These findings are likely a 
reflection of differences in parkin protein levels that may result from differences in 
translation efficiencies or turnover rates in the different mouse strains.  Interestingly, no 
differences in the steady-state levels of other PD relevant proteins including α-syn, DJ-1, 
or tau were observed between mouse strains (data not shown). Neither were there 
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differences in the levels of the E3 ligase, ARIH1 (data not shown), which shares close 
functional homology to parkin (275). Thus, the differences that were observed in parkin 
between mice strains appear to be specific and not due to the consequence of more 
generalized effects. 
There has been no report of a naturally occurring human E399Q parkin 
polymorphism or pathogenic mutation, however there are several reported pathogenic 
mutations that are in close proximity to the this residue [R396G (475), A398T(282;452), 
R402C (26;270), R402H (416), R402W(359)], suggesting that it may affect protein 
structure or function. In addition, this glutamic acid residue at the 398 is conserved in 
other species including rat, pig, and macaque (208;210); NCBI protein database 
accession numbers NP_064478, NP_001038068, and ACL68652). Directly supporting 
this hypothesis, it was shown in this study that the E399Q mutant parkin exhibited 
reduced solubility when it was overexpressed in mammalian cells. However, this did not 
lead to the formation of aggregated protein that could be observed at the microscopic 
level.  This suggests that the E399Q parkin mutation may result in protein misfolding 
without the accumulation into large aggregates.   Changes in parkin solubility have been 
associated with a variety of stimuli including oxidative stress, heat shock, as well as a 
battery of other types of stress and may have a consequence on parkin function 
(243;459;470). For instance, changes which induce a shift in parkin solubility could 
thereby deplete soluble pools of parkin and may result in the impairment of parkin’s 
function toward substrates.   
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It was further shown in this report that the E399Q mutant parkin is deficient in the 
ability to mediate the degradation of the parkin substrate, synphilin-1, similar to the 
T240R parkin pathological mutant. Neither the steady-state levels nor the turn-over rate 
of synphilin-1 were affected by co-expression of the E399Q or T240R parkin mutants in 
HEK293T cells, while expression of WT parkin dramatically reduced the levels of 
synphilin-1 in these studies. These data supported previous findings which showed a 
marked decrease in synphilin-1 steady-state levels with the co-expression of WT parkin 
at a parkin to synphilin-1 cDNA ratio of 4:1, findings which were not observed under the 
same conditions for the T240R parkin mutant (257). It is of interest to note that high 
molecular weight forms of polyubiquitylated synphilin were not detected in any of the 
parkin co-expression experiments performed in the studies herein (Fig. 7). This could be 
because typical ubiquitination “smears” are below detectable levels under the 
experimental conditions used and/or these observations may be related to the finding by 
Lim et al. which suggests that parkin can mediate different types of ubiquitin linkage 
(257). Nevertheless, the data herein demonstrates impaired function of E399Q and 
T240R parkin mutants towards down-regulating synphilin protein levels in comparison to 
WT parkin protein. This was not due to the inability for these mutants to interact with 
synphilin since WT, E399Q, and T240R parkin all showed similar interactions with 
synphilin by co-immunoprecipitation studies, consistent with previous findings (72).   
It is interesting that the novel E399Q parkin mutation lies between the IBR and 
RING2 domains of the parkin protein. This feature is also common to the previously 
characterized T415N pathogenic parkin mutant. The T415N parkin mutation interfered 
with the proper recruitment of E2 enzymes to parkin (490) and resulted in impairments in 
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parkin-mediated degradation (407). However, this was not associated with a loss in 
substrate binding activity (72;407). Similarly, in the current study, in comparison to the 
other parkin variants analyzed, the E399Q parkin mutant showed dramatically reduced 
binding with the E2 enzyme, UbcH7.  This aberration likely partially contributes to the 
deficiencies exhibited by the E399Q parkin mutant related to degradation of the 
synphilin-1 substrate.  
The novel E399Q parkin mutant showed reduced solubility and functional 
impairments when it was analyzed in mammalian cells indicating that the homologous 
E398Q mutation in C3H mice may result in mice that are deficient or impaired in parkin 
activity. To support this hypothesis, there was a 2 fold increase in the cortical levels of 
synphilin-1 in 8 month old C3H mouse brains in comparison to BL6 mice. This 
difference was not observed in mice at 10 weeks of age which suggests that other E3 
ligases or other modes of degradation play a more prominent role in the turnover of 
synphilin-1 at this age.  While C3H mice do not show any overt behavioral characteristics 
that may be attributed to a functional parkin deficiency, the attempts to identify in vivo 
effects of parkin’s loss-of-function in mice have proven to be very difficult. Genetically 
generated parkin null mice fail to display any major differences in most of the behavioral, 
morphological, and biochemical analyses that have been previously conducted 
(349;350;431;453). Subtle differences in parkin null mice have been identified in a few 
studies, but many inconsistencies have also been reported (116;135;186;335;379;496). 
Interestingly, no differences in synphilin-1 levels were detected in brain tissues of  parkin 
null animals in comparison to WT animals in  previous studies (217). However, this does 
not discredit the finding of the increased steady-state levels of synphilin-1 observed in 
153 
 
C3H mice in the current study. It is possible that this discrepancy could be due to a 
number of factors including antibody specificity, tissue extraction method, or tissue-
specific differences in parkin regulation of synphilin-1. Further, since it is likely that 
synphilin-1 may also be regulated by parkin independent mechanisms, it is unknown how 
this may be affected in a model system that is completely devoid of parkin versus a 
system where parkin is available, albeit impaired. Analysis of other putative parkin 
substrates such as Pael-R or p38/JTV-1 (217) could also indirectly help to confirm a loss 
of parkin function in C3H mice. However, while specific antibodies are not readily 
available, future studies to assess for alterations in these putative substrates would be 
informative. 
In summary, these studies demonstrate that parkin protein levels differ in various 
mouse background strains. Additionally, the C3H mouse harbors a previously unreported 
mutation (E398Q) in parkin that abolishes immunoreactivity with antibodies PRK8 and 
PRK28. Characterization of this novel mutation revealed that it promotes the misfolding 
of parkin, impairs its ability to interact with E2 conjugating enzymes, and disrupts its 
function towards the synphilin-1 substrate. These findings indicate that C3H mice are 
carriers of a missense parkin mutation and that they may be a suitable model of parkin 
loss-of-function similar to human patients that have missense mutations. In addition, the 
difference in the level of parkin expression demonstrated here in various widely-used 
mouse strains is an important confound that should be taken into account in mouse 
studies.  
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5.5 EXPERIMENTAL PROCEDURES 
Mouse strains 
C57BL/6, C3H, BALB/c, and 129S mice at 10-12 weeks and 8 months of age were used 
for studies. All mice were purchased from Charles River Laboratories Inc (Wilmington, 
MA). Mice were sacrificed by CO2 euthanization as approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee. 
Antibodies 
PRK8, PRK28, and PRK109 are mouse monoclonal antibodies raised against human 
parkin but that react with parkin from various species, including murine  (347). Mouse 
anti-(GST) monoclonal antibody clone A00865.01 was obtained from GenScript 
(Piscataway, NJ). Affinity purified mouse anti-actin (clone C4) monoclonal antibody 
reacts with all forms of vertebrate actin (Millipore, Billerica, MA). Two c-Myc 
antibodies were used in these studies: purified anti-c-Myc monoclonal antibody clone 
9E10 (M4439, Sigma-Aldrich, Saint Louis, MO) and an affinity purified anti-c-Myc 
polyclonal antibody (Sigma-Aldrich, Saint Louis, MO). Two HA antibodies were used in 
these studies: anti-HA monoclonal antibody clone 12CA5 (Roche Diagnostics, 
Indianapolis, IN) and affinity purified polyclonal antibody, HA.11 (Covance, Emeryville, 
CA). UPN79 is an affinity purified polyclonal antibody raised against human full-length 
recombinant synphilin-1 (312). 
Relative quantification of the mouse parkin mRNA transcript 
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Cerebral cortical tissues were harvested from 10 week old Balb/c, BL6, C3H, and 129S 
mice and divided in half. Half of the tissue was frozen on dry ice for subsequent protein 
analysis and total RNA was extracted from the remaining half using TRIzol reagent 
(Invitrogen Corporation, Carlsbad, CA) according to the manufacturer’s protocol. Three 
tissue samples were prepared for each mouse strain. The RNA products were reverse 
transcribed to cDNA using Taqman RT-PCR reagents (Applied Biosystems Inc, Foster 
City, CA) with oligo dT primers that were supplied in the kit.  The RT reactions were 
conducted according to the manufacturer’s protocol. Real-time PCR analyses were 
performed on the cDNA products using 2X SYBR Green Master Mix reagent (Applied 
Biosystems) and Applied Biosystems 7000 Real-Time PCR System (Applied 
Biosystems). Reactions were performed in duplicate for each cDNA sample in a 96 well 
plate. Primers were designed to amplify a 98 base pair product of mouse parkin cDNA 
that corresponds to nucleotides 396-494. The sequences for the parkin primers were as 
follows. Forward: 5’-AGCAGCCAGAGGTCCAGTTA-3’ and Reverse: 5’-
CACTGAACTCGGAGCTTTCC-3’. Additionally, a mouse β-actin loading control was 
amplified. Mouse β-actin primers were designed to amplify a 99 base pair product 
corresponding to cDNA nucleotides 698-797. The sequences of the β-actin primers were 
as follows. Forward: 5’-CTTCCTCCCTGGAGAAGAGC-3’ and Reverse: 5’-
AAGGAAGGCTGGAAAAGAGC-3’.  The thermo cycling conditions for the 
amplification were as follows: 1 cycle for 2 minutes at 50ºC, 1 cycle for 10 minutes at 
95ºC, followed by 40 cycles of 15 seconds at 95ºC and 1 minute at 60ºC, followed by 1 
cycle for 15 seconds at 95ºC, 1 cycle for 20 seconds at 60ºC, and 1 cycle for 15 seconds 
at 95ºC. The CT values for each sample were obtained. Parkin values were normalized to 
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β-actin by taking the ratio of parkin to β-actin for each sample. The normalized results 
were averaged for replicate samples and graphed. Error bars represent standard deviation 
where n=6. After the reaction, equal volumes of the PCR products, one for each sample 
type, were loaded onto 7-8% non-denaturing polyacrylamide/Tris Borate EDTA (TBE) 
gels and were resolved by electrophoresis. The gels were then stained with ethidium 
bromide at 1ug/mL for 20 minutes and the DNA bands were visualized with a UV light 
and photographed. Additionally, the reaction products were confirmed by DNA 
sequencing. 
RT-PCR analysis and DNA sequencing of the mouse parkin cDNAs 
Mouse total RNA was extracted and reverse transcribed from cortical tissue as described 
above. Polymerase chain reactions were conducted on the cDNA products using 
AccuPrimeTM  SuperMix II (Invitrogen) in order to amplify nucleotides 895-1395 of the 
mouse Parkin cDNA sequence. The primer sequences for the reaction were as follows. 
Forward: 5’-GAGCTCCATCACTTCAGGATCCTTGGA-3’ and Reverse: 5’-
CTACACGTCAAACCAGTG ATC TCC CAT-3’.  The PCR products were digested 
with ExoSAP-IT ® reagent (USB Corporation, Cleveland, OH) and sequenced by the 
DNA sequencing facility of the University of Pennsylvania.  
Mouse protein analysis 
Cerebral cortical tissues were harvested from mice as described above. The tissue was 
sonicated in 3 tissue volumes of either high salt (HS) buffer (50mM Tris [pH 7.5], 750 
mM NaCl, 5mM EDTA, with a protease inhibitor cocktail at 1:1000 and PMSF at 1:500) 
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or 2% SDS/8M urea. Tissue extracts were then quantified using the bicinchoninic acid 
(BCA) assay (Pierce Biotechnology, Rockford, IL) and bovine serum albumin as the 
standard. Equal amounts of protein extracts were resolved by SDS-PAGE. The samples 
were analyzed by western blot with PRK8, PRK28, PRK109 and UPN79 antibodies. 
Additionally, membranes were blotted with anti-actin antibody to assess equal loading. 
At least 4 independent tissue samples were analyzed for each mouse strain at each 
respective age.  
Parkin antibodies epitope mapping 
Using full length human parkin cDNA as a template, primers were designed to generate 
various truncated parkin constructs by PCR. See Table 5-1 for the oligonucleotide 
sequences used for PCRs. AccuPrime SuperMix II (Invitrogen) was used for the 
reactions. PCR products were cloned by topoisomerase reaction into the shuttling vector 
pCR8/GW/TOPO (Invitrogen) and confirmed by DNA sequencing. These cDNA 
fragments were introduced into the Gateway pDEST15 vector by recombinase reaction 
using LR Clonase II enzyme (Invitrogen). BL21 cells were then transformed with 
positive pDEST15 clones. Transformed cultures were subsequently induced with 500uM 
Isopropyl Beta-D-1-thiogalatopyranoside (IPTG)  for 2 hours at 37ºC in a shaking 
incubator. After induction of protein expression, the cells were lysed by sonication in 3 
pellet volumes of 2% SDS/8M urea. Protein extracts were then quantified using the BCA 
assay and analyzed by immunoblot with anti-GST, PRK8, PRK28, and PRK109 
antibodies. 
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Table 5-1 Oligonucleotide sequences used to generate N-and C- terminal truncated human parkin 
mutants for PRK8, PRK28 and PRK109 epitope mapping studies. 
Nucleotides 
amplified in PCR 
Corresponding 
Amino Acid 
Sequence 
Forward Oligonucleotide 
sequence 
Reverse Oligonucleotide 
sequence 
1-1398 1-465 5’-ATG ATA GTG TTT GTC 
AGG TTC AAC TCC-3’ 
5’- CTA CAC GTC GAA CCA 
GTG GTC CCC CAT -3’ 
1-1260 1-420 5’-ATG ATA GTG TTT GTC 
AGG TTC AAC TCC-3’ 
5’-CTA GCG GGG ACA GGG 
CTT GGT GGT TTT CTT-3’ 
 
1-1224 1-408 5’-ATG ATA GTG TTT GTC 
AGG TTC AAC TCC-3’ 
5’-CTA TTT GGA GGC TGC 
TTC CCA ACG AGC CTG-3’ 
 
1-1197 1-399 5’-ATG ATA GTG TTT GTC 
AGG TTC AAC TCC-3’ 
5’-CTA CTC GGC GGC TCT TTC 
ATC GAC TCT GT-3’ 
661-1398 221-465 5’-GAA ACA CCA GTA GCT 
TTG CAC CTG AT-3’ 
5’- CTA CAC GTC GAA CCA 
GTG GTC CCC CAT -3’ 
1141-1398 381-465 5’-TTT GAA GCC TCA GGA 
ACA ACT ACT CAG-3’ 
5’- CTA CAC GTC GAA CCA 
GTG GTC CCC CAT -3’ 
1195-1398 399-465 5’-GAG CAG GCT CGT TGG 
GAA GCA GCC-3’ 
5’- CTA CAC GTC GAA CCA 
GTG GTC CCC CAT -3’ 
 
Generation of E399Q human parkin construct for bacterial expression 
For expression in bacteria, using the Gateway pDEST15 human parkin 381-465 construct 
as a template (described above), the QuickChange Site Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA) was used in order to generate the E399Q mutant form of 
human parkin protein. The oligonucleotide sequence for the mutagenesis reaction was as 
follows: forward-5’- GAAAGAGCCGCCCAGCAGGCTCGTTGG-3’ and reverse-5’-
CCAACGAGCCTGCTG GGCGGCTCT TTC-3’. The sequence of the construct was 
confirmed by DNA sequencing. The plasmid was subsequently expressed in BL21 cells, 
harvested, and analyzed as described in the previous section. 
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Generation of human parkin constructs for expression in mammalian cells 
The full-length untagged WT human parkin cDNA was cloned into the XhoI and Apa I 
restriction sites on the pcDNA3.1(+) mammalian expression vector (Invitrogen). This 
WT parkin construct was used as a template to perform site directed mutagenesis in order 
to generate the full-length E399Q mutant. The same oligonucleotides were used as in the 
E399Q mutagenesis reaction as described in the previous section. Additionally, the WT 
parkin/pcDNA 3.1 construct was used as a template in a site directed mutagenesis 
reaction to generate the human parkin T240R pathogenic mutant. The oligonucleotide 
sequences for the T240R mutagenesis reaction were as follows: forward-5’- 
ATCACTTGC ATTAGGTGCACAGACGTC-3’ and reverse-5’- 
GACGTCTGTGCACCTAATGCAAGTGAT-3’. The sequence for both the E399Q and 
T240R parkin mutants were verified by DNA sequencing. 
Cell culture 
Neuro-2A mouse neuroblastoma (N2A) cells and human embryonic kidney (HEK)-293T 
cells were cultured in Dulbecco-modified Eagle medium (DMEM) (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (FBS)  (Sigma, St.Louis, MO), 100 
U/mL penicillin and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA). Cells were 
incubated at 37ºC and 95% air/5% CO2 atmosphere. 
Biochemical fractionation of human parkin variants 
HEK293T cells were cultured in 10 cm dishes. In duplicate, cells were transfected with 
either the pcDNA3.1 full-length WT, E399Q, or T240R human parkin constructs using 
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Lipofectamine Reagent (Invitrogen), following the manufacterer’s protocol. At 48 hours 
post transfection, cells were rinsed and scraped in 1X PBS and sedimented at 13,000  g. 
Cells were vortexed vigorously in 2 pellets volumes of ice-cold PBS/0.1% Triton buffer 
containing protease inhibitors. The cell debris were sedimented at 13,000 g for 2 minutes 
and the supernatants were stored on ice. The PBS/0.1% Triton extraction was repeated 
and following sedimentation, the supernatants from both extractions were pooled together 
as the TX fraction. The remaining pellet was rinsed with the PBS/0.1% Triton buffer and 
the rinse was discarded. The cell pellet was then resuspended into 2 pellet volumes of ice-
cold RIPA buffer with protease inhibitors, vortexed vigorously, stored on ice for 5-10 
minutes, and then vortexed again. The cell debris were sedimented at 13,000 g for 2 min 
and the supernatant was collected as the RIPA fraction. The remaining pellet was rinsed 
with RIPA buffer and the rinse was discarded. Lastly, the pellet was solubilized in 1 
pellet volume of 2% SDS/8M urea which was collected as the SDS fraction. All extracts 
were quantified by BCA assay and analyzed by western blot analysis with the PRK109 
and actin antibodies. Western blot images were scanned using a CanoScan Lide30 
scanner (Canon U.S.A., Inc., Lake Success, NY). The levels of PRK109 signal were 
quantified for each sample using ImageQuant 5.0 analysis software (GE Healthcare, 
Piscataway, NJ). 
Immunofluorescence and Confocal Analyses of parkin 
HEK293T cells were cultured in 35 mm dishes. Cells were transfected in duplicate either 
with the pcDNA3.1 full-length WT, E399Q, or T240R human parkin constructs using 
Lipofectamine Reagent (Invitrogen), following the manufacterer’s protocol. At 24 hours 
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post transfection, cells were rinsed in PBS and fixed by incubation in ice-cold acetic-
methanol (1:20) at -20 °C for 30 minutes. Cells were rehydrated with water, rinsed with 
PBS, and blocked in PBS/2% FBS/0.1% Triton. Cells were then incubated with PRK109 
antibody diluted into PBS/2% FBS at a concentration of 1:2000 overnight at 4°C, washed 
3 times with PBS at 10 minutes each, and then incubated at room temperature (~23 ºC) 
with a goat anti-mouse secondary antibody conjugated to Alexa Fluor ® 594 (Invitrogen) 
diluted into PBS/2% FBS for 1 hour. Cells were rinsed 3 times with PBS and then stained 
with Hoerscht 33342 trihydrochloride trihydrate ( 0.5ug/mL) (Invitrogen) for 5 minutes at 
room temperature (~23 ºC). Cells were rinsed with water and then coverslipped with 
CytosealTM 60 mounting media (Richard-Allen Scientific, Kalamazoo, MI). The images 
were visualized with a Zeiss LSM-510 Meta confocal microscope (Carl Zeiss 
MicroImaging Inc, Thorwood, NY, USA). 
Effects of parkin on synphilin-1 steady-state levels 
A mammalian expression construct expressing C-terminal myc-tagged full-length human 
synphilin-1 (synphilin-c-myc/pcDNA 3.1) was kindly provided by Dr. Virginia Lee. In 
triplicate, HEK293T cells were co-transfected with synphilin-c-myc/pcDNA 3.1 and 
either pcDNA3.1 mock vector, or pcDNA3.1 human full-length WT parkin, E399Q 
mutant parkin, or T240R mutant parkin constructs. Cells were co-transfected with parkin 
to synphilin-1 cDNA ratio of 4:1 using the calcium phosphate transfection protocol 
described by Gallagher et al. (120). At 21 hours post transfection, fresh complete media 
was added to the cells that were cultured for an additional 16 hours with or without 5uM 
clasto-lactacystin-β-lactone (Omuralide)(EMD Chemicals Inc, Gibbstown, NJ). Cells 
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were then rinsed in PBS and lysed by sonication in 2% SDS/8M urea. Cell extracts were 
quantified by BCA assay and analyzed by western blot with monoclonal antibodies anti-
c-myc clone 9E10, PRK109, and anti-actin. The 9E10 signal was quantified as described 
in previous sections. 
Pulse-chase synphilin-1 turnover analysis 
In triplicate, HEK293T cells were cultured in 35mm dishes. Cells were co-transfected 
with synphilin-c-myc/pcDNA 3.1 and either pcDNA3.1 mock vector, or pcDNA3.1 
human WT parkin, E399Q mutant parkin, or T240R mutant parkin constructs. Cells were 
co-transfected with a parkin to synphilin-1 cDNA ratio of 4:1 using the calcium 
phosphate transfection protocol described above. At 24 hours post transection, cells were 
methionine-deprived for 20 minutes by incubation in pre-warmed methionine-free 
DMEM (Invitrogen, Carlsbad, CA)/10% dialyzed FBS before adding 100μCi [35S]-
methionine (Invitrogen, Carlsbad, CA) per ml of methionine free DMEM/10% dialyzed 
FBS for 1 hour.   Chase experiments were conducted with normal DMEM/FBS for 0, 1, 
3, and 6 hours. Cells were then rinsed with PBS and harvested in ice-cold cytoskeleton 
(CSK) buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 % Triton X-100, 
protease inhibitors). The radiolabelled protein extracts were pre-cleared with a rabbit 
serum pre-incubated with protein A-agarose (Santa Cruz Biotechnologies, Santa Cruz, 
CA)  for 3 hours at 4ºC and radiolabelled extracts were then immunoprecipitated 
overnight at 4ºC with anti c-Myc polyclonal antibody (Sigma) pre-incubated with protein 
A-agarose (Santa Cruz Biotechnology, Inc). The antibody-protein complexes were 
washed 3 times with 10 volumes of CSK buffer, resuspended in 2 volumes of 2X SDS 
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sample buffer and boiled at 100 ºC for 5 minutes. The beads were removed by 
centrifugation and the samples were loaded onto 13 % polyacrylamide gels. Following 
electrophoresis, gels were fixed with 50% methanol/5% glycerol, dried and exposed to a 
PhosphorImager plate and the signal was quantified using ImageQuant 5.0 analysis 
software. 
Co-immunoprecipitation/Western studies of parkin and synphilin-1 
 In triplicate, using the calcium phosphate transfection method, HEK293T cells were 
transfected in 35mm dishes with either synphilin-c-myc/pcDNA 3.1 alone or co-
transfected with synphilin-c-myc/pcDNA 3.1 as well as either the pcDNA3.1 untagged 
full-length human WT, E399Q, or T240R parkin constructs. At 21 hours post 
transfection, fresh complete media was added to the cells that were cultured for an 
additional 24 hours. Cells were then rinsed, scraped, and harvested in PBS by 
centrifugation at 13,000 g for 2 minutes. The cell pellets were lysed in 500 uL of ice-cold 
CSK buffer (100 mM NaCl, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 % Triton X-100) and 
cell debris was sedimented at 13,000 x g for 2 minutes. 30 uL of the supernatant was 
incubated at 100ºC for 5 minutes with SDS sample buffer as the “Input” fraction. The 
remaining supernatant was incubated overnight at 4ºC with anti-c-Myc polyclonal 
antibody (Sigma-Aldrich) that had been pre-incubated with protein A-agarose beads 
(Santa Cruz Biotechnologies, Santa Cruz, CA). The antibody-protein complexes were 
then washed 3 times with 10 volumes of CSK buffer, resuspended in 20uL of 2X SDS 
sample buffer, and incubated at 100ºC for 5 minutes as the immunoprecipitate (“IP”) 
fractions. 30uL of the unbound supernatants were also incubated at 100ºC for 5 minutes 
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with SDS sample buffer as the “Unbound” fractions. The Start, IP, and Unbound 
fractions were resolved by SDS-PAGE and immunoblotted with PRK109 antibody.  
Co-immunoprecipitation/Western studies of parkin with UbcH7 and UbcH8- 
The mammalian expression vectors expressing N-terminal HA-tagged full-length human 
UbcH7 or UbcH8 (pRK5-HA-UbcH7 and pRK5-HA-UbcH8, respectively) were kindly 
donated by Dr. Ted Dawson. In triplicate, using the calcium phosphate transfection 
method, HEK293T cells were co-transfected in 35mm dishes with either pRK5-HA-
UbcH7 or pRK5-HA-UbcH8 and pcDNA 3.1 mock vector or pcDNA3.1 untagged full-
length WT, E399Q, or T240R human parkin constructs. Cells were cultured, harvested, 
and lysed as described in the previous section. 50uL of the lysate was incubated at 100°C 
for 5 minutes with SDS sample buffer as the “Input” fraction. The remaining lysate was 
incubated for 3 hours at 4°C with HA.11 polyclonal antibody (Covance) that had been 
preabsorbed to protein A-agarose beads (Santa Cruz Biotechnologies). The antibody-
protein complexes were then washed 3 times with 10 volumes of CSK buffer, 
resuspended in 20uL of 2X SDS sample buffer, and incubated at 100ºC for 5 minutes as 
the “IP” fractions. The Input and IP fractions were resolved by SDS-PAGE and 
immunoblotted with the monoclonal antibodies PRK109 and anti-HA (Roche).  
Quantification of mouse synphilin-1 protein 
Western blot images were obtained (described above) and scanned using a CanoScan 
Lide30 scanner. The levels of UPN79 and actin were quantified for each mouse using 
ImageQuant 5.0 analysis software. The levels of UPN79 were normalized between mice 
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by calculating the ratio between the UPN79 value to that for actin. The normalized results 
for the mice of the same genetic background were averaged together and graphed.   
Relative quantification of the mouse synphilin-1 mRNA transcript 
 Cerebral cortical tissues were harvested from 8 month old BL6 and C3H mice.  Half of 
the tissue was frozen on dry ice for protein analysis and total RNA was extracted from 
the remaining half using TRIzol reagent (Invitrogen) as described in detail in previous 
sections.  Three tissue samples were prepared for each mouse strain. Reverse 
transcription reactions and real-time PCR analyses were performed as described above. 
Primers were designed to amplify a 107 base pair product of mouse synphilin-1 cDNA 
that corresponds to nucleotides 988-1095. The sequences for the synphilin-1 primers 
were as follows. Forward: 5’-ATATCGCTCTTGCCACACCTA-3’ and Reverse: 5’-
CAGGCATTCTGCATGGCCCTT-3’. Additionally, a mouse β-actin loading control was 
amplified as described above. The CT values for each sample were obtained. Synphilin-1 
values were normalized to β-actin by taking the ratio of synphilin-1 to β-actin for each 
sample. 
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CHAPTER SIX 
Discussion 
In efforts to gain insights into the biochemical pathways involved in idiopathic 
PD, much attention has been devoted towards understanding the roles for a number of the 
gene products implicated in familial forms of the disease. This thesis aimed to investigate 
the biochemical and cellular properties of mutant DJ-1, α-syn and parkin proteins using 
cell culture and mouse models. Based on the findings described herein (chapters 2-5), 
several conclusions can be drawn regarding the relevance of these studies as it relates to 
the field at large.   
6.1 DJ-1 acts to mitigate oxidative stress but can also protect against a 
variety of other toxic insults. 
In chapter 2, stable overexpression of WT and E163K human DJ-1variants in 
N2A cells revealed that in response to noxious stimuli, DJ-1 is generally a protective 
protein. DJ-1 acted to protect against proteolytic stress induced by inhibitors of the 26S 
proteasome. It also protected against toxicity caused by mitochondrial complex I and III 
inhibitors. Remarkably, while WT DJ-1 efficiently ameliorated the harmful effects of 
oxidation, E163K DJ-1 failed to protect against oxidative stress and rendered cells to be 
selectively vulnerable to oxidative insults.  This suggests that the E163K DJ-1 mutation 
acts as a dominant-negative, specifically during conditions of oxidative stress.  It also 
implies that specific DJ-1 residues affect individual functions of the protein and may 
implicate DJ-1 in a variety of biochemical pathways.    
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It remains to be elucidated how DJ-1 mechanistically protects against cell toxicity 
and thus it is unknown why E163K DJ-1 renders cells to be selectively vulnerable to 
oxidative insults.  It is thought that oxidation of DJ-1 residue C106 to cysteine sulfinic 
acid acts to regulate the protective properties of DJ-1 protein 
(43;53;185;301;328;455;494). Blackinton and colleagues discovered that hydrogen 
bonding of C106 with DJ-1 residue E18 modulates C106 oxidation propensity (43). 
Based on knowledge gained from crystallization studies, residue E163 is not thought to 
be in close proximity to C106 (233;471). It is worth mentioning that additional DJ-1 
residues other than C106 can be modified by oxidation both in vitro and in vivo 
(65;207;389).  Perhaps the E163K substitution creates electrostatic abnormalities that 
could account for the oxidative deficiencies exhibited by mutant protein in the studies 
herein. It is known that the E163K DJ-1 substitution disrupts a salt bridge that normally 
occurs between residues E163 and R145 in DJ-1 and that this alteration thereby weakens 
a network of hydrogen bonds that span the DJ-1 dimer interface (233). Future studies to 
assess for changes that occur to specific residues of E163K DJ-1 protein under oxidative 
conditions would be insightful. 
It was somewhat surprising to find that E163K DJ-1 behaved as a dominant-
negative when expressed in mouse N2A cells during oxidative stress. One plausible 
explanation for this finding is that E163K DJ-1 dimerizes with and inactivates 
endogenous murine DJ-1 protein, thereby rendering cells expressing E163K DJ-1 to be 
selectively vulnerable to oxidative insults.  In the studies herein, we were unable to co-
immunoprecipitate E163K human DJ-1 together with endogenous murine DJ-1, 
suggesting that co-dimerization of the two DJ-1 isoforms does not occur.  However, our 
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co-immunoprecipitation studies were not completely exhaustive since alternative 
approaches utilizing additional types of tagged DJ-1 constructs and/or additional 
antibodies may have yielded different results. Thus, it would be premature to definitively 
conclude that E163K human DJ-1 does not somehow inactivate endogenous murine DJ-1 
under oxidative conditions. 
There can also be other explanations for the dominant-negative effect exhibited 
by E163K DJ-1 in N2A cells. It is thought that while oxidation of DJ-1 residue C106 to 
sulfinic acid activates the protective function of DJ-1 protein, further oxidation of C106 
to sulfonic acid under extreme oxidizing condition inactivates the protein 
(43;53;301;494). Though it has never been investigated, one would expect that 
inactivated or damaged forms of DJ-1 would need to be cleared from the cell by one of 
the cardinal protein degradation pathways. Perhaps E163K DJ-1 is particularly vulnerable 
to inactivation following oxidation and thus in a model system in which the inactivated 
E163K DJ-1 mutant is overexpressed during oxidative insult, this could result in a 
combinatorial strain on cellular antioxidant mechanisms as well as protein degradation 
machineries. The proposed combination of events could be the cause for the dominant-
negative effect exhibited by E163K DJ-1 during oxidative stress.  It would be interesting 
to determine the effects of oxidative stress on the turn-over rate of E163K mutant DJ-1 in 
efforts to address the question of whether oxidation plays a role in modulating 
degradation of the E163K mutant. Additionally, studies to assess for the pathogenicity of 
inactivated DJ-1 protein on cells during stress would be enlightening.   
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Since we showed that E163K DJ-1 can effectively protect against mitochondrial 
stress in N2A cells, it was unexpected to find that in response to oxidative stress, E163K 
DJ-1 demonstrated reduced redistribution towards mitochondria. Mitochondrial 
localization sequences have not yet been identified for DJ-1 neither is it fully understood 
what mechanistic role DJ-1 plays to maintain mitochondrial homeostasis. However, since 
E163K DJ-1 retained protective properties in the presence of mitochondrial toxins but 
failed to redistribute to mitochondria in response to oxidative stress specifically, it 
suggests that DJ-1 may have a variety of mitochondrial functions and that these functions 
may be regulated by different mechanisms.  Canet-Aviles and colleagues argued that 
mitochondrial localization of DJ-1 is driven by C106 oxidation (53). If this is true, it is 
possible that residue C106 in E163K DJ-1 has aberrant redox properties. Thus, it would 
be interesting to determine the role of C106 in the regulation of E163K DJ-1 
mitochondrial localization.  
Though we and others have shown that DJ-1 protects against oxidative stress 
(27;137;181;196;204;252;253;418;479;482), Gorner and colleagues argue that DJ-1 is 
not a direct antioxidant but instead indirectly influences cell viability by modulating 
redox signaling pathways (139). Since we showed that the cytoprotective properties of 
the E163K DJ-1 mutant were impaired during oxidative stress, it would be interesting to 
determine the impact of this on signaling pathways. It is worth noting that we were 
unable to detect differences in any of the signaling molecules analyzed in the studies 
herein including phosphorylated and nonphosphorylated Akt and phosphorylated and 
nonphosphorylated ERK1 and 2 (data not shown). However, the discrepancies between 
our findings and those reported in literature (129;142;252;484), may be due to differences 
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between cell-types used for studies. Thus, it would be interesting to assess for the effects 
of E163K DJ-1 on signaling pathways during oxidative stress by conducting studies using 
cell lines better fitted for protein signaling analyses.  
6.2 Misfolded DJ-1 mutants can be degraded by the proteasome pathway but 
alternative catabolic mechanisms are likely. 
In chapter 3, it was shown that in comparison to WT DJ-1 protein, pathogenic DJ-1 
mutants, L10P, L166P, and P158DEL, were dramatically destabilized when expressed in 
CHO cells. Interestingly, the analyzed mutant proteins were only partially stabilized by 
MG-132, albeit to variable degrees. It was also discovered that all of the DJ-1 mutants 
exhibited aberrant folding patterns. Additionally, insoluble forms of mutant L10P and 
L166P DJ-1 proteins could be stabilized following treatments with either MG-132 or 
epoxomicin, and P158DEL DJ-1 demonstrated reduced solubility even in the absence of 
these treatments. Further, L10P, L166P, and P158DEL DJ-1 proteins were associated into 
atypical intranuclear and cytoplasmic protein inclusions in CHO cells following exposure 
to MG-132. Conversely, the biochemical properties of WT DJ-1 protein were completely 
unaffected by proteasome inhibition in the analyses herein.  Taken together, these 
findings suggest that L10P, L166P, and P158DEL DJ-1 mutations contribute to disease as 
a function of decreased protein stability and indicate that the 26S proteasome can regulate 
specific variants of DJ-1 protein. 
It is interesting to note that turnover of WT DJ-1 protein was unaltered by inhibition 
of the proteasome. Additionally, the highly unstable pathogenic DJ-1 mutants analyzed 
could only be stabilized in part by MG-132. While neither L10P nor P158DEL DJ-1 
171 
 
proteins have been characterized prior to the studies herein, L166P DJ-1 has been shown 
by others to be stabilized in cells treated with various proteasome inhibitors 
(138;139;298;307;324). Interestingly, however, among all of these studies, it was only 
Gorner and colleagues who chose to report that MG-132 and epoxomicin were not 
sufficient to completely stabilize L166P DJ-1 in mammalians cells (138;139).  Perhaps 
others chose to overlook this observation, though it is also possible that proteasome 
regulation of mutant DJ-1 proteins could be cell-type specific. Notwithstanding, our 
findings support a role for degradation of both WT and mutants forms of DJ-1 by 
proteasome-independent mechanisms. 
To date, it is not fully elucidated what alternative proteolytic pathways may act to 
regulate DJ-1 protein. A recent study by Giaime and colleagues revealed that DJ-1 could 
be cleaved by caspase-6 enzyme (129). It was also determined in the study by Giaime et 
al. that the L166P mutation enhanced DJ-1 susceptibility to caspase-6 cleavage. Further, 
since DJ-1 cleavage by other caspases was not discovered in the study, it was implied that 
proteolysis of DJ-1 by caspase-6 is specific. Ironically however, though it was 
demonstrated that caspase-6 cleavage of DJ-1 could occur in vitro, the proteasome 
inhibitor, lactacystin, and the calpain inhibitor, ALLN, acted to stabilize L166P DJ-1 
much more potently than caspase-6 inhibitors (129). Thus, this suggests that regulation of 
DJ-1 likely occurs via diverse catabolic pathways and it will be interesting to determine 
what factors act to target DJ-1 for degradation by these distinct mechanisms.  
Since pathogenic DJ-1 mutants are partially destabilized by the proteasome, it is of 
interest to ascertain which E3 ligases may act to mediate this effect. Interestingly, Moore 
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et al. showed that WT DJ-1 associated with the E3 ligase, parkin, during oxidative 
conditions (304). Additionally, when co-expressed together in mammalian cells, various 
pathogenic DJ-1 mutants, including L166P, were able to interact with parkin (304).  
However, in the study by Moore et al., parkin failed to enhance the degradation of DJ-1 
but instead acted to stabilize WT and L166P DJ-1 variants (304). Olzmann and 
colleagues also reported that parkin failed to mediate the degradation of L166P DJ-1, 
though interaction between the two proteins was also detected in that study (325). We 
were unable to detect any interactions between parkin and WT, L10P or P158DEL DJ-1 
variants in the studies herein (data not shown) and thus, it is unlikely that these DJ-1 
variants are regulated by parkin-mediated mechanisms. 
Novel DJ-1 interacting proteins including TNF receptor-associated protein (TTRAP) 
and Bcl-2-associated athanogene 1 (BAG1) may be involved in modulating DJ-1 
(91;498). TTRAP selectively interacted with L166P DJ-1 in mammalian cells and this 
association was potently enhanced in the presence of MG-132 (498). BAG1 was also 
discovered to interact with both WT and L166P DJ-1 proteins and was reported to 
increase the dimer/monomer ratio for both variants (91), although the latter finding may 
be somewhat controversial since L166P DJ-1 fails to dimerize in our studies or in other 
reports.  It remains to be determined whether TTRAP or BAG1 proteins can modulate the 
turn-over rates of WT DJ-1 or pathogenic DJ-1 mutants. Thus, studies to investigate the 
effects of TTRAP and BAG1 on DJ-1 turnover would clarify the regulatory effects of 
these proteins on DJ-1. 
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It is possible that BAG1 and/or TTRAP may act to regulate the solubility of 
pathogenic DJ-1 mutants. Deeg and colleagues reported that L166P DJ-1 accumulated 
abnormally in cell nuclei under normal culturing conditions and that this aberration could 
be down-regulated by BAG1 protein (91). Interestingly, Zucchelli et al. showed that upon 
treating neuroblastoma cells with MG-132, TTRAP protein formed large juxtanuclear 
aggresomes, though it wasn’t reported whether DJ-1 localized to these inclusions (498).  
In the studies herein, L10P, L166P, and P158DEL DJ-1 variants formed intranuclear and 
cytoplasmic inclusions following treatments with MG-132. The majority of these 
inclusions were not classical aggresomes and this finding was somewhat surprising. To 
date, there have been no other reports describing the type of atypical DJ-1 positive 
inclusions that were observed in the studies herein. Previously, Olzmann and colleagues 
had reported that L166P and parkin colocalized into perinuclear aggresomes following 
proteasome impairments (325); however, the observations described in this thesis do not 
fit that profile. Thus, more thorough investigations into the mechanisms of DJ-1 inclusion 
formation are needed.  
It has been shown that L166P DJ-1 can exhibit a gain-of-function toxicity effect when 
expressed in mammalian cells (91;389;418;487;498). Zucchelli and colleagues showed 
that while TTRAP protected against MG-132-induced apoptosis in neuroblastoma cells, 
L166P DJ-1 significantly inhibited the protective activity of TTRAP by modulating 
signaling of pro-apoptotic mediators (498). Expression of L166P DJ-1 rendered 
transiently expressing mammalian cells to be selectively vulnerable to endoplasmic 
reticulum stress (487) and H2O2 induced cell death (389;418).  L166P DJ-1 was also 
shown to reduce cell viability when expressed in cells under normal culturing conditions 
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(91), although this finding has never been reported by others. Since L10P, L166P, and 
P158DEL DJ-1 variants form atypical protein inclusions following proteasome 
impairments, it is hypothesized that all three DJ-1 mutants may be toxic to cells, though 
this question has never been addressed. Further, autopsy tissues are currently unavailable 
for PD patients harboring L10P, L166P or P158DEL DJ-1 mutations. Thus, it will be 
interesting to determine whether any of the three mutant DJ-1 proteins can act to enhance 
protein aggregation in vivo. 
6.3 Genetically altered mice may not fully recapitulate the molecule pathways 
affected by genes associated with PD. 
Pathogenic DJ-1 mutations are thought to cause PD as a consequence of the loss of 
DJ-1 protective function (47). In efforts to model a DJ-1 loss-of-function in vivo, DJ-1 
deficient mice were generated as described in chapter four. However, mice lacking DJ-1 
did not demonstrate any of the cardinal signs of parkinsonism, neither were there any 
signs of nervous system degeneration in these animals. This was not completely 
surprising since similar findings have been reported by other groups (13;60;63;136;274). 
Nevertheless, many have shown DJ-1 null mice to be susceptible to a variety of toxic 
insults (204;354;483) and this suggests that DJ-1 acts in a protective capacity in vivo. 
It was reported that DJ-1 could modulate the aggregation of α-syn and/or act to 
alleviate the toxic effects of pathogenic forms of α-syn in vitro (27;389;493;494); 
however, prior to the findings described herein, it had never been reported whether 
similar functions for DJ-1 could be recapitulated in vivo. As detailed in chapter four, 
generation of homozygous double-transgenic M83-DJnull mice enabled us to address this 
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question for the first time.  M83-DJnull mice were analyzed and compared to previously 
characterized M83 mice (131) as it related to survival rate, distribution of α-syn 
pathologies, biochemical properties of the α-syn protein, and the secondary effects of 
expressing mutant α-syn. Since no significant differences were discovered between 
mouse genotypes, it was concluded that DJ-1 may not directly modulate α-syn, nor 
protect against the harmful effects that result from α-syn aggregation in vivo.    
The findings reported in this thesis suggest that attempting to gain insights into 
familial forms of PD using mouse models may prove to be difficult. While in humans, 
DJ-1 deficiency may result in early-onset PD (47;152;200), we and others have shown 
that mice lacking DJ-1 are relatively normal (13;60;63;136;211;274). Similarly, although 
patients harboring the A53T α-syn mutation develop PD marked by nigrostriatal 
dopamine neurodegeneration and associated nigral LB pathologies (134), it is clear that 
transgenic mice expressing human A53T α-syn exhibit a phenotype that is distinct from 
human disease (51;131;247;279;444).   Further, in chapter 5, we describe our discovery 
of a novel endogenous E398Q parkin mutation in C3H mice which appears to inactivate 
parkin in these animals. A variety of parkin mutations are causative of juvenile to early-
onset forms of PD which are thought to result from parkin loss-of-function 
(26;154;155;270;282;359;416;478). Our analyses in chapter 5 reveal that C3H mice may 
be suitable parkin loss-of-function models; however, unlike patients harboring parkin 
missense mutations, C3H mice do not demonstrate any of the classical symptoms of PD. 
Future thorough anatomical, biochemical, and behavioral characterizations of the 
nigrostriatal dopaminergic system in C3H animals may be insightful.   
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Stories told from the studies of genetically altered mice suggest that it may be 
presumptuous to assume that any single genetic mutation alone can be causative of PD. 
Instead, one could argue that patients harboring PD-linked mutations may just be more 
susceptible to environmental stimuli and/or other noxious insults that may synergistically 
lead to nigral neurodegeneration and the onset of behavioral impairments.  If this is true, 
it is possible that if insulted with the proper stimuli, genetically altered mice may be able 
reproduce some of the classical symptoms of PD. To support this idea, it has been shown 
that parkin deficient mice are particularly susceptible to nigral degeneration caused by 
neuroinflammatory stimuli (116). Similarly, in comparison to normal mice, DJ-1 
deficient animals are more vulnerable to paraquat exposure (483) as well as exposure to 
mitochondrial inhibitors (204;354). Paraquat exposure also exacerbates disease in 
transgenic mice expressing human A53T α-syn (321). Nonetheless, it is not fully 
elucidated what mechanisms contribute to the vulnerabilities displayed by the genetically 
altered animals used in these studies. Future studies to identify factors that can enhance 
the effects of modulating parkin, DJ-1, or α-syn in vivo will give insights into the roles of 
these proteins in the pathogenesis of both inherited and sporadic forms of PD.   
6.4 Oxidative stress, mitochondrial dysfunction and protein degradation 
impairments may all impinge on PD pathogenesis. 
This thesis presented a range of studies involving the effects of mutations on DJ-1, 
parkin, and α-syn proteins in efforts to gain insights into the molecular mechanisms that 
may be causal of PD. Based on the findings presented herein, it is fair to conclude that 
PD is a complex disorder that may develop subsequent to a combination of events that 
177 
 
synergistically result in the disease. Our findings from the studies of the E163K DJ-1 
mutant suggest that oxidative stress may be a pathogenic factor in PD and also support a 
role for DJ-1 in acting to mitigate this insult. It is known that oxidative damage of DJ-1 is 
linked to sporadic PD (65;374). Further, we have shown that DJ-1 can effectively protect 
against oxidative toxicity. Thus it is proposed that development of therapeutic strategies 
that would act to upregulate DJ-1 and thereby ameliorate any harmful oxidation that may 
occur in vivo would likely serve to protect against the development of PD in humans. 
It is also suggested from our studies that interactions of DJ-1 with mitochondria may 
be required for the protective effects of DJ-1 against oxidative insults.  Though there is 
much to be learned regarding this idea, it is possible that impairments in DJ-1 activity 
may somehow link oxidative stress to mitochondrial dysfunction in PD. It’s known that 
mitochondrial complex I is vulnerable to oxidative damage (64;435). We have shown that 
DJ-1 can assuage H2O2 toxicity and can also protect against inhibitors of mitochondrial 
complexes. Whether these protective mechanisms exhibited by DJ-1 are somehow related 
remains to be determined. Future studies to assess for the mitochondrial role of DJ-1 
especially as it relates to how oxidation may modulate this would be beneficial in 
determining how mitochondrial impairments may contribute to the onset of PD.      
It is also apparent from our studies of DJ-1, parkin, and α-syn mutations that protein 
degradation impairments may be involved in PD pathogenesis. We showed that L10P, 
L166P and P158DEL DJ-1 mutants were capable of promoting the formation of 
intracellular inclusion bodies in a proteasome dependent manner. Though it remains to be 
elucidated, if similar effects occur in patients, it is possible that certain DJ-1 mutations 
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may contribute to disease as a consequence of proteasome impairments and/or 
impairments in other protein degradation machineries.  Our studies also revealed that 
parkin mutations, such as T240R and E399Q, may disrupt parkin E3 ligase function. In 
patients harboring parkin mutations, accumulation of parkin substrates such as synphilin-
1 may work to induce proteolytic stress and this may act to instigate subsequent disease. 
The latter idea is supported in the literature (212;265;461). Further, in agreement with 
previous studies (131;247;444), we showed that pathogenic mutant A53T α-syn protein 
tended to aggregate in mice, forming intracellular inclusions that were reminiscent of LB 
pathologies, similar to those observed in patients with disease. We did not investigate the 
effects of α-syn inclusion formation on activities of the proteasome or other known 
cellular proteases. Studies by other groups have attempted to address this question; 
however many of the reported findings are in disagreement (280;319;410).  We showed 
that many of the α-syn inclusions in mice were positive for ubiquitin, and this finding 
may support a role for the ubiquitin-proteasome pathway in clearing misfolded forms of 
pathogenic α-syn protein in vivo. Taken together, we provide evidence to suggest that 
therapeutic strategies that aim to directly modulate and/or mitigate the effects of impaired 
protein degradation in humans may help to prevent neurodegeneration observed in PD.  
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